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ABSTRACT 
 
The association of tumor cells and lymphocytes has led to the hypothesis that our 
immune system actively inhibits the formation and progression of cancer, a phenomenon called 
tumor immune surveillance. T cells specific to mutant proteins have been identified in cancer 
patients and the recent success of cancer immunotherapies provides evidence that the immune 
system can fight this disease. Yet the frequent occurrence of malignant disease despite T cell 
recognition presents a significant medical problem. Only after we determine how tumors bypass 
the immune system can immunotherapeutic approaches be improved. 
To understand how tumors subvert immune responses, tumor transplantation or 
transgenic mice expressing tumor-associated antigens have been used to model cancer. To 
assess the role of anti-tumor T cells in models that more accurately reflect the human disease, I 
developed new systems to introduce exogenous antigens, to mimic neoantigens, into 
genetically engineered mouse models of lung cancer and sarcomas. 
Utilizing the mouse model of lung cancer, I show that endogenous T cells respond to 
and infiltrate lung tumors, delaying malignant progression. Despite continued antigen 
expression, T cell infiltration does not persist and tumors ultimately escape immune attack. 
Transplantation of cell lines derived from lung tumors that express these antigens or 
prophylactic vaccination against autochthonous tumors, however, results in rapid tumor 
eradication or selection of tumors that lose antigen expression. These results support clinical 
data that suggest a role for the immune system in cancer suppression rather than prevention. 
Tumor immune surveillance and immunoediting have largely been defined using 
carcinogen-driven models of sarcomagenesis. Using a genetically engineered model of 
sarcomagenesis, I show that immunoediting requires potent T cell antigens and that 
lymphocytes drive the evolution of less immunogenic tumors by selecting for antigen loss. 
Finally, immunotherapies have historically been ineffective in treating cancer patients. I 
show that vaccination against specific antigens expressed in mouse lung cancers leads to 
sustained anti-tumor T cell responses that eradicate recently initiated tumors. Vaccination also 
stimulates anti-tumor T cell responses in an antigen-independent fashion by enhancing the 
expansion and activity of T cells that recognize antigens only expressed in tumors. 
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INTRODUCTION 
  10 
 
Cancer is a disease that results from the uncontrolled proliferation of cells that ultimately 
invade and disrupt the function of vital organs, causing death. Cancer is a complex disease that 
can originate from many different tissues and progress through many different stages during its 
development. Despite their diversity, cancers are unified by a shared etiology. Cancer is a 
genetic disease that arises as a result of the culmination of multiple disruptions in intrinsic 
cellular pathways, most importantly, mutations in the DNA encoding proto-oncogenes and tumor 
suppressors. However, after over three decades of research since the initial discovery that 
mutations in cellular genes underlie this disease, it is clear that cancer is much more 
complicated than the culmination of disrupted genes in hyperproliferating cells; cancer is also a 
product of the surrounding environment in which it originates and grows. Normal cells and 
factors surrounding tumors are clearly implicated in shaping the disease, but the cells of the 
immune system stand at the forefront as critical regulators of cancer. Indeed, the immune 
system is viewed by many to be a “hallmark” of cancer (Condeelis and Pollard, 2006; Dunn et 
al., 2006; Hanahan and Weinberg, 2000; Mantovani, 2009; Zitvogel et al., 2006), as it seems 
that immune cells can act in opposing fashions to either promote or inhibit the initiation and 
progression of this disease (de Visser et al., 2006; Grivennikov et al., 2010; Swann et al., 2008).  
This thesis will focus on the ways in which T cells, primarily CD8+ cytotoxic T 
lymphocytes (CTLs), may act to prevent or inhibit cancer progression. Utilizing new 
experimental models in mice to investigate CTL responses to cancer, this thesis provides 
insights into the natural role of CTLs reacting against cancer. This thesis also reveals that CTL 
responses to cancers may be altered by the nature of the antigenic elements that target T cells 
to the cancer cells as well as by the origin of the disease. Lessons learned from this work may 
have important implications for how the immune system may be used to treat patients with 
cancer. 
  11 
I. HISTORTICAL PERSPECTIVE 
 
 The role of the immune system in cancer has been an active area of basic and clinical 
research since the turn of the 20th century; however, a clear understanding of how the immune 
system interacts with and potentially regulates cancer has only recently come into focus. The 
convergence of our understanding of the biology of cancer and the immune system combined 
with the acquisition of new tools to study their complexities has allowed greater insight into 
immune-tumor interactions. However, a century’s worth of research was required to reach our 
present understanding of tumor immunology, the study of immune responses to cancer. A field 
steeped in this much history requires a brief historical perspective in order to appreciate not only 
how we reached our current understanding of immune-tumor interactions, but also to 
acknowledge the many important discoveries made from research in this field. Key discoveries 
in the history of cancer and tumor immunology are highlighted in Figure 1. 
 
The potential for important interactions between a developing tumor and the surrounding 
immune system has been appreciated for over a century. Upon some of the first histological 
examinations of cancer during the 19th century, Rudolf Virchow, the leader in cellular pathology 
at the time, reported that most cancers were infiltrated by leukocytes (Balkwill and Mantovani, 
2001). It wasn’t long before a functional connection between inflammatory cells and cancer 
could be shown. The work of William Coley, and the generation of Coley’s toxins derived from 
bacterial components, demonstrated that the induction of immune responses, at least when 
provoked by pathogens, could suppress and even eradicate some tumors, particularly sarcomas 
(Dranoff, 2004). However, it wasn’t until 1975 that the active agent in Coley’s toxin, tumor 
necrosis factor (TNF), was purified (Carswell et al., 1975), providing a fitting example of the  
  12 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tremendous lag time (80 years!) between key observations in tumor immunology and a true 
biological understanding of the phenomenon.  
At about the same time – the turn of the 20th century – investigators had begun to 
propagate spontaneous tumors in animals by serially transplanting the tumors from one animal 
to the next. Through the course of this procedure, it was discovered that first, tumors could not 
be passaged into different species, but more interestingly, some tumors would spontaneously 
regress after transplantation into animals of the same species. Subsequent experiments 
showed that animals could be immunized against a transplanted tumor if they were first 
inoculated with a sub-lethal challenge of the same tumor (Schreiber, 2003; Scott, 1991). In 
1909, perhaps as a result of these findings, or the work of William Coley, Paul Ehrlich first 
introduced the idea that cancer may be regulated by the immune system. He speculated that 
the immune system served to protect the host from the progression of neoplasms into malignant 
cancer, and that an attenuation of the immune response was responsible for tumor outgrowth 
(Dunn et al., 2004a; Witkowski, 1990). Ehrlich was truly ahead of his time. 
Peyton Rous soon published his landmark paper describing the transmission of an avian 
sarcoma from one chicken to another “by means of a cell free filtrate” (Rous, 1911). Although it 
took some time before it was understood that viruses within the cell-free filtrate were 
responsible for transmitting the cancer (Rous, 1965), it took much longer for the development of 
vaccines to prevent the infection of such viruses as hepatitis B virus (HBV) or human 
papillomavirus (HPV) that can cause hepatocellular carcinomas or cervical cancers, 
respectively. 
Experimentation with transplantation of spontaneous tumors continued for several 
decades in the early 20th century, but typically with inconclusive and irreproducible results. The 
discovery that normal, untransformed tissues grafted from one animal to another were rejected 
in a similar fashion to transplanted tumors temporarily sidelined the progress of tumor 
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immunology because of a fundamental lack of understanding about the immunobiology of 
allograft rejection. However, these discoveries bolstered interest in the genetics of allograft 
rejection, leading such mouse geneticists as Clarence Cook Little and George Snell to begin 
generating inbred mouse strains at the Jackson Laboratory. Investigations into the mechanisms 
of graft rejection ultimately led to the discovery of the major histocompatibility complex as the 
key determinant in allograft rejection.  
By the 1940s, the development of inbred mice and chemically induced carcinogenesis 
provided new opportunities for experimentation by tumor immunologists. Ludwik Gross was now 
able to demonstrate for the first time that mice could be specifically immunized against cancer 
by using the carcinogen methylcholanthrene (MCA) to induce tumors and transplant them within 
mice of the same inbred strain (Gross, 1943). Thus, tumor transplant rejection could no longer 
be explained by “residual heterozygosity,” i.e. inherent differences between different strains of 
mice. Although work by E.J. Foley, confirmed the results of Gross with MCA-induced sarcomas; 
parallel experiments utilizing mammary tumors that arose spontaneously revealed that 
immunization against spontaneous tumors was not possible (Foley, 1953a, b). Therefore, a 
fundamental difference was observed between spontaneously arising tumors and carcinogen-
induced tumors – only the latter tumors could be successfully immunized against. This is in fact 
a critical issue that will be revisited throughout this thesis: do carcinogen-induced animal models 
of cancer accurately reflect the disease in humans, specifically with respect to immune 
responses?  
Nevertheless, the work of R.T. Prehn and J.M. Main in the late 1950s, solidified the 
importance of Gross’ earlier work by reproducing his results with tumor-specific immunization 
but also demonstrating that normal tissue grafts did not protect mice from subsequently 
transplanted tumors, and prior challenge with these tumors did not lead to the rejection of 
subsequently grafted normal tissues, conclusively ruling out residual heterozygosity as the 
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means of rejection (Prehn and Main, 1957). Taking the system one step further, George Klein 
showed that individual mice could be immunized against their own autochthonous tumors by 
inducing sarcomas with MCA, surgically removing them, and then subsequently retransplanting 
them back into the original host (Klein et al., 1960). Indeed, the foundation for tumor-specific 
immunity had been laid. Yet, because most spontaneous tumors and some MCA-induced 
tumors were not immunogenic, even these early investigators responded cautiously to their 
influential work, stating that “the altered antigenicity [of the MCA-induced tumors] was not an 
intrinsic part of the carcinogenic process but rather an incidental concomitant change” (Scott, 
1991). The final piece of the puzzle came together with the work of Avrion Mitchison who 
showed that lymphocytes were the critical mediators of the immune response that was 
responsible for tumor rejection (Clayton, 2006; Mitchison, 1953, 1955). 
These experiments formed the foundation for the theory that the immune system 
naturally protects hosts from cancer through lymphocyte recognition of tumor-specific antigens. 
Thus it is not surprising that Macfarlane Burnett and Lewis Thomas re-instigated this concept in 
the early 1960s, coining the phenomenon tumor immune surveillance. Although both agreed 
that the immune system served as an extrinsic tumor suppressor of cancer; Burnett believed 
that cancer was recognized by the immune system due to the generation of distinct neoantigens 
in tumors, whereas Thomas believed the response was due to the neoplastic process itself – 
the role of the immune system was to monitor and maintain tissue homeostasis (Dunn et al., 
2002; Smyth et al., 2001). Despite evidence that the immune system could provide protection 
from cancer, proof was lacking that tumor immune surveillance occurred naturally.  
The theory of tumor immune surveillance was soon shattered in the 1970s by the work 
of Osias Stutman who began using T cell deficient athymic nude (nu/nu) mice to induce 
sarcoma formation. By comparing the susceptibility to MCA-induced tumor formation of nu/nu 
and nu/+ littermates, Stutman found no difference in susceptibility to MCA-induced or 
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spontaneous cancers (Stutman, 1974). This led researchers to conclude that the tumor immune 
surveillance theory was an artifact of transplantation and not representative of naturally arising 
cancers. However, such conclusions may have been premature. First, the strain of mice used in 
these studies is thought to be abnormally susceptible to MCA-induced tumor formation, 
potentially causing tumors to arise “at a rate that overwhelms host immunological defense 
mechanisms” (Dunn et al., 2002). Second, MCA was injected into newborn mice. This could be 
of critical importance because we now know that particularly in mice, the adaptive immune 
system does not completely develop until after birth. Therefore, if transformation began before 
the complete development of T cells, it is possible that tumors would not be rejected due to the 
establishment of tolerance during the first weeks after birth (Adkins et al., 2004; Billingham et 
al., 1953; Medawar, 1961). Finally, and perhaps most importantly, nude mice are not completely 
immune deficient. They possess some mature T cells and normal numbers of antibody-
producing B cells and natural killer (NK) cells, an innate population of lymphocytes with 
cytotoxic activity similar to CTLs. Interestingly enough, NK cells were discovered as a direct 
consequence of the investigation of immune responses to cancer (Kiessling and Klein, 1973; 
Kiessling et al., 1976). Although originally thought to be an artifact of in vitro experiments, NK 
cells were discovered and named because of their “natural” (antigen-independent) ability to kill 
tumor cell lines in culture. 
Support for tumor immune surveillance was largely stalled until new technologies 
allowed for more refined investigations of immune-tumor interactions. A key advance was the 
development by Kohler and Milstein of techniques to produce and maintain monoclonal 
antibodies, allowing the identification and characterization of the different immune cell subsets 
based on the expression of cell surface antigens. Perhaps more important to the field of tumor 
immunology was the use of monoclonal antibodies injected into mice as a means for depleting 
specific immune cell subsets or blocking key receptor-ligand interactions in mouse cancer 
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models. Depletion of a critical immune-regulatory cell population (Tregs), using the monoclonal 
antibody PC-61 that targets CD25, demonstrated a key role for these cells in suppressing anti-
tumor immune responses (Shimizu et al., 1999). The use of monoclonal antibodies to block 
interactions with an inhibitory receptor on T cells (CTLA-4) in vivo, proved to enhance anti-tumor 
immunity in mice (Leach et al., 1996). Recently antibodies against CTLA-4 have shown efficacy 
in Phase III clinical trials of patients with metastatic melanoma (Hodi et al., 2010). 
The advent of molecular cloning techniques led to the isolation and recombinant 
expression of several genes encoding cytokines, of which interleukin-2 (IL-2) was the first 
(Taniguchi et al., 1983). Shortly thereafter, Steven Rosenberg and colleagues began testing 
recombinant IL-2 in clinical trials to treat cancer with the hope that it would stimulate existing 
anti-tumor T cell responses (Lotze et al., 1986; Rosenberg et al., 1994a). The next trials 
administered so-called “lymphokine-activated killer cells” (LAKs) in conjunction with IL-2 therapy 
(Rosenberg et al., 1987; Rosenberg et al., 1985). LAKs were lymphocytes harvested from 
patients’ blood and activated in vitro with IL-2. The final step for Rosenberg’s team was the first 
incarnation of the modern form of adoptive cell transfer therapy (ACT). In this therapeutic 
regimen, tumor-infiltrating lymphocytes (TILs), rather than LAKs, are harvested directly from a 
patients tumors, expanded in vitro, and used as the anti-cancer immune effector cells (Dudley et 
al., 2002; Rosenberg and Dudley, 2004; Rosenberg et al., 1986; Rosenberg et al., 1994b).  
Molecular cloning also allowed the generation of cDNA libraries that provided a path to 
the discovery of the first antigen expressed in tumors that could be recognized by T cells (van 
der Bruggen et al., 1991). The use of cDNA libraries to screen for novel tumor antigens (called 
SEREX for serological identification of antigens by recombinant expression cloning) has proven 
to be the most rapid method available for discovering shared tumor antigens (Old and Chen, 
1998). 
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With an understanding of how T cells recognize antigens, by complexing their TCR with 
peptide-loaded MHC molecules, came the recombinant engineering of so-called “tetramers,” 
multivalent MHC molecules that could be loaded with any peptide antigen of interest (Altman et 
al., 1996). The use of tetramers has dramatically accelerated our capacity to identify and 
characterize T cells responding to cancers in patients and animal models (Lee et al., 1999; 
Romero et al., 1998; Savage et al., 2008; Yee et al., 1999). Finally, molecular cloning has 
provided the means to artificially endow tumor-specificity to a cancer patient’s lymphocytes by 
manually introducing recombinant TCRs that recognize tumor antigens into their T cells for use 
in ACT-based therapy (Cohen et al., 2005; Morgan et al., 2006; Pule et al., 2008). 
Finally, the technology of targeted gene disruption in mice allowed the generation of 
better defined models of immunodeficiency to study tumor immune surveillance. Seminal 
studies using mice that lack critical components of immunity – interferon-γ or its receptor, 
perforin, or recombinase-activating gene deficient mice – were shown to have increased 
susceptibility to carcinogen-induced or spontaneous tumor formation compared to wild-type 
mice (Kaplan et al., 1998; Shankaran et al., 2001; van den Broek et al., 1996). The recent work 
of Robert Schreiber and colleagues has expanded the notion of tumor immune surveillance to 
encompass a role for the immune system in shaping tumor development. They propose that the 
immune system plays a role in the evolution of cancer by selecting for tumors with decreased 
immunogenicity, a concept termed cancer immunoediting (Dunn et al., 2002; Dunn et al., 2006; 
Dunn et al., 2004b). This concept is supported by experiments showing that tumors that arise in 
immune-deficient mice are susceptible to rejection upon subsequent transplantation into 
immune competent mice (Dunn et al., 2005; Shankaran et al., 2001). It is proposed that tumors 
of reduced immunogenicity arise either through the outgrowth of tumors that lack (or have lost) 
antigens recognizable by the immune system or through the outgrowth of tumors that gain the 
capacity to suppress an anti-tumor immune response (Pardoll, 2003). 
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Despite our increased understanding of the immune system and cancer, the availability 
of new tools to study immune responses to cancer, and the technological leap to using 
genetically engineered mouse models of immunodeficiency to reveal a role for immune 
surveillance of cancer; most investigations continue with highly artificial tumor models. In these 
models, carcinogen-induced tumors or long-term cultured tumor cells are transplanted into mice 
to assess immune-tumor interactions. As discussed before, carcinogen-induced cancers may 
harbor abnormally large numbers of mutations which may lead to artificially robust immune 
responses (Scott, 1991), while the act of transplantation itself presents a plethora of 
complications that likely make it a poor model of cancers that arise naturally in the human 
population (Frese and Tuveson, 2007; Garbe et al., 2006; Willimsky and Blankenstein, 2000). 
Tumor cells administered via injection are at a great disadvantage immunologically because 
such routes can initiate proinflammatory responses or traffic tumor cells directly to lymphoid 
organs making tumors more susceptible to rejection (Khong and Restifo, 2002). More 
importantly, transplant models are inadequate because they do not allow researchers to study 
the dynamics of the immune-tumor interface as normal cells become transformed, evolve, and 
obtain the genetic changes necessary to initiate, promote and progress toward malignancy. 
Finally, due to the rapid growth kinetics of transplanted cells, researchers are forced to study an 
acute immune response to the tumor, whereas immune-tumor interactions in cancer patients 
are more likely to be a chronic affair. Therefore, it is imperative that we begin to use tractable 
and reproducible models of autochthonous disease that more accurately recapitulate the 
stepwise progression of human cancer, both histopathologically and genetically, to study tumor 
immune surveillance (Frese and Tuveson, 2007; Khong and Restifo, 2002; Tuveson and Jacks, 
2002; Van Dyke and Jacks, 2002). The major goal of this thesis research was to employ the use 
of such models to investigate the role of immune-tumor interactions in regulating the 
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development and progression of cancer (see Chapters 2 and 3). In the next section I will briefly 
discuss evidence that the immune system can paradoxically promote cancer in some settings. 
 
 
II. IMMUNE PROMOTION OR SUPPRESSION OF CANCER 
 
 Before continuing with a description of how T cells respond to and regulate cancer, it is 
important to point out that the immune system has also been shown to promote cancer in 
several settings. Notably, cells of the innate immune system have typically been associated with 
aiding cancer progression, but adaptive immune cells such as B cells and CD4+ T cells have 
also been implicated. CD8+ T cells have not been implicated in tumor promotion. 
 When Virchow first reported the presence of immune cells in multiple forms of cancer, he 
actually speculated that the inflammatory cells associated with cancer might promote the 
disease. Much more recently, it has been proposed that the tumor microenvironment, often 
harboring a large composition of inflammatory cells, shares many properties with wounds. In 
1986, Harold Dvorak first posed the notion that cancers are what he described as “wounds that 
do not heal” (Dvorak, 1986). Recent studies comparing gene expression data from wounded 
tissues and cancers in the same tissues have corroborated this hypothesis (Chang et al., 2004; 
Riss et al., 2006). 
 Inflammatory cells recruited to sites of injury are clearly important for providing protection 
from pathogens. However, inflammatory cells also play an important role in wound healing, 
promoting tissue regeneration, cell migration, and new blood vessel formation through the 
secretion of growth factors, chemokines and pro-angiogenic cues, all factors that could 
conceivably promote cancer progression (see reviews: (Coussens and Werb, 2002; Grivennikov 
et al., 2010; Mantovani et al., 2008)). Even the production of reactive oxygen species by innate 
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inflammatory cells, as a means to remove pathogenic invaders, could serve as a mutagenic 
agent promoting the initiation or progression of cancers (Weitzman and Gordon, 1990). In fact, 
we know that chronic inflammatory syndromes are associated with several forms of cancer in 
humans, such as hepatitis and hepatocellular carcinomas, pancreatitis and pancreatic 
carcinomas, inflammatory bowel disease and colorectal carcinomas, and bronchitis and lung 
carcinomas (Coussens and Werb, 2002). Although these are only correlative associations, not 
causal links between inflammation and cancer induction, several lines of evidence point to a 
positive role for the immune system in cancer formation and progression. 
Screens for cDNAs that could modify the activity of p53 provided one of the first direct 
links between inflammation and cancer. The identification of macrophage migration inhibitory 
factor (MIF), a cytokine produced by immune cells, as an inhibitor of the tumor suppressor p53, 
provided a means for tumor induction by inflammatory cells (Hudson et al., 1999). Elegant work 
in mouse models of cancer have provided direct evidence that certain cells of the immune 
system can promote cancer formation and progression (Qian and Pollard, 2010). Several 
investigations have demonstrated that inflammatory cells recruited to the tumor 
microenvironment induce the activation of NF-κB signaling in cancer cells, a critical pathway 
driving the progression of many forms of cancer (Greten et al., 2004; Meylan et al., 2009; 
Pikarsky et al., 2004). The activation of STAT3 signaling in tumor cells as a consequence of 
inflammation has also been shown to not only promote multiple aspects of tumorigenesis, but 
also potentially inhibit aspects of anti-tumor immunity (Yu et al., 2009). Tumor-associated 
macrophages, neutrophils, and mast cells have all been shown to promote tumor angiogenesis 
in mouse models of breast, skin, and pancreatic cancers, primarily through the activity of matrix 
metalloproteinases that can release vascular endothelial growth factor (VEGF) from the 
extracellular matrix (Coussens et al., 1999; Coussens et al., 2000; Lin et al., 2006; Nozawa et 
al., 2006). Metastasis is promoted in models of mammary tumorigenesis through the 
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establishment of paracrine chemotactic signals between macrophages and tumor cells 
(DeNardo et al., 2009; Lin et al., 2001; Wyckoff et al., 2004). Notably, adaptive immune cells 
such as B cells or CD4+ T cells have been implicated in initiating the recruitment of these innate 
inflammatory cells that ultimately carry out the tumor-promoting activities of the immune system 
(Daniel et al., 2003; de Visser et al., 2005; DeNardo et al., 2009). Therefore, cells of the immune 
system can play critical roles in promoting cancer in some settings. However, depending on the 
type of immune cells recruited to the tumor, and the phenotype of these cells, the immune 
response can function in opposing ways to either promote or inhibit cancer initiation and 
progression (Figure 2). 
The remainder of this thesis will now focus exclusively on how T cell responses to 
cancer can act to negatively regulate the progression of this disease. I will begin by providing 
the mechanisms by which T cells can recognize, respond to, and regulate cancer. 
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Figure 2. Immune cells and their effectors can act to suppress or promote cancer. 
Critical effectors and cells of the immune system that provide anti-tumor activities are depicted 
in red (left side) and immune effectors and cells that act in a pro-tumor fashion are depicted in 
green (right side). Several examples of anti-tumor and pro-tumor effects are listed above. 
DC, dendritic cell; NK, natural killer cell; CTL, cytotoxic T lymphocyte; M or Mac, macrophage; 
N, neutrophil; MC, mast cell; Gz, granzyme; ROS, reactive oxygen species; MIF, macrophage 
inhibitory factor; EGF, epidermal growth factor; CSF1, colony-stimulating factor 1; ECM, 
extracellular matrix; MMPs, matrix metalloproteinases. 
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III. T CELL RESPONSES TO CANCER 
 
 To understand how T cell interactions with cancer can shape this disease we will explore 
three phases or parameters that describe how these interactions take place. These interactions 
begin with the detection of cancer by T cells, are followed by the regulation of cancer by T cells, 
and finally end with the cessation of the T cell response against cancer during tumor evasion 
(Figure 3). 
 
A. Detection 
At the outset, in order for T cells to respond to cancers they require a means to “see” the 
tumor. Cytotoxic T lymphocytes (CTLs) have evolved to recognize and kill host cells harboring 
cellular pathogens. Impressively, CTLs have nearly a limitless capacity to recognize foreign 
invaders because of an acute capacity to recognize foreign or “non-self” proteins (called 
antigens) produced by the pathogen. Importantly, unlike antibodies produced from B cells that 
can recognize nearly any foreign chemical structure, T cells are restricted to proteinaceous 
antigens. This is because T cells utilize a surface bound receptor, the T cell receptor (TCR), to 
recognize protein fragments (peptides) produced within the target cell but presented on its 
surface in conjunction with the major histocompatibility proteins (MHC). These interactions 
between the TCR and peptide/MHC complexes provide a means for CTLs to sample and screen 
the inner contents of host cells for the presence of foreign proteins within each cell’s complex 
proteome. In this way, CTLs can promote the clearance of cellular infections by seeking out and 
destroying all pathogen-infected cells within the host. This presents a problem for understanding 
how T cells recognize cancer cells, as these are “self” cells and only in a minority of cases do 
cancer cells produce antigens from foreign pathogens. Therefore, alternative classes of 
antigens must be produced by the tumors that allow for engagement by T cells. We will begin  
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Figure 3. The three phases of T cell responses to cancer. 
The detection phase (in blue, left) involves the acquisition of tumor antigens at the tumor site by 
dendritic cells (DC) that migrate to the draining lymph node to present antigens to CD8 and CD4 
T cells that with additional signals (green arrows) can activate T cells which migrate back to the 
tumor site and engage tumors cells directly via TCR-pep/MHCI interactions. The regulation 
phase (in red, middle) is mediated by CTL recognition and direct killing of tumor cells or indirect 
mechanisms involving cytokine secretion. The evasion phase (in green, right) can occur through 
a variety of processes involving selection, suppression, or T cell tolerance (details are listed in 
the green boxes). 
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the discussion of how T cells detect cancer by introducing the classes of antigens, called tumor 
antigens, which drive the T cell response against cancer. 
 
Tumor antigens 
 Tumor antigens recognized by T cells have been discovered in patients with cancer and 
in experimental models of cancer (Novellino et al., 2005; Schreiber, 2003). These antigens can 
be broadly subdivided into two major classes: tumor-specific antigens (TSAs) and tumor-
associated antigens (TAAs) (Table 1). The significance of the class of antigen, whether it’s 
specific to the tumor or not, in determining the reactivity and function of T cells responding to 
cancers is the subject of great debate (Finn, 2008b; Parmiani et al., 2007; Schietinger et al., 
2008). TSAs are postulated to be better targets for immunotherapy because these antigens 
have been shown to be more immunogenic than TAAs and T cell responses against them do 
not pose the threat of inducing autoimmunity due to their exclusive expression in tumors. 
However, TSAs are usually specific to each individual’s cancer and thus necessitate 
personalized therapies, whereas TAAs have been identified in multiple types of cancer and 
present the potential for broad applicability to many patients and cancers. 
TABLE 1: Classification of tumor antigens 
Antigen Type: Class: Examples: 
Mutation Ras, CDK4, β-catenin 
Protein fusion BCR-ABL 
Viral HPV E6 and E7, EBNA-1 
Tumor-specific antigens 
Modified glycosylation Cosmc (mouse) 
Cancer-testis MAGE-1, NY-ESO-1 
Oncofetal CEA 
Differentiation Gp100, MART-1, Tyrosinase 
Tumor-associated antigens 
Overexpressed Her2/Neu, CycB, hTERT, p53 
Cryptic transcription Gp75 Non-classical antigens 
Protein splicing Gp100, FGF-5 
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Tumor-specific antigens 
 Antigens that are expressed uniquely in cancer cells represent enticing targets for 
cancer immunotherapy because of the potential for T cells to clearly differentiate cancer cells 
from normal cells. Tumor-specific antigens (TSAs) are the products of mutated proteins, fusion 
proteins, and viral proteins. The role of TSAs in the rejection of chemically-induced and UV-
induced mouse models of cancer has been appreciated since the 1950s (Schreiber, 2003). In 
seminal experiments in which a multitude of distinct carcinogen-induced tumors were screened 
for the capacity to provide protection from subsequent transplants after prophylactic vaccination, 
it was demonstrated that protection only occurred after vaccination with the same tumor 
(Mondal et al., 1970; Prehn, 1968). This provided the first evidence that the tumor antigens 
capable of eliminating cancers may be unique to each individual cancer. It wasn’t until several 
decades later that the first TSA arising from a mutation in a UV-induced mouse tumor was 
identified (Monach et al., 1995). In this case, the neoantigen required for tumor rejection was 
derived from a single point mutation in the L9 ribosomal protein. Although this mutation has not 
been identified to play a role in driving the development of cancer, mutations in the critical tumor 
suppressor p53 from methylcholanthrene-induced mouse sarcomas have also been shown to 
generate peptides that can be recognized by T cells (Noguchi et al., 1994). More importantly, 
several mutations have been identified in human cancers that are both oncogenic and antigenic, 
such as mutations in Ras (Fossum et al., 1994a; Fossum et al., 1994b; Fossum et al., 1995), 
CDK4 (Wolfel et al., 1995), CDC27 (Wang et al., 1999), and β-catenin (Robbins et al., 1996). 
These may be ideal targets for immunotherapy because the neoantigens are in fact essential for 
tumorigenesis, making it unlikely that tumors would lose expression of these proteins during the 
course of targeted immunotherapy (Cavallo et al., 2007). The recent sequencing of multiple 
cancer genomes has revealed that hundreds of point mutations exist in any given tumor, 
increasing the likelihood that one or more of these mutant proteins can be recognized by T cells 
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(Sjoblom et al., 2006). In fact, recent computational analyses, based on the cancer genomes 
from breast and colorectal cancer patients, predict that individual tumors harbor from 7-10 novel 
antigens capable of being presented to T cells on the most ubiquitous MHC class I allele (Segal 
et al., 2008). 
 Chromosomal rearrangements and translocations can generate new antigens through 
the fusion of normally distinct polypeptide sequences and are common in some cancers, 
especially hematopoietic malignancies. Indeed, T cells recognizing the BCR-ABL or TEL-AML1 
fusion proteins have been found in patients with chronic myelogenous leukemia or acute 
lymphoblastic leukemia, respectively (Novellino et al., 2005). 
 Finally, viral proteins produced by DNA viruses that stably integrate into the host cell’s 
genome and are associated with certain malignancies can serve as TSAs. Viral proteins from 
human papillomavirus (E6 and E7) expressed in cervical cancers, Epstein-Barr virus (EBNA-1) 
expressed in Burkitt's lymphoma and nasopharyngeal-carcinomas, and Hepatitis B virus 
expressed in hepatocellular carcinomas have all been found to be targeted by T cells in patients 
with these cancers (de Vos van Steenwijk et al., 2010; Finn, 2008a; Fogg et al., 2009; 
Schreiber, 2003). Although it would seem that viral antigens would instigate the most robust 
anti-tumor T cell responses, surprisingly, viral-peptide-specific T cells are found to be largely 
non-functional in cancer patients (de Vos van Steenwijk et al., 2010; Fogg et al., 2009). This 
may be the result of viral mechanisms of immune escape during the history of the infection, 
however, the inactivity of anti-tumor T cells is a characteristic of natural T cell responses to 
nearly all cancers, regardless of the class of tumor antigens targeted. 
 
Tumor-associated antigens 
Tumor-associated antigens (TAAs) represent antigens that can be recognized by T cells 
in patients with cancer, but are not exclusively expressed in tumors. The overwhelming data 
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from carcinogen-induced mouse tumors indicated that the antigens that cause tumor rejection 
were almost always unique to the individual tumors (Schreiber, 2003). Therefore, it came as a 
surprise when the first human tumor antigen identified in a patient with melanoma was the 
melanoma antigen (MAGE-1), a TAA (van der Bruggen et al., 1991). This class of antigens is 
grouped into four categories based primarily on their expression patterns in normal versus 
tumor tissues.  
MAGE-1 is now known as a cancer-testis antigen, a class of antigens that are normally 
only expressed in the male germline or the placenta but that are often re-activated and 
expressed in various tumors (Novellino et al., 2005). Cancer-testis antigens may have 
similarities to TSAs because they are expressed only in germ cells – tissues that do not express 
MHC molecules and are therefore not recognized by T cells. However, these antigens have also 
been found to be expressed in the thymus, making T cells potentially reactive to these antigens 
susceptible to mechanisms of central and peripheral tolerance, a caveat of all TAAs (Schietinger 
et al., 2008). Similar to cancer-testis antigens, oncofetal antigens, such as carcinoembryonic 
antigen (CEA), are normally expressed only in embryonic tissues but are also expressed in 
many cancers. Differentiation antigens represent antigens that are expressed in a specific 
lineage of cells that may also give rise to a tumor. These have mostly been characterized in 
melanoma, and melanocyte-specific genes, such as Gp100, MART-1, and Tyrosinase, 
exemplify this class of TAAs. Overexpressed antigens are ubiquitous antigens that are found to 
have elevated expression levels in tumors. Often these antigens are directly associated with the 
neoplastic state of the transformed cells (Finn, 2008b). Her2/Neu, p53, cyclin B1, and hTERT 
are examples of these overexpressed antigens. 
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Non-conventional tumor antigens 
In addition to TSAs and TAAs, a class of non-conventional, alternative tumor antigens 
resulting from abnormal transcripts or post-translational modifications have been recently 
defined. T cells have been found that recognize novel open reading frames initiated from non-
classical start codons in tumors (Schwab et al., 2003; Wang et al., 1996), and T cell clones have 
been isolated from cancer patients that recognize post-translationally spliced proteins (Hanada 
et al., 2004; Vigneron et al., 2004; Warren et al., 2006). These types of tumor antigens may 
represent a new type of target for anti-tumor T cells, though it remains to be seen whether these 
antigens are specific to cancer. In contrast to these examples, a unique TSA was recently 
described in a mouse fibrosarcoma that resulted from a mutation disrupting the function of a 
glycosyltransferase chaperone that altered the glycosylation of a protein and as a result, 
generated a neoantigen (Schietinger et al., 2006). In addition, loss of function mutations in 
multiple components of the machinery for generating peptides for presentation by MHC 
molecules, such as TAP and ERAAP, have been shown to lead to the presentation of novel 
immunogenic antigens that can be recognized by T cells in experimental tumor models 
(Hammer et al., 2007; van Hall et al., 2006). Therefore, it is clear that there are many routes to 
generating many types of tumor antigens in cancer. 
 
T cell priming 
Although the presence of tumor antigens is essential for T cell responses to cancer, 
potentially more relevant is the context in which the antigens are first encountered by T cells. 
The manner in which a naïve T cell first encounters its cognate antigen can directly influence a 
diversity of T cell fates including death, proliferation, effector function, anergy, trafficking, and 
memory development. The importance of proper priming for generating T cell responses against 
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tumor antigens is exemplified by the fact that in the absence of active vaccination against tumor 
antigens expressed in tumors, many patients lack T cells specific to these antigens. 
Exactly where and how T cells first encounter tumor antigens is an actively debated 
topic. Some of the earliest experiments using multiple types of transplantable mouse tumors 
indicated that T cells were primed directly by tumor cells after dissemination into lymph nodes 
and as a result, T cells remain “ignorant” of tumors (unprimed) until the latter stages of disease 
when tumor cells eventually metastasize to lymphoid organs (Ochsenbein et al., 1999; 
Ochsenbein et al., 2001). These conclusions were supported by early studies using transgenic 
mouse cancer models (RIP-Tag2) in which T cell responses to pancreatic β-cell tumors 
expressing a model TAA (LCMV-GP) were absent without a viral vaccination against the TAA to 
initiate a T cell response (Speiser et al., 1997). However, in subsequent, and more sensitive 
studies, it was determined that with increasing tumor burden, T cells were stimulated by the 
TAA in pancreatic tumors. More importantly, in this model, as well as other transplantable tumor 
models, priming did not occur by the direct recognition of tumor cells by T cells, but by bone 
marrow-derived antigen-presenting cells that had acquired the TAAs from the tumors and cross-
presented them to T cells in the tumor draining lymph nodes (Nguyen et al., 2002; Spiotto et al., 
2002). Although tumor cells may directly prime naïve T cells in certain contexts, the prevailing 
view is that bone marrow-derived dendritic cells are in fact responsible for the initial presentation 
of tumor antigens to T cells in lymph nodes (Dranoff, 2004). As such, dendritic cells (DCs) 
represent a critical link between tumors and T cells. DCs may ultimately be the master 
regulators of the anti-tumor T cell response because they can dramatically alter the potency of 
the T cell response depending on additional signals they supply to T cells during their initial 
encounter with antigen. 
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Dendritic cells prime T cell responses 
Just as T cells have evolved to respond to and eliminate foreign pathogens, DCs have 
evolved to prime T cell responses specifically in response to foreign intruders. Therefore, it is 
questionable whether DCs can induce productive T cell responses against tumors, and how 
they can do so, when their purpose is to respond to infections. Indeed, this remains to be a 
leading theory as to why anti-tumor T cell responses are so often ineffective; DCs do not 
adequately prime T cells to respond to tumors or DCs may even induce the differentiation of 
non-functional T cells specific for tumor antigens (Vicari et al., 2002).  
A clear difference between antigens acquired from a tumor and antigens acquired from 
the site of an infection is the presence of pathogen-associated materials and inflammation at 
sites of infections. To recognize foreign pathogens, DCs and other innate immune cells have 
evolved mechanisms to recognize various building blocks commonly used by many types of 
pathogens, but absent from the host organism, called pathogen-associated molecular patterns 
(PAMPs). PAMPs are recognized by a multitude of pattern recognition receptors (PRRs) on 
DCs and the ligation of PRRs and PAMPs on DCs can provide signals that instruct DCs to 
engulf antigens, migrate to lymph nodes, and fully prime T cells. The major class of PRRs are 
the Toll-like receptors (TLRs) that recognize a range of pathogen materials such as sugars 
(LPS) and certain nucleic acid structures such as unmethylated CpG DNA and double-stranded 
RNA (Rakoff-Nahoum and Medzhitov, 2009). The absence of such molecules in the 
microenvironment of tumors may limit inflammation and not allow for the proper maturation of 
DCs presenting tumor antigens. It has long been appreciated that antigen presentation by DCs 
in the absence of inflammation does not induce T cell responses (Jenkins and Schwartz, 1987). 
The recognition of PAMPs by DCs induces the upregulation of co-stimulatory molecules (B7-1 
and B7-2) on the surface of DCs and these provide a critical “second signal” to T cells (via 
CD28) that synergizes with TCR signals to fully activate T cells. The importance of PAMPs in 
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inducing anti-tumor immune responses is supported by experiments that have shown enhanced 
immunity to tumors by the administration of TLR ligands or by selective blockade of pathways 
found to negatively regulate TLR signaling in DCs (Shen et al., 2004; Verdeil et al., 2008; 
Whitmore et al., 2004). 
However, it is clear that T cells respond to many cancers and therefore, must not require 
PAMPs (Albert et al., 1998b; Preynat-Seauve et al., 2006). A breakthrough in our understanding 
of how this occurs came with the discovery of alternative, non-pathogenic ligands that could 
activate innate immune cells. These are collectively called danger-associated molecular 
patterns (DAMPs) and represent a means to alert the immune system of damage, stress, or cell 
death, traits common to many cancers, in the absence of infection (Gallucci et al., 1999; 
Gallucci and Matzinger, 2001; Petrilli et al., 2007). DAMPs have now been shown to contribute 
to DC activation and the induction of anti-tumor T cell responses against cancer in much the 
same way PAMPs can during infections, often utilizing the same receptors used to recognize 
microbial structures. During natural or chemotherapy-induced death of cancer cells, the 
translocation of calreticulin and phosphatidylserine (PS) to the surface of tumor cells can signal 
DCs to engulf the dying cells via the coordinated activities of scavenger receptors, such as 
CD36, CD91, and the PS receptor, and integrin αvβ5 (Albert et al., 1998a; Basu et al., 2001; 
Obeid et al., 2007). Uric acid released from dying cells can serve as a potent adjuvant, leading 
to the upregulation of costimulatory molecules on DCs (Shi et al., 2003). Heat shock proteins 
released or surface-exposed during tumor cell death have also been shown to induce the 
maturation of DCs (Asea et al., 2002; Chen et al., 2009; Feng et al., 2002; Millar et al., 2003), 
and DC recognition of high-mobility-group box 1 (HMGB1) released from dying tumor cells via 
TLR-4 can promote antigen processing and presentation (Apetoh et al., 2007). Finally, ATP 
shed during tumor cell death can induce an inflammatory response in the tumor 
microenvironment by activating the NLRP3 inflammasome in DCs (Ghiringhelli et al., 2009). 
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Therefore, there are a host of signals generated in the tumor microenvironment that can 
promote the functional maturation of DCs that acquire tumor antigens. Additionally, 
chemotherapeutic drugs may provide an enticing means for enhancing therapeutic anti-tumor T 
cell responses by magnifying these cues through increased tumor cell stress and death 
(Zitvogel et al., 2008). 
 
A role for CD4 T cell help 
Although DCs are essential for inducing CD8 T cell responses, CD4 (helper) T cells can 
play an important role in augmenting CD8 responses to pathogens and potentially cancers 
(Rocha and Tanchot, 2004; Toes et al., 1999). Like CD8 T cells, CD4 T cells utilize the TCR to 
recognize peptide antigens presented on major histocompatibility molecules. However, CD4 T 
cells engage a different class of MHC, MHC class II, that presents a distinct pool of peptides 
due to different characteristics of the MHC class II peptide-binding pocket. In addition, unlike 
MHC class I which is expressed on nearly all nucleated cells of the host, MHC class II 
expression is restricted to a select group of immune cells called professional antigen-presenting 
cells – DCs, B cells, and macrophages. Due to the unique role of CD4 T cells in interacting 
specifically with professional antigen-presenting cells, they are believed to be the key 
orchestrators of adaptive immune responses, guiding and regulating the cellular (CTL) and 
humoral (B cell) effector arms of the adaptive immune response. 
CD4 T cells have been found to be critical to the quality of CD8 T cell responses for 
quite some time, as a lack of CD4 T cells curtails or disrupts CD8 T cell responses in several 
settings (Cardin et al., 1996; Keene and Forman, 1982). How CD4 T cells help CD8 responses 
has since been narrowed primarily to the initial encounter of cross-presented antigens to CD8 T 
cells by DCs (Bennett et al., 1997). Upon encounter of its cognate antigen on a DC, a CD4 T 
cell can relay back to the DC a positive signal that boosts the activity of the DC to prime CD8 T 
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cell responses, a phenomenon called “licensing” (Lanzavecchia, 1998). This communication is 
mediated by the expression of CD40L at the surface of CD4 T cells that interacts with CD40 on 
DCs (Bennett et al., 1998; Ridge et al., 1998; Schoenberger et al., 1998). In response to self 
antigens expressed in tissues, it was demonstrated that while CD4 T cell licensing of DCs via 
the CD40/CD40L axis was required for CD8 proliferative responses, a second signal produced 
by DCs, the cytokine IL-12, was required for the acquisition of CD8 effector function (Hernandez 
et al., 2002). Although DC licensing by CD4 T cells has been shown in multiple situations, it is 
clear that in many scenarios, CD8 T cells do not require CD4 T cell help for efficient priming 
(Lanzavecchia, 1998). Instead, CD4 T cells have more recently been shown to play a critical 
role in setting up the proper differentiation of CD8 T cells into memory cells (Janssen et al., 
2003; Shedlock and Shen, 2003; Sun and Bevan, 2003). Finally, CD4 T cells can even play a 
role in helping CD8 T cells gain access (or home) to sites of infection (Nakanishi et al., 2009). 
Thus, in particular contexts, CD4 T cells can promote seemingly all facets of the CD8 T cell 
response. 
Indeed, CD4 T facilitation of CD8 responses against tumors has also been described in 
experimental models of cancer. Early experiments hinted that CD4 T cells were not efficiently 
primed by transplanted tumors expressing their cognate antigen, leading to the development of 
non-functioning, “anergic,” T cell responses (Staveley-O'Carroll et al., 1998). However, in the 
same experimental model, it was shown that in vitro activation of CD4 T cells into TH1 type 
effectors prior to their transfer could induce the rejection of tumors in a CD8 T cell-dependent 
manner (Nishimura et al., 1999b). Likewise, in a TRAMP autochthonous model of prostate 
cancer, naïve T cells were not adequately primed by the endogenous tumors. However, by 
inducing massive tumor apoptosis with androgen ablation, CD4 T cells responded to tumor 
antigens with a massive proliferative response and acquired effector functions (Drake et al., 
2005). Additional experiments in this model showed that effective anti-tumor immunity is 
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mediated by CD8 T cells, but that CD4 T cells were required to fully stimulate CD8 T cell 
priming by activating DCs via the CD40/CD40L axis (Shafer-Weaver et al., 2009). In response 
to endogenous pancreatic tumors in a RIP-Tag2 model, coordinate CD4 T cell responses were 
demonstrated to help prime naïve CD8 T cells to develop effector function and proliferate in 
response to antigen encounter (Lyman et al., 2004), as well as facilitate the accumulation of 
greater numbers of activated CD8 T cells in the tumors (Wong et al., 2008). 
 
T cell trafficking to tumors 
 In the final phase of detection, T cells activated in the lymph nodes that drain the tumor 
site must home back to and recognize the tumors. This presents yet another obstacle because 
as compared to sites of infection, the tumor microenvironment lacks foreign pathogens that can 
initiate inflammatory and chemotactic cues that normally direct the recruitment of immune cells. 
However, there is mounting evidence that cancers also may provide signals that recruit cells of 
the immune system.  
The activity of many oncogenes has been found to induce the expression of 
inflammatory molecules. Oncogenic K-ras mutations are among the most common genetic 
lesions in cancer. Experiments in human cell lines and autochthonous mouse models of lung 
cancer have shown that signaling by oncogenic K-ras directly activates the expression of the 
orthologous chemokines IL-8 and ENA-78 in humans or CXCL1 (KC), CXCL2 (MIP-2), and LIX 
(CXCL5) in mice (Ji et al., 2006; Sparmann and Bar-Sagi, 2004). Consequently, in vivo 
experiments showed that the expression of these cytokines in K-ras-expressing tumors led to 
the recruitment of immune cells (Sparmann and Bar-Sagi, 2004). Expression of the Src 
oncoprotein has been shown to activate the NF-κB pathway and lead to increased expression of 
the proinflammatory cytokine, IL-6 (Iliopoulos et al., 2009). In a similar fashion, the expression of 
the RET/PTC3 fusion protein, commonly found in thyroid cancers, could activate NF-κB as well, 
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but its expression was associated with the upregulation of the chemokine MCP1 and the 
cytokine GM-CSF (Russell et al., 2004). Tumor cell expression of CCL21, a chemokine normally 
associated with immune cell homing to lymphoid organs, is a common feature of several 
cancers and can lead to the recruitment of immune cells in tumors. However, expression of 
CCL21 has been associated with poor prognosis in patients with ovarian cancer and poor 
outcomes in mouse models of melanoma due to the preferential recruitment of immune 
regulatory cell populations (Curiel et al., 2004; Shields et al., 2010). From these studies it is 
clear that even the earliest steps of tumorigenesis – cellular transformation by oncogenes – may 
initiate a proinflammatory network of molecules that alerts the immune system and brings about 
the recruitment of immune cells to tumors. 
As tumors progress to more invasive stages of disease, it is speculated that disruptions 
to the normal architecture of organs (penetration of the basement membrane), tissue damage, 
and tumor cell death can all trigger the release of proinflammatory signals that beckon immune 
cells to cancers (Pardoll, 2003). Molecular cues may also alert immune cells to the stresses 
tumor cells undergo during their progression. The process of tumorigenesis itself has been 
shown to cause the upregulation of stress ligands, like the Rae-1 family and H60, in murine 
tumors due to the activation of DNA damage response (DDR) pathways in cancer cells (Gasser 
et al., 2005). Indeed, genomic instability and active DDR signaling are common features of most 
cancers (Jackson and Bartek, 2009). The homologous stress ligands MIC-A/B in human cells 
have also been found to be highly expressed on various forms of human cancers (Groh et al., 
1999). By engaging the NKG2D receptor on NK cells and T cells, these stress ligands can serve 
as instigators of anti-tumor immune responses by providing a complementary means (to TCR 
engagement) for immune cell detection of cancer cells in the tumor microenvironment (Raulet 
and Guerra, 2009). 
  39 
The capacity of CTLs to efficiently extravasate from blood vessels may also affect their 
ability to home to tumors. Extravasation from the blood vessels into tumors may be regulated by 
endothelin receptors. Low expression of endothelin B receptor (ETBR) on endothelial cells in 
ovarian cancers was associated with higher amounts of infiltrating T cells and ETBR antagonists 
improved CTL homing to tumors in transplantable mouse models of ovarian cancer 
(Buckanovich et al., 2008). The functionality of anti-tumor CTLs may also affect their ability to 
extravasate from the blood. TNF-α production from CD8 T cells was shown to be critical for their 
recruitment to mouse pancreatic tumors by mediating TNFR1-dependent upregulation of the 
adhesion molecule VCAM-1 on pancreatic endothelial cells, allowing for CTL extravasation into 
the tumor bed (Calzascia et al., 2007).  
T cell recognition of the peptide/MHC molecules on tumor cells to which they were 
originally primed is the final requirement for tumor detection. Two-photon microscopy studies 
that followed CTL migration into transplanted mouse tumors, in real time, found that the 
recognition of cognate antigen in tumors was the critical determinant for CTL recruitment in 
tumors, arguing against the importance of chemokine gradients for tumor infiltration by CTLs 
(Boissonnas et al., 2007; Mrass et al., 2006). In addition, the functionality of the CTLs may be 
critical for tumor cell detection. IFN-γ is known to upregulate the expression of MHC molecules 
on the surface of cells, and the capacity for T cells to secrete IFN-γ in the tumor 
microenvironment may be necessary for directly detecting the peptide/MHC molecules derived 
from tumor antigens on the surface of tumor cells (Riond et al., 2009). The importance of IFN-γ 
to CTL detection is supported by the fact that tumors expressing a dominant negative IFN-γ 
receptor are resistant to rejection after transplantation (Dighe et al., 1994). 
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B. Regulation 
 After T cells are primed in the tumor-draining lymph nodes, they migrate into the tumor 
and interact directly with tumor cells via TCR engagement of peptide/MHC molecules presenting 
tumor antigens. Here CTLs can kill tumor cells, providing the major mechanism for T cell-
dependent regulation of cancer. The ways in which T cells may kill tumor cells upon 
engagement is no different than responses during the engagement and killing of pathogen-
infected cells. T cell cytotoxicity is mediated by either of two pathways, the perforin/granzyme 
pathway or the FasL/Fas pathway (Kagi et al., 1994b; Lowin et al., 1994b). Both pathways 
ultimately converge through the activation of caspases that induce apoptosis in targeted cells. 
Perforin and granzymes are contained within lytic granules in CTLs and they are released into a 
synaptic cleft that forms between T cells and target cells as a consequence of TCR 
engagement. Perforin polymerizes to form pores in target cells, causing membrane 
destabilization as well as supporting the entry of serine proteases called granzymes. The 
granzymes, particularly granzyme B, cleave several substrates, including multiple caspases, 
initiating a pro-apoptotic cascade in target cells. T cells from mice deficient for perforin by gene 
targeting have greatly diminished cytotoxic activity in vitro and in vivo (Kagi et al., 1994a; Lowin 
et al., 1994a). CTLs also induce apoptosis of target cells by engaging the Fas receptor (CD95 or 
Fas/APO-1) with Fas ligand (FasL). FasL on T cells can activate Fas on target cells, leading to 
the recruitment and activation of caspase-8 through the Fas-associated death domain of Fas, 
initiating apoptosis. The importance of these two pathways in mediating tumor cell death and 
cancer regulation has been highlighted in various experimental cancer models. 
 
Direct killing of tumor cells 
 Indeed, the first report of perforin knockout mice included experiments that showed a 
decreased capacity to control the growth of transplanted fibrosarcomas (Kagi et al., 1994a). 
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Subsequent work found similar results with a multitude of cell lines from multiple origins and 
also showed that tumor induction with the carcinogen methylcholanthrene (MCA) was enhanced 
in perforin-deficient mice (though apparently in a CTL-independent fashion) (van den Broek et 
al., 1996). Perforin-deficient mice also have an increased incidence of spontaneous 
disseminated lymphomas in p53 wild-type as well as p53 heterozygous backgrounds and tumor 
protection appears to be CD8 T cell-dependent (Smyth et al., 2001). The importance of 
granzymes in mediating tumor cell killing was demonstrated when the overexpression of a 
serpin (SPI-6, an inhibitor of granzymes) in a T cell lymphoma protected the transplanted 
tumors from CTL-mediated killing (Medema et al., 2001). In a similar experimental fashion, the 
overexpression of cFLIP, an inhibitor of Fas-mediated cell death, in tumor cells lines allowed the 
outgrowth of tumors that were normally rejected by CTLs (Medema et al., 1999). Two-photon 
imaging of CTL-mediated tumor regression has been recently documented in vivo (Boissonnas 
et al., 2007; Breart et al., 2008; Mrass et al., 2006). In these studies, investigators could 
visualize that direct contacts between individual CTLs and tumor cells immediately preceded 
tumor cell apoptosis (Breart et al., 2008; Mrass et al., 2006). Therefore, CTLs can regulate 
cancer by inducing apoptosis in tumor cells after making direct cell-cell contacts. 
 
Cytokine-mediated cancer regulation 
 Complementing these direct pathways of inducing target cell death, cytokine release by 
T cells upon target cell recognition is also a critical effector function of T cells. Cytokines 
released by T cells may orchestrate the responses of other immune cells, induce the expression 
of adhesion molecules on target cells, alter the expression or activity of proteins responsible for 
antigen processing and presentation on target cells, or even affect the proliferative capacity of 
target cells. The production and secretion of two key effector cytokines, IFN-γ and TNF-α, have 
been shown to be important in the regulation of cancer, though the mechanisms of action are 
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not as clear. IFN-γ receptor-deficient mice (IFNGR1-/-) develop MCA-induced sarcomas with an 
increased penetrance and decreased latency compared to wild-type mice and develop 
spontaneous tumors with decreased latency in a p53-deficient background (Kaplan et al., 1998). 
IFNGR1 expression was found to be critical in the tumor cells themselves and restoration of the 
receptor in tumor cell lines made the tumors susceptible to rejection by adaptive immune cells, 
presumably T cells, in an IFN-γ-dependent manner (Kaplan et al., 1998). Spontaneous 
development of lymphomas was also increased in IFN-γ-deficient mice, although the critical 
cells lacking IFN-γ that contribute to the increased cancer predisposition (tumor cells or T cells) 
could not be determined (Street et al., 2002). Although TNF-α-deficient mice do not have an 
increased incidence of lymphomagenesis (Street et al., 2002), and TNF-α deficiency in mice 
has been shown to actually reduce the experimental induction of skin cancer (Moore et al., 
1999), the incidence of MCA-induced sarcomas was enhanced in the absence of TNF-α (Swann 
et al., 2008). More importantly, studies in which TNF-α deficiency was targeted specifically to 
the anti-tumor CTLs showed that TNF-α production from CTLs is essential for the regulation of 
endogenous pancreatic tumors (Calzascia et al., 2007). In a transplantable fibrosarcoma model, 
secretion of IFN-γ and TNF-α from anti-tumor CTLs that were activated and transferred into 
tumor-bearing mice was necessary to cause the complete regression of established tumors 
(Zhang et al., 2008a). In addition, production of IFN-γ and TNF-α by CD4 T cells was shown to 
regulate tumor proliferation by inhibiting tumor angiogenesis in a transplantable sarcoma model 
as well as an endogenous pancreatic cancer model (RIP-Tag2) (Muller-Hermelink et al., 2008; 
Qin and Blankenstein, 2000). Therefore, effector cytokines also provide a critical means of 
regulating cancer. 
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NKG2D receptor mediated anti-tumor T cell activity 
 In addition to its role in detecting tumors, the NKG2D receptor can also act to further 
stimulate the activity of the anti-tumor T cell response. Enforced expression of NKG2D ligands 
on tumor cells led to enhanced CTL-mediated cytotoxicity in vitro and tumor rejection in vivo 
(Diefenbach et al., 2001). Treatment of mice with antibodies that block NKG2D interactions with 
its ligands enhanced the penetrance of MCA-induced sarcomagenesis in a manner that was 
dependent on adaptive immune cells, implying that NKG2D activity is critical in controlling the 
initiation of cancer (Smyth et al., 2005). However, NKG2D-deficient mice had a reduced 
capacity to control the progression of cancer in prostate (TRAMP) and lymphoma (Eµ-myc) 
models, indicating that the activity of NKG2D on T cells may also influence their capacity to 
regulate cancer progression (Guerra et al., 2008). 
 
 
C. Evasion 
 The fact that cancer is a leading cause of morbidity worldwide indicates that the immune 
response must ultimately be ineffective in preventing the incidence or progression of this 
disease. Therefore, if a T cell response against a tumor is induced, ultimately mechanisms must 
arise that allow the tumor to evade this response. Two competing, but not mutually exclusive, 
theories to account for the evasion of T cell responses by tumors have been postulated. The 
first, called cancer immunoediting, hypothesizes that just as tumors evolve to bypass intrinsic 
cellular pathways that inhibit tumorigenesis, tumors also evolve to bypass extrinsic mechanisms 
of tumor suppression, such as anti-tumor immune responses, during the course of their 
development. Therefore, tumors are “shaped” by anti-tumor immune responses and this can be 
exemplified by identifying changes in tumor cells that make them less susceptible to immune 
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recognition and destruction. The second hypothesis, called immune tolerance, asserts that T 
cell responses to cancer are likely to be fundamentally different than responses to acute 
pathogenic infections which the immune system has evolved to resist (Restifo et al., 2002). As a 
consequence, immune responses against cancer are incomplete and ultimately result in the 
immune tolerance of the cancer. Similarities in immune phenotypes in response to cancer and 
chronic infections have been described (Pardoll, 2002). It is possible that immune tolerance to 
cancer results from the induction of immune regulatory pathways that have evolved to prevent 
autoimmune disease in the setting of chronic immune responses toward self tissues or 
persistent disease. 
 
i. Cancer Immunoediting 
 The term immunoediting, although described indirectly for many years, was only recently 
coined by Robert Schreiber and colleagues in 2001 (Shankaran et al., 2001). Evidence of 
immunoediting in human and mouse cancers can be measured by the occurrence of disruptions 
in nearly all of the critical parameters previously described in this section. Seemingly every facet 
of a productive immune response to cancer, from the expression of T cell-targeted tumor 
antigens, to the proper priming, homing and effector function of anti-tumor T cells, have been 
found to be subverted in one way or another by various cancers. Although there is a wealth of 
evidence for cancer immunoediting in response to multiple immune cell populations, I will only 
focus on immunoediting in response to anti-tumor T cell responses here. For the purposes of 
organization, I have classified examples of immunoediting into two forms: those that are 
recessive, arising passively by immunoselection and those that act in a dominant fashion, 
actively suppressing T cell responses. 
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Immunoediting by passive selection 
 The clearest example of cancer immunoediting is the selective outgrowth of tumors that 
have lost the expression of antigen(s) targeted by T cells, thereby preventing T cell recognition 
of the tumor (Khong and Restifo, 2002). This has been described extensively in mouse cancer 
models and also in the context of active immunotherapy against specific antigens in cancer 
patients. The first descriptions of antigen loss as a mechanism by which tumors could be 
selected that were resistant to rejection came from the laboratories of Thierry Boon and Hans 
Schreiber (Urban et al., 1982; Uyttenhove et al., 1983). Using different types of transplantable 
tumors, P815 mastocytoma or UV-induced fibrosarcoma, both groups showed that tumors 
capable of growing out after transplantation into syngeneic mice had selectively lost the 
antigenic determinants required for CTL killing and showed that the “antigen-loss variants” had 
increased tumorigenicity upon secondary transplantation. More recent studies have indicated 
that reductions in target antigen expression in tumors in combination with decreased T cell 
activity may be sufficient to allow transplanted renal cell tumors to escape (Zhou et al., 2004). 
Thus, combinations of immunoediting mechanisms may be involved in tumor evasion. In 
melanoma cancer patients receiving immunotherapy, specific reductions in the expression of 
the targeted antigens have been noted, providing evidence that immune selection of antigen-
loss variants also occurs in cancer patients (Jager et al., 1996; Riker et al., 1999).  
 Thus some caution must be lent to the hope that T cell-based immunotherapy can 
ultimately cure cancer. However, it is possible that by targeting multiple tumor antigens 
simultaneously, the likelihood of tumor escape via antigen-loss may be dramatically reduced 
(Schreiber, 2003). Alternatively, recent work has shown that tumor antigen-loss variants can still 
be destroyed indirectly by anti-tumor T cell responses (Spiotto et al., 2004; Zhang et al., 2007; 
Zhang et al., 2008b). T cell-mediated destruction of stromal cells that cross-present the tumor 
antigens in the tumor microenvironment could also lead to tumor eradication (Spiotto et al., 
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2004). In Chapters 2 and 3 of this thesis, I will discuss the role of antigen loss as a mechanism 
of tumor evasion and provide data to support the contention that the type of cancer, and the 
model used – autochthonous or transplantable, can greatly influence whether antigen-loss 
occurs in the tumors. 
 Similar to the selective loss of antigens targeting T cell responses to tumors, selective 
loss of the machinery required to present the peptide antigens at the surface of tumor cells 
would also impede T cell recognition of cancer cells. Early experiments using the transplantation 
of UV-induced tumors, however, failed to demonstrate a loss of surface expression of the MHC 
proteins on progressively growing tumors (Ward et al., 1990). Furthermore, mice deficient in 
antigen processing by targeted mutation of TAP-I (transporter associated with antigen 
processing) or LMP-2 (a component of the 20S proteasome) were not found to be more 
susceptible to spontaneous tumor development in the context of p53 deficiency (Johnsen et al., 
2001). Despite these examples in mice, there are numerous pieces of data from human cancers 
that suggest a selective pressure is in place that drives the outgrowth of cancers with defects in 
antigen presentation (Algarra et al., 2004; Chang and Ferrone, 2007; Khong and Restifo, 2002; 
Pardoll, 2003; Restifo et al., 1993). 
 Reduced surface expression of MHC class I alleles is a common feature of multiple 
cancers of epithelial origin (Hicklin et al., 1998; Maeurer et al., 1996b; Restifo et al., 1993; 
Sanda et al., 1995). Furthermore, reductions in MHCI on the surface of tumors can often be 
correlated with the progression of the disease, with metastatic tumors having the lowest levels 
of MHCI expression (Cromme et al., 1994b; Maeurer et al., 1996a; Vitale et al., 1998). The 
ability of many cancer cell lines to re-express MHCI upon manipulation with cytokines such as 
IFN-γ in vitro indicates that MHCI down modulation may frequently be epigenetic in nature 
(Khong and Restifo, 2002; Pardoll, 2003; Raffaghello et al., 2005). However, there are also 
numerous examples of mutations that permanently inactivate antigen processing or 
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presentation in human cancers, such as disruption of β2 microglobulin a common component 
required for the stability of all MHCI alleles (Chang et al., 2006; Chen et al., 1996a; Chen et al., 
1996b; Cromme et al., 1994a; Hicklin et al., 1998). A study of human neuroblastoma tumor 
samples examined multiple components of the antigen-processing and presentation machinery 
using mRNA expression and a panel of antibodies to multiple different components. They 
reported that defects in different components accounted for disrupted antigen presentation in 
each tumor (Raffaghello et al., 2005).  Evidence that the modifications in antigen presentation 
identified in human cancers are in fact mechanisms providing for tumor evasion of T cell 
responses can only be correlative, but it is intriguing that multiple studies have found that 
disruptions in antigen processing and presentation in many different forms of cancer are 
associated with poorer prognoses for patients (Anichini et al., 2006; Leys et al., 2007; Ogino et 
al., 2006). 
 
Immunoediting by active mechanisms of immune suppression 
 By definition, all edited tumors arise as a consequence of selective forces imposed by 
the immune system. However, in this form of immunoediting, cancers are selected that have 
acquired a new capacity to thwart the anti-tumor T cell response rather than become inert or 
invisible to responding T cells. A tremendous wealth of research has been aimed at identifying 
mechanisms by which tumors evade T cell responses by inducing immune suppression, far too 
many to examine all of them here (for a more complete review see: (Rabinovich et al., 2007)). 
Therefore I will limit this section to only a few mechanisms of tumor-induced immune 
suppression that highlight the diversity of ways tumors can evolve to evade T cell responses. 
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Altered expression of immune modulatory ligands 
Costimulatory receptors expressed on T cells are likely critical for the efficient execution 
of effector function upon encounter of tumor cells. However, T cells also express inhibitory 
receptors that act to moderate T cell responses and prevent the occurrence of autoimmune 
reactions. A key mechanism of tumor evasion of T cell responses is the co-opted expression of 
ligands for these inhibitory receptors (Zou and Chen, 2008). The first example of tumor evasion 
by over-expressing a ligand recognized by T cells was paradoxically the MIC-A/B ligands. 
Indeed, these are stimulatory ligands for the NKG2D receptor, but in patients with various forms 
of cancer that over-expressed MIC-A/B, these ligands were found to be shed from the tumors 
(Groh et al., 2002). Soluble MIC-A/B was discovered to bind NKG2D and cause its 
internalization, thus reducing NKG2D expression on the surface of anti-tumor T cells and 
presumably decreasing the CTLs capacity to kill tumor cells. Further work from Spies and 
colleagues has provided evidence that soluble MIC-A/B may also serve to recruit a unique 
population of CD4+ T cells that have immunosuppressive activities (Groh et al., 2006). 
 The best characterized over-expressed T cell inhibitory ligand on cancers it B7-H1, or 
programmed cell death ligand 1 (PD-L1). PD-L1 expression on tumor cells can engage PD-1 
expressed on T cells to transmit inhibitory signals that disrupt the anti-tumor CTL effector 
function (Blank et al., 2004). In the original work implicating B7-H1 in tumor evasion, it was 
demonstrated that B7-H1 over-expression on tumor cells could direct the apoptosis of 
responding CTLs (Dong et al., 2002). Subsequent work has shown that B7-H1 may also serve 
as an autocrine signal in tumor cells to promote cell survival and resistance to T cell-mediated 
cytotoxicity (Azuma et al., 2008). In any case, common oncogenic mutations have been shown 
to directly feed into the upregulation of B7-H1 on tumors (Marzec et al., 2008; Parsa et al., 
2007), and the over-expression of B7-H1 is associated with poor prognosis in patients with renal 
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cell carcinoma as well as many other forms of cancer (Thompson et al., 2006; Zou and Chen, 
2008). 
The inhibitory receptor B and T lymphocyte attenuator (BTLA) expressed on T cells can 
also be engaged by tumor cell expression of its ligands. Although there is some disagreement 
about the ligands for BTLA (Sedy et al., 2005; Watanabe et al., 2003), both predicted ligands 
B7x and HVEM are found to be upregulated on various cancers, and BTLA was found highly 
expressed on melanoma-antigen-specific CTLs in melanoma patients (Derre et al., 2010; Zang 
et al., 2003). In addition, B7x expression on prostate cancers correlates with a poor prognosis 
(Zang et al., 2007), and like the MIC-A/B ligands, B7x has been found at high concentrations in 
the serum of renal cell carcinoma patients (Thompson et al., 2008). 
  
Secretion of immunosuppressive molecules 
 A characteristic feature of cancer is the mass production and secretion of transforming 
growth factor-β (TGFβ) (Flavell et al., 2010; Siegel and Massague, 2003). TGFβ was originally 
thought to impede cancer progression by binding TGFβ receptors on tumor cells and signaling 
growth inhibitory signals to tumor cells via activation of the SMAD transcription factors (Siegel 
and Massague, 2003). This hypothesis was confirmed by the frequent detection of inactivating 
mutations in TGFβ receptors in human colon carcinomas or deletions of SMAD4/DPC4 in 
pancreatic carcinomas (Hahn et al., 1996; Markowitz et al., 1995). However, TGFβ signals are 
now recognized to have pleiotropic effects in cancer progression, potentially acting to suppress 
tumorigenesis early, and then acting to promote the process later through inhibition of anti-
tumor immune responses (Siegel and Massague, 2003; Yang and Moses, 2008). TGFβ 
production by tumor cells has been shown to inhibit CTL effector function by inducing SMAD 
transcription factors to bind and inhibit the expression of multiple genes involved in cytolytic 
activity in CTLs such as granzyme A, granzyme B, Fas ligand (FasL), and IFN-γ (Thomas and 
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Massague, 2005). Furthermore, CTLs recovered after peptide vaccination of melanoma patients 
had reduced capacity to secrete IFN-γ and TNF-α or upregulate the expression of the T-bet 
transcription factor (a marker of effector function) by the addition of TGFβ in vitro (Ahmadzadeh 
and Rosenberg, 2005). Acting as a growth inhibitor, tumor-derived TGFβ can also reduce the 
proliferative capacity of anti-tumor CTLs in mouse models (Gorelik and Flavell, 2001). Most 
importantly, inhibition of TGFβ signaling specifically in tumor-reactive CTLs can lead to tumor 
protection or eradication in transplantable mouse cancer models (Gorelik and Flavell, 2001; 
Zhang et al., 2005a).  
 In addition to TGFβ, tumor production and/or secretion of multiple other proteins or 
metabolites are associated with tumor-induced immune suppression. Tumors produce vascular 
endothelial growth factor (VEGF) and prostaglandin E2 (PGE2), generated in excess by 
heightened expression of the enzyme cyclooxygenase-2 (COX-2), both of which can inhibit APC 
maturation (Khong and Restifo, 2002; Zou, 2005). Tumor production of the enzyme indoleamine 
2,3-dioxygenase (IDO) can lead to the depletion of tryptophan in the tumor microenvironment, 
reducing the proliferative capacity of anti-tumor CTLs or potentially inducing apoptosis 
(Uyttenhove et al., 2003). Interestingly, blockade of IDO in transplantable mouse cancer models 
using competitive inhibitors or RNA interference could lead to tumor regression (Uyttenhove et 
al., 2003; Zheng et al., 2006). Thus there are many examples from mouse models and cancer 
patients that indicate tumor-derived molecules are produced as a means of tumor evasion. 
 
Recruitment of immunoregulatory cells 
 Tumor-induced recruitment of immunoregulatory cells is now considered to be the critical 
mechanism underlying tumor evasion in multiple settings (Nagaraj and Gabrilovich, 2008; 
Rabinovich et al., 2007; Zou, 2006). T regulatory cells (Tregs), defined by the surface expression 
of CD4 and CD25 and the lineage-specific transcription factor Foxp3, may be the most critical 
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immunoregulatory cell population recruited to the tumor microenvironment to suppress anti-
tumor CTL responses from their initial priming in the DLN to their effector function upon 
encounter with tumor cells (Zou, 2006). Even before Tregs were implicated in human cancer, the 
mere discovery of Tregs led to experiments that showed that the specific depletion of these cells 
could promote the rejection of transplanted tumors (Sakaguchi et al., 1995; Shimizu et al., 
1999). Since then, numerous studies have found that Tregs are specifically recruited to the tumor 
microenvironment in patients with various forms of cancer and that their presence is associated 
with poor outcomes (Curiel et al., 2004; DeLong et al., 2005; Liyanage et al., 2002; Viguier et 
al., 2004; Woo et al., 2001). Recruitment is likely a direct consequence of chemokine 
production, such as CCL21 or CCL22, in tumor cells that preferentially attract these 
immunosuppressive cells (Curiel et al., 2004; Shields et al., 2010). Tregs from cancer patients 
have been demonstrated to potently inhibit the proliferation of tumor-infiltrating lymphocytes 
(TILs) in an antigen-specific manner (Bonertz et al., 2009; Wang et al., 2004; Woo et al., 2002). 
In mouse models of cancer, Tregs have also been shown to block the priming phase of CD8 T 
cell responses (Ercolini et al., 2005). In addition to blocking T cell activation, Tregs can block the 
effector function of TILs (Chen et al., 2005). In one particular study, Tregs were shown to prevent 
the degranulation of lytic vesicles, thus blocking the final stage of T cell-mediated cytotoxicity 
(Mempel et al., 2006). Additional mechanisms by which Tregs can mediate the suppression of 
anti-tumor CTLs include TGFβ secretion, direct cell-cell contacts, and competition for growth 
signals such as IL-2 (Zou, 2006).  
 Myeloid-derived suppressor cells (MDSCs), defined as Gr-1+CD11b+ cells in mice, 
represent a diverse population of antigen-presenting cells (APCs) that like Tregs, are T cell-
suppressive in nature and often found in association with tumors (Nagaraj and Gabrilovich, 
2008; Zou, 2005). Although MDSCs are APCs, they seem to inhibit anti-tumor CTL responses in 
an indirect manner. MDSCs have been shown to interfere with the initial priming of T cells in 
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tumor-draining lymph nodes (DLNs) by the secretion of TGFβ which can directly inhibit the 
proliferation of CD8 T cells or indirectly inhibit the CD8 response by promoting the proliferation 
of Tregs (Ghiringhelli et al., 2005; Yang and Moses, 2008). MDSC production of nitric oxide (NO), 
which can disrupt IL-2 receptor signaling, and IFN-γ production can also suppress T cell 
proliferation in tumor DLNs (Kusmartsev et al., 2000; Mazzoni et al., 2002; Movahedi et al., 
2008). MDSCs in the tumor bed can suppress the cytolytic activity of T cells by producing TGFβ 
(Terabe et al., 2003) or by disrupting the capacity of the TCR-CD8 complex to interact with 
peptide/MHC on tumor cells (Nagaraj et al., 2007). Interestingly, by producing reactive oxygen 
species and peroxynitrite that induce the nitration of tyrosines in the TCR complex, MDSCs 
were found to impede TCR engagement of peptide/MHC (Nagaraj et al., 2007). Finally, it is 
important to note that MDSCs have been shown to also directly enhance tumor progression by 
promoting tumor vascularization and metastasis (Yang et al., 2004; Yang et al., 2008). As of yet, 
it is unclear what signals drive the accumulation of MDSCs in tumors and tumor DLNs, but 
experiments ex vivo with tumor cell lines at least suggest that tumor-derived factors can be 
secreted that induce the suppressive phenotype of MDSCs (Ghiringhelli et al., 2005).  
 
Inhibition of immune cell migration in tumors 
Limited T cell access to tumors has long been considered a mechanism by which tumors 
escape CTL responses. Experimental systems in mice indicate that promoting T cell migration 
into tumors artificially by the enforced expression of the TNF family member LIGHT, can 
dramatically improve anti-tumor CTL responses to transplanted tumors (Yu et al., 2004). 
Although potentially useful for immunotherapeutic strategies, such experiments do not indicate 
that tumors actively engage in mechanisms to block the migration of immune cells to evade T 
cell responses. However, as mentioned previously while describing T cell detection of tumors, 
the expression of endothelin B receptor (ETBR) on endothelial cells in human ovarian cancers 
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was found to correlate with reduced T cell infiltration into tumors and reduced patient survival 
(Buckanovich et al., 2008). It is speculated that ETBR may be upregulated in the tumor 
vasculature as a direct consequence of over-expression of the ligand, endothelin-1 (ET-1) 
(Buckanovich et al., 2008). Indeed, endothelins have been found to be overexpressed in 
multiple cancers (Nelson et al., 2003). Alternatively, tumor expression of liver X receptor (LXR) 
ligands can prevent the migration of dendritic cells (DCs) out of the tumor site by causing the 
down-modulation of the chemokine receptor CCR7 required for lymph node migration 
(Villablanca et al., 2010). Thus, tumors evaded the immune system by preventing the migration 
of DCs to lymph nodes where they could initiate an anti-tumor T cell response. 
 
ii. Immune tolerance of cancer 
 The idea that tumor evasion of T cell responses occurs as a result of the selective 
evolution of tumors that can hide from or suppress T cell responses is not universally accepted 
(Restifo et al., 2002). Indeed a large body of literature supports the idea that T cell responses to 
cancer are incomplete or wither away as a result of natural immune regulatory networks that are 
in place to prevent inappropriate immune responses that are harmful to the host. Thus T cell 
responses against cancer may become inactivated by mechanisms that normally prevent 
autoimmune disease. In this light, it may not be surprising that T cell responses against cancer 
have many features in common with T cell responses against pathogens during chronic 
infections (Kim and Ahmed, 2010; Pardoll, 2002). In both cases, a persistent and prolonged 
immune response may trigger the induction of tolerance (or exhaustion) as a means to prevent 
what may be “perceived” as autoimmune reactions. This may be why successful 
immunotherapy in cancer patients is so often associated with autoimmune side effects (Caspi, 
2008). Here I will briefly discuss some evidence to support the contention that autoregulation of 
anti-tumor immune responses provides an alternative explanation for tumor evasion. 
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Importantly, autoregulatory mechanisms may complement, rather than exclude, tumor-intrinsic 
mechanisms of immune evasion. 
 
Tolerance phenotypes are characteristic of anti-tumor T cells  
 In response to multiple forms of cancer in humans as well as autochthonous mouse 
cancers, tumor-specific T cells commonly exhibit features associated with tolerance or 
exhaustion (Anderson et al., 2007; Bai et al., 2008; Cheung et al., 2008; de Vos van Steenwijk 
et al., 2010; Inokuma et al., 2007; Kuss et al., 2003; Lyman et al., 2004; Roberts et al., 2009; 
Savage et al., 2008; Willimsky and Blankenstein, 2005). These characteristics most often 
include a decreased capacity to produce effector cytokines, such as IFN-γ, TNF-α, or IL-2, and 
a reduced ability to kill target cells in vivo or in vitro. Such characteristics are identical to those 
of viral-specific T cells during chronic infections (Wherry and Ahmed, 2004; Wherry et al., 2003). 
Decreased functionality is often associated with high surface expression of the PD-1 inhibitory 
receptor on T cells, considered to be a bona fide marker of exhausted T cells (Bai et al., 2008; 
Barber et al., 2006; Day et al., 2006; Wherry et al., 2007). Importantly, PD-1, along with CTLA-4 
and LAG-3, which are also inhibitory receptors upregulated on tumor-specific and chronic viral-
specific T cells, appear to play functional, albeit distinct roles, in maintaining the tolerant state of 
the T cells. This is supported by experiments in which antibody blockade of receptor-ligand 
interactions greatly restored CTL activity in the context of chronic viral infections or cancer 
(Barber et al., 2006; Freeman et al., 2006; Grosso et al., 2009; Grosso et al., 2007; Kaufmann 
and Walker, 2009; Liakou et al., 2008). Nevertheless, these inhibitory pathways did not evolve 
to suppress potentially beneficial T cell responses against viruses and cancers; they most likely 
evolved as safety mechanisms to prevent autoimmune reactions. This is exemplified by the fact 
that mice with targeted disruptions in these receptors (CTLA-4 or PD-1), or in some cases their 
ligands (PD-L1/2), all have various forms of autoimmune disease (Keir et al., 2006; Nishimura et 
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al., 1999a; Waterhouse et al., 1995). These autoimmune reactions are triggered by the 
breakdown of pathways mediated by these receptors that establish or maintain the peripheral 
tolerance of T cells, i.e. after development in the thymus (Fife et al., 2006; Martin-Orozco et al., 
2006; Perez et al., 1997). Therefore, many of the inhibitory pathways engaged on most tumor-
reactive T cells are the same pathways that are critical for maintaining tolerance to host tissues. 
 
Chronic antigen exposure drives T cell tolerance 
 It is essential to the host that the immune system properly regulates the induction of 
immunity or tolerance; therefore, specific signals must be responsible for instructing T cells to 
switch to a tolerant state in response to cancer. One potential mechanism to explain tolerance 
induction in both cancer and chronic infections is prolonged exposure to antigen (Kim and 
Ahmed, 2010). Persistent antigen exposure has long been known to induce tolerance or 
exhaustion in reactive T cells (Redmond and Sherman, 2005). Recent work utilizing two 
different models of chronic viral infection in mice showed that persistent exposure to antigen 
was sufficient to drive T cell exhaustion (Bucks et al., 2009; Mueller and Ahmed, 2009). 
Therefore, T cell responses to cancer may be influenced by immune regulatory pathways that 
have evolved to terminate T cell responses to antigens that persist as a means to prevent 
autoimmune disease. 
 
 
IV. TUMOR IMMUNE SURVEILLANCE IN CANCER PATIENTS 
 
 Evidence presented in the previous section provides overwhelmingly support for the 
contention that T cells can recognize and respond to many forms of human cancer. The fact that 
human cancers often have reduced expression (or mutations) in proteins related to antigen 
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processing and presentation provides some coincidental evidence that human cancers may be 
under the selective pressure of T cell responses. However, the role of anti-tumor T cells in 
regulating cancers in these patients has not been fully addressed. Several lines of investigation 
point to a clear role of tumor immune surveillance in the human population by: (1) examining the 
incidence of cancer in genetically or pharmacologically immunosuppressed individuals, (2) 
looking at the degree of T cell reactivity (and T cell phenotypes) in individual cancers and 
correlating the T cell response to patient outcome, and (3) interpreting the results of multiple 
clinical trials utilizing various forms of immunotherapy to treat cancer. 
 
Cancer in genetically or pharmacologically immunosuppressed patients 
Just as the importance of immune surveillance against cancer was revealed in various 
immune-compromised mice, individuals with inherited immune deficiencies or patients receiving 
immunosuppressive drugs to tolerate organ transplants can provide evidence to support tumor 
immune surveillance in humans. However, analyzing sporadic tumor formation in people with 
immunodeficiencies presents several important complications. First, it is important to consider 
that most animal studies providing evidence for tumor immune surveillance used high doses of 
carcinogens to rapidly provoke a very high incidence of cancer, a phenomenon that occurs 
rarely in the human population (see review: (Dunn et al., 2006)). In addition, the few animal 
studies that did examine spontaneous tumor development were often performed in a tumor-
prone background such as p53 deficiency, a characteristic uncommon to the majority of human 
cancers (Dunn et al., 2006). Therefore, the evidence from mouse models of increased 
spontaneous tumor development with immune deficiency is sparse. Second, in the few cases 
where enhanced tumorigenesis was found in immune-compromised mice, it was necessary to 
age the animals for extended periods of time to detect spontaneous cancers (Shankaran et al., 
2001; Street et al., 2002). Indeed, spontaneous cancers typically arise late in life, making similar 
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observations in the human population difficult because genetically comparable, severely 
immune-compromised individuals do not typically live past their fourth decade (Pardoll, 2003). 
Third, immune-compromised individuals are inherently more susceptible to various infections. 
This leads to a substantially increased incidence of cancers that are pathogen-induced, 
potentially obscuring the incidence of spontaneous cancers that could arise with a greater 
latency in these individuals (Schreiber, 2003). Nevertheless, immune-compromised individuals, 
either genetically or pharmacologically, are much more susceptible than the general population 
to develop certain types of lymphomas, sarcomas, or epithelial cancers of the stomach or cervix 
(Penn, 1988). However, as is the case with individuals with acquired immune-deficiency 
syndromes (AIDS), it is clear that all of these cancers are pathogen-associated – herpesvirus-8 
with Kaposi’s sarcoma, Epstein-Barr virus with non-Hodgkin’s lymphoma, human papillomavirus 
with cervical cancer, hepatitis B virus with hepatocellular carcinoma, and Helicobacter pylori 
with gastric cancer (Boshoff and Weiss, 2002). The most common cancers of the general 
population – epithelial cancers of the lung, colon, prostate, or breast – are not typically 
increased in these individuals. However, there is some evidence from long-term analyses of 
immune-suppressed patients receiving organ transplants that they also have an increased risk 
of developing epithelial cancers of nonviral etiology (Dunn et al., 2004b; Finn, 2008a). 
A handful of studies of individuals with more minor immune defects, or polymorphisms in 
immunoregulatory genes, also point to a role for the immune system in regulating human 
cancers. One study showed that childhood hematological malignancies of nonviral origin were 
increased 50% in children who inherited two mutant versions of the perforin gene which 
severely reduced their T cell’s cytotoxic activity (Chia et al., 2009). In addition, women with a 
particular polymorphism in FasL, the other effector of CTL cytotoxicity, had a threefold increase 
in the risk of cervical cancer (Sun et al., 2005). A multitude of other investigations have linked 
polymorphisms in immunoregulatory genes, such as cytokines, CTLA-4, or PD-1, with cancer 
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incidence (Cozar et al., 2007; Dehaghani et al., 2009; Nikolova et al., 2007; Welsh et al., 2009; 
Zhang et al., 2005b). Interestingly, polymorphisms in CTLA-4 associated with autoimmune 
disease were also associated with decreased incidence of basal or squamous cell carcinomas 
of the skin (Welsh et al., 2009). 
 
Tumor infiltrating lymphocytes and patient prognoses 
 A critical role for tumor immune surveillance is also evident by correlating the degree of 
tumor-infiltrating lymphocytes (TILs) in various forms of cancer and patient outcome. Multiple 
studies have reported that immune infiltrates in tumors correlate with lower grade or non-
metastatic disease and/or improved survival (Dunn et al., 2002; Kohrt et al., 2005; Pages et al., 
2005; Piersma et al., 2007). One particularly exhaustive study examined immunohistochemically 
stained biopsies from patients with colon cancer and determined that the degree of infiltrating T 
cells, and particularly CTLs, was a better indicator of the patient’s survival than predicted by 
standard histopathological criteria, such as the size and invasiveness of the tumors (Galon et 
al., 2006). Flow cytometry-based analyses indicate that the presence of large numbers of tumor-
specific CTLs in the tumor, blood or tumor-draining lymph nodes of cancer patients are 
predictive of better outcomes (Goodyear et al., 2005; Molldrem et al., 2000; Pages et al., 2005; 
Wahlin et al., 2007). Finally, microarray-based experiments of human tumor tissues and lymph 
nodes from breast or hepatocellular carcinoma patients have indicated that the expression of 
genes associated with cytotoxic anti-tumor immune responses are predictive of better patient 
prognoses (Budhu et al., 2006; Finak et al., 2008). In Chapter 2, I will present data to show that 
the presence of increased numbers of lymphocytes in lung adenocarcinomas (by gene 
expression analysis) is also predictive of prolonged patient survival. 
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Cancer immunotherapy 
 The successful treatment of cancer with immune-based therapies, particularly those that 
harness CTLs, indicates that the immune system is capable of regulating cancer, at least under 
the right conditions. Rather than detail the various forms of immunotherapy that have been 
tested in cancer patients, my goal in this section will be to draw on the commonalities of 
successful cancer immunotherapies as a means to better understand natural immune 
responses to cancer in humans. 
 By far the most clinically tested form of cancer immunotherapy is the cancer vaccine 
(Goldman and DeFrancesco, 2009). Cancer vaccines utilizing peptides, tumor cells, dendritic 
cells, and various immune adjuvants have been used to try to actively boost T cell responses 
against patients’ tumors. However, a sobering review by Steven Rosenberg and colleagues 
pointed out that vaccine-based clinical trials have been largely unsuccessful (Rosenberg et al., 
2004). In fact, at the time of his review, no therapeutic cancer vaccine had ever been approved 
for use in treating cancer. The failure of cancer vaccines is important because it tells us that it is 
in fact very difficult to stimulate T cell responses against cancers in patients with the disease. 
This may indicate that the immune environment in cancer patients is not conducive to activating 
T cell responses. It is also reminiscent of failed attempts to therapeutically vaccinate patients 
with chronic infections, such as HIV (Kim and Ahmed, 2010; Smith, 2001). These failures may 
be the result of T cell tolerance induced by chronic antigenic stimulation; especially since the 
targeted antigens are often tumor-associated antigens, rather than tumor-specific antigens 
(Goldman and DeFrancesco, 2009).  
The first FDA-approved cancer vaccine, Sipuleucel-T, which has proven to be 
efficacious in the treatment of advanced prostate cancer, utilizes a patient’s own antigen-
presenting cells (APCs) that are manipulated ex vivo and then transferred back into the patients 
to stimulate anti-tumor T cell responses (Kantoff et al., 2010). It is interesting that rather than try 
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to actively manipulate the APCs in cancer patients (as so many failed cancer vaccines have 
tried to do in the past), this technique removes the APCs from the patients and activates, 
matures and loads them with tumor antigens in culture. Therefore, a critical parameter that may 
contribute to the success of this therapy is the manipulation of immune cells outside of the host, 
potentially avoiding a multitude of immunoregulatory mechanisms that act to maintain immune 
tolerance against the cancer in the host. The importance of manipulating immune cells ex vivo is 
echoed by the prior success of adoptive cell transfer therapy (ACT), perhaps the most effective 
immunotherapy against cancer (Dudley et al., 2002; Rosenberg and Dudley, 2004). In this 
approach, T cells infiltrating a patient’s tumor are harvested and then activated and expanded in 
culture before being transferred back into the patient (Rosenberg et al., 2008). Thus, while 
vaccines that attempt to provoke the anti-tumor immune response in cancer patients are 
ineffective, techniques that stimulate the immune cells outside of the cancer patient can be 
effective. 
 The only example of a cancer immunotherapy that has worked to boost the endogenous 
anti-tumor immune response within cancer patients is Ipilimumab, a monoclonal antibody that 
targets CTLA-4, to treat metastatic melanoma (Hodi et al., 2010). However, this immunotherapy 
is fundamentally different than vaccine therapies. Rather than provoking the induction of new 
anti-tumor T cell responses, anti-CTLA-4 antibodies modulate the existing T cells by blocking 
signals from this key inhibitory receptor. Thus, Ipilimumab acts as an immunomodulatory drug 
that can unleash preexisting anti-tumor T cell responses in cancer patients. The success of 
Ipilimumab reinforces the notion that immune regulatory networks in cancer patients are the 
major obstacles for successful immunotherapy, as targeting them directly in patients or 
subverting them by manipulation of immune cells ex vivo provide the best clinical results. 
 Perhaps the most important lesson from these cancer immunotherapy trials is that T cell 
responses against cancer are naturally engaged during the course of tumor progression. We 
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know this is true because Ipilimumab and ACT would not work if T cell responses weren’t 
already established in the cancer patients. The success of these particular forms of therapy also 
lends support to the theory that tumors escape immune surveillance because T cell tolerance is 
induced in response to cancer. Chapter 4 of this thesis is dedicated to investigating the potential 
for therapeutic vaccinations against human cancers utilizing our lung adenocarcinoma mouse 
model. 
 
 
V. MODELING IMMUNE-TUMOR INTERACTIONS IN MICE 
 
 Nearly all of the hallmarks of cancer can be, and were, defined through experimentation 
in vitro with cells grown in culture. Self-sufficiency in growth signals, insensitivity to antigrowth 
signals, evasion of apoptosis, limitless replicative potential, were all demonstrated with 
transformed cells in culture, whereas sustained angiogenesis and tissue invasion and 
metastasis were largely inferred directly from clinical observations. Although in vitro assays for 
invasion and metastasis have contributed to our understanding, the underlying mechanisms 
governing tumor vascularization and metastasis required the use of animal models. Similarly, 
the role of T cells in regulating cancer can be inferred from clinical data. However, investigating 
the role of the immune system in human cancer absolutely necessitates the use of sophisticated 
animal models to faithfully recapitulate the interactions of immune cells with cancers in humans. 
Therefore, this section is devoted to introducing the models of cancer used to study immune-
tumor interactions in mice, as well as to discussing the strengths and weaknesses of these 
models and some attainable goals for the next generation of cancer models. See Figure 4 and 
Table 2 for a comparison of some of the key features of the different mouse cancer models. 
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Figure 4. Mouse models of cancer to study antigen-specific T cell responses. 
(A) Transplantable models allow the introduction of model antigens in culture prior to 
transplantation. 
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(B) Chemically-induced models of cancer do not allow the study of antigen-specific T cell 
responses in the primary setting, but endogenous tumor antigens may be identified after culture 
and investigated upon transplantation. 
(C) Germline genetically engineered mice (GEM) develop tumors spontaneously due to targeted 
genetic knock-out (KO) of endogenous loci or transgenic (Tg) expression of oncogenes from 
tissue-specific promoters (TSP). Antigen-specific responses can be studied by crossing tumor-
prone mice with mice that express model antigens transgenically under the control of TSP. 
(D) Conditional GEM provide spatial and temporal control of tumor induction utilizing tissue-
specific expression of Cre-ER or doxycycline-inducible transactivators (TA) in combination with 
timed administration of tamoxifen (Tam), doxycycline (Dox) or viruses (such as lenti-viruses) 
that express Cre ± tumor antigens. Model antigen expression can be regulated concurrently with 
the cancer-promoting genetic events (top, black arrow) or subsequently using combinations of 
these technologies (bottom, red arrows). Brackets denote whether antigen expression is 
controlled using a combination of LSL+CreERT+Tam or TRE+TA+Dox technologies. 
 
Ag, tumor antigen; EP, endogenous promoter; TSP, tissue-specific promoter; LSL, LoxP-STOP-
LoxP cassette inhibits gene expression until it is removed by Cre recombinase; floxed, LoxP 
sites flank exons of a gene such that Cre-mediated recombination removes these exons and 
disrupts the gene; TRE, Tet(Dox)-regulated promoter elements; TA, a doxycycline-inducible 
transactivator; Cre, Cre recombinase; Flp, Flp recombinase; triangles represent LoxP (or 
potentially FRT) sites, boxes represent cDNAs or exons. 
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Table 2: A comparison of the different mouse models of cancer 
Features: Transplanted Chemically-induced 
Germline-
GEM 
Conditional-
GEM 
Cancers modeled: 
Examples: 
All 
B16 melanoma 
EL4 lymphoma 
MC57 fibrosarcoma 
Lewis Lung carc. 
TRAMPC prostate 
Limited 
MCA sarcoma 
UV fibrosarcoma 
DMBA+TPA skin carc. 
All 
RIP-Tag2 pancreatic 
   β-cell hyperplasia 
Erbb2/Neu mammary 
TRAMP (Pro-Tag2)  
   prostate  
LSL-SV40 many type:    
   sarc., lymph., carc. 
All 
KrasLSL-G12D lung 
KrasLSL-G12D;PTENf/f 
   ovarian 
KrasLSL-G12D;p53f/f 
   sarcoma 
KrasLSL-G12D 
   pancreatic 
Time to progression: 
(survival time) 
0-4 weeks 
(after transplant) 
2-4 months 
(after induction) 
2-6 months 
(mouse age) 
2-12 months 
(after induction) 
Genetics alterations 
mimic human cancers? 
Unknown 
 
Unknown/yes 
 
Yes  
(some models) 
Yes 
 
Histopathology mimics 
human cancers? Limited cases 
Yes 
(limited tumor types) Yes Yes 
Tumor initiated by 
transformation of 
normal cells? 
No Yes Yes Yes 
Timing of tumor 
initiation controlled? Yes 
Partially  
(variable latency & 
penetrance) 
No 
(empirically defined) 
Yes 
Location of tumor 
formation controlled? 
Yes  
(orthotopic) 
Yes 
(limited tumor types) 
Yes (transgenic); 
No (tumor 
suppressor KO) 
Yes  
(limited technology) 
Tumors in natural 
microenvironment? 
No 
(maybe orthotopic) 
Yes 
(carcinogens may 
affect environment) 
Yes  
(oncogenic events not 
restricted to tumor) 
Yes 
Multifocal disease? No ? Yes Yes 
Track tumor antigen 
specific T cell 
responses? 
Yes No Yes Yes 
Restrict tumor antigen 
expression to tumors? Yes NA No Possible 
Regulated tumor 
antigen expression? Possible No No Possible 
 
GEM, genetically engineered mice; carc., carcinoma; RIP-Tag2, rat insulin promoter driven 
SV40 Tag; TRAMP, rat probasin promoter driven SV40 Tag; ?, unknown; NA, not applicable. 
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Cancer by transplantation 
 Transplantable models of cancer have historically been the models of choice for the 
investigation of T cell responses against cancer. The cancers used for transplantation 
experiments are typically cell lines that were generated from a tumor that arose spontaneously 
in a mouse. Cell lines derived from a multitude of different types of cancer (B16 melanoma, EL4 
lymphoma, MC57 sarcoma, or 4T1 breast-, Lewis lung- and TRAMP-C prostate-carcinomas) 
are routinely transplanted subcutaneously as models of the human cancers. While these tumor 
models provide a rapid and reproducible system to assess T cell responses to cancer, they 
have several critical limitations (Becher and Holland, 2006; Frese and Tuveson, 2007), 
especially with regards to evaluating the activity of anti-tumor T cell responses (Scott, 1991; 
Williams, 1982).  
Transplantable models require the introduction of large numbers of cells via injection. 
The injection itself can incite the immune system by inducing pro-inflammatory reactions at the 
site of implantation (Khong and Restifo, 2002). Transplanting cells from culture into ectopic 
environments in mice inevitably leads to tremendous tumor cell death. However, large numbers 
of dead or dying tumor cells can be engulfed by phagocytic cells that initiate anti-tumor T cell 
responses, a phenomenon that does not occur at the initiation of human cancer. Transplanted 
tumors do not develop the normal architectural elements of endogenously arising tumors, and 
lack key cellular and extracellular components of their human counterparts. Even orthotopic 
transplants, in which tumor cells are put back into the organ from which they originally arose, fail 
to recapitulate the process of human tumorigenesis. Unlike human cancer which begins with the 
transformation of normal cells in situ followed by the progression of genetically heterogeneous 
descendent cells that acquire additional mutations, transplanted tumors deliver large numbers of 
fully progressed, homogeneous tumor cell clones that simply grow and rarely progress 
phenotypically. The growth of transplanted tumors is significantly faster than most human 
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cancers, with doubling rates of < 2 days (Sausville and Burger, 2006). This rapid growth rate is 
an important consideration for immunotherapeutic investigations because it necessitates that 
therapies work quickly, and in an acute setting unlike clinical trials in cancer patients. Another 
consideration when using these models is that these are cell lines derived from a single tumor 
that has been passaged in vitro and in vivo by multiple investigators, for extended periods of 
time. The role of selective pressures and genetic drift on the immunogenicity as well as other 
features of these cells during passage are impossible to predict, but are likely significant 
(Becher and Holland, 2006; Scott, 1991). Thus, it may be dangerous to put too much stock into 
the results of experiments using these “venerable” cell lines (Scott, 1991). Cautions were raised 
as many as 30 years ago that transplantable models of cancer may not be appropriate models 
of the human disease (Alexander, 1977; Williams, 1982). Indeed the limitations of these models 
have recently been demonstrated in experiments that revealed differences in the 
neovascularization and therapeutic response of transplanted compared to autochthonous 
cancers in mice (Olive et al., 2009; Sikder et al., 2003). Such findings may explain the failure of 
clinical trials in which transplantable cancer models were used to predict the success of 
therapies in cancer patients (Becher and Holland, 2006). In Chapter 2 of this thesis, I will 
provide additional evidence that T cell responses against transplanted and autochthonous 
models of the same mouse cancer are inherently different, and that T cell responses to 
autochthonous tumors more closely mimic the situation in human cancer. 
 
Cancer by chemical induction 
 The theory of tumor immune surveillance is predicated upon the use of chemically (or 
carcinogen)-induced mouse models of cancer. Methylcholanthrene (MCA)-induced cancer 
models were used to demonstrate that various immune-deficient mice have an increased 
susceptibility to cancer and that tumors harbor tumor-specific, transplant-rejection antigens.  
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Carcinogen-induced cancers provide vast improvements over transplantable models of cancer. 
They allow investigators to roughly control the location and timing of tumor onset, and tumors 
arise from the transformation of normal cells in their natural setting, surrounded by a 
physiologically normal architecture. Importantly, carcinogens are known to be an important 
driver of cancer in humans and synonymous mutations are often induced in human and mouse 
tumors. 
Nevertheless, there are only a limited number of models available for chemical cancer 
induction, often requiring particular genetic backgrounds and only providing a few types of 
cancer to study. Although the administration of a carcinogen allows for some control over tumor 
onset, tumor induction is often incomplete with low doses of carcinogens. There can also be 
considerable variability in the progression of cancer, likely as a consequence of differences in 
the underlying genetics of each independently arising tumor. However, there are greater 
concerns with regards to the immunological aspects of carcinogen-induced cancer models. The 
application of carcinogens may induce local inflammation preceding or during transformation by 
the upregulation of stress ligands (NKG2D ligands) on premalignant and stromal cells (Khong 
and Restifo, 2002). To increase the penetrance and reduce the latency of tumorigenesis, high 
doses of carcinogens are often used. This can lead to abnormally rapid tumor progression and 
the potential to generate artificially large numbers of carcinogen-induced neoantigens that can 
serve as transplant-rejection antigens (Khong and Restifo, 2002). The generation of 
neoantigens as a byproduct of massive carcinogenesis, rather than tumorigenesis, has been a 
concern since the 1950s (Foley, 1953a, b; Prehn and Main, 1957). Early comparisons of 
spontaneously arising tumors and MCA-induced tumors led investigators to the realization that 
most spontaneous tumors did not contain rejection antigens, thus antigenicity was not an 
intrinsic property of all cancers (Prehn and Main, 1957). Indeed, many consider the 
immunogenicity of MCA-induced tumors to be unrepresentative of human cancers (Hewitt et al., 
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1976). Inherent in these concerns, however, is the necessity to transplant these tumors in order 
to assess immune-tumor interactions, primarily because tumor induction with carcinogens is so 
variable and once tumors become palpable, their growth is so rapid. 
 
Cancer by germline genetically engineered mice 
 Germline genetically engineered mice (GEM) encompass two types of GEM that are 
typically separated but, because of their many shared properties in the context of cancer 
immunology, will be grouped together here. Germline GEM include transgenic GEM and 
endogenous GEM since they both harbor constitutive (not conditional) germline phenotypes 
(Frese and Tuveson, 2007). Transgenic GEM utilize pronuclear injection of cDNAs into zygotes 
to randomly insert oncogenes, either mammalian or viral (i.e. SV40 Tag), into the mouse 
genome. Endogenous GEM disrupt the endogenous proto-oncogenes or tumor suppressors in 
the mouse genome to mimic the natural disruptions of these genes in human cancers. 
Transgenic GEM can be engineered and selected for tissue-specific expression of oncogenes, 
allowing the development of tumors in selected organs. While endogenous GEM benefit from 
the fact that the actual loci in mice are disrupted, they cannot restrict the mutations to specific 
cells in the animal due to the manipulation of the endogenous genes. In any case, both systems 
can be considered germline in nature because the expression of oncogenes or loss of tumor 
suppressors cannot be controlled temporally or restricted specifically to tumors.  
 By causing the transformation of normal cells in situ with defined genetic events, 
germline GEM can generate nearly all forms of human cancer, while recapitulating many of the 
pathophysiological characteristics observed during the progression of the human disease. In 
addition to expanding the spectrum of tumors that can be studied, germline GEM also provide 
more tractable and reproducible models of cancer compared to carcinogen-induced models. 
However, due to the constitutive nature of germline GEM, it is not possible to control tumor 
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initiation, tumor multiplicity, or restrict genetic disruptions exclusively to tumors. Although these 
are features in common with inherited forms of cancer, they may not accurately reflect the 
physiologic setting of sporadic forms of human cancer in which a somatic mutation in a single 
cell initiates tumor development. 
 
Cancer by conditional genetically engineered mice 
 Conditional GEM are similar to the germline GEM in that the genetic events driving the 
cancers as well as the progression of the disease closely recapitulates features of the human 
disease. However, conditional GEM provide considerably more control over tumor development 
because the genetic disruptions can be controlled in a spatiotemporal fashion. In this way, the 
activation of oncogenes or deletion of tumor suppressors is completely dependent upon specific 
manipulations made by the investigator in adult animals. Control of the timing and location of the 
genetic disruptions, and thus tumor formation, can be achieved using variations of two basic 
strategies. The first strategy utilizes the combination of ligand-regulated transcriptional 
activators (TAs) and TA-regulated promoters (TREs), such as the bacterial tetracycline operon, 
to regulate the transcription of transgenic loci. The second strategy uses site-specific 
recombinases (SSRs), such as Cre/LoxP, to control the expression of endogenous genetic loci. 
Tissue-specific expression of TAs and timed administration of doxycycline – a tetracycline 
analog that activates the TA to induce the expression of TRE-regulated genes – can allow the 
controlled expression of oncogenes. The use of LoxP recombination sites, engineered so as to 
delete tumor suppressor genes or allow the expression of oncogenes upon Cre-mediated 
recombination, can be controlled by tissue-specific expression of a ligand-regulatable Cre, such 
as the tamoxifen-regulated CreERT (Cre-estrogen receptor fusion protein), or alternatively, by 
sporadic infection of cells in a given tissue with viral vectors that express Cre. Finally, the 
combination of both systems can provide a means for spatiotemporal control of endogenous 
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Cre/LoxP-conditional oncogenes or tumor suppressors by way of a tissue-specific TA and TRE-
regulated Cre recombinases. 
 The use of these conditional GEM provides investigators with exquisite control over the 
timing of tumor initiation in specific tissues, making it possible to follow the complete evolution of 
tumor progression that is not possible with any other system. However, these models are limited 
by the development of reagents to specifically control gene expression in targeted organs, i.e. 
mice with tissue-specific TAs or CreERT alleles (Gidekel Friedlander et al., 2009). However, 
tissue-specific expression with transgenic and even endogenously targeted TAs or SSRs can be 
difficult due to ectopic expression in multiple tissues. Furthermore, the ligand-regulated TAs and 
SSRs are often leaky, leading to sporadic oncogene activation or tumor suppressor loss. Finally, 
even if these reagents are not leaky and are specific for cells of a given tissue, administration of 
the regulating ligands can lead to the widespread activity of TAs or SSRs throughout the entire 
targeted organ, making it difficult to induce the genetic events sporadically in a given tissue. 
While the delivery of viral vectors that express Cre to specific organs can provide temporal 
control and the induction of the genetic changes in a sporadic fashion, it is currently limited to 
only a few cancer models (Dinulescu et al., 2005; Jackson et al., 2001; Kirsch et al., 2007; 
Willimsky and Blankenstein, 2005). In addition, it is difficult to target viral infection exclusively to 
the tumor-initiating cells, although the use of avian sarcoma leukosis virus and targeted 
expression of its cell entry receptor may provide a means for cell-type specific infectivity (Frese 
and Tuveson, 2007). 
 
Investigating T cell responses to mouse models of cancer 
 To understand the role of T cell responses against cancer, investigators can analyze the 
phenotypes of bulk CD8 T cell populations or assess CTL anti-tumor activity by depleting the 
entire CTL population with anti-CD8 antibodies, but ideally, investigators would narrow their 
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analysis to the tumor antigen-specific T cell populations responding to the cancers. Such 
analyses are impossible to do with carcinogen-induced cancers as they develop in their 
endogenous setting because the tumor antigens are unknown when tumors arise. However, by 
generating cell lines from carcinogen-induced tumors, tumor-specific antigens can be identified 
that allow the investigation of antigen-specific T cell responses upon transplantation. In addition, 
by generating cell lines, all transplantable models, whether spontaneous or carcinogen-induced, 
benefit from the ease of introducing model tumor antigens into the tumor cell lines. 
Transplantable models offer one of the few systems to obtain truly tumor-specific expression of 
model tumor antigens, thus avoiding the complexities of T cell responses to antigens expressed 
in tumors and other tissues of the mouse. 
 To study T cell responses to cancers arising in germline GEM, the approach has been to 
cross the GEM to mice that express model tumor antigens in the organ that gives rise to the 
tumors, usually employing the same tissue-specific promoters that drive the expression of the 
oncogenes, such as the rat insulin promoter (RIP) in pancreatic β-islet cells or the rat probasin 
promoter in prostate epithelial cells (Drake et al., 2005; Lyman et al., 2004; Speiser et al., 1997). 
Alternatively, the oncogene itself can serve as the tumor antigen, such as with SV40 Tag or 
Her2/Neu transgenic mice (Anderson et al., 2007; Ercolini et al., 2005; Muller-Hermelink et al., 
2008; Willimsky and Blankenstein, 2005). However, expression of model tumor antigens 
throughout the targeted organs can limit investigations because the antigens are also expressed 
in normal cells of the targeted tissue, and well before tumor formation. Studies have indicated 
that the recognition of antigens in the context of tumors or normal tissues can induce distinct 
phenotypes in responding T cells (Getnet et al., 2009). T cells responding to the expression of 
model antigens in normal tissues are often deleted or rendered tolerant to these antigens (Adler 
et al., 1998; Morgan et al., 1998; Ohashi et al., 1991). Typically model antigens in these 
systems are also expressed in the thymus, leading to the deletion of endogenous antigen-
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specific T cells and forcing investigators to study the effect of transferred TCR-transgenic T cells 
on tumor development. While this may provide a powerful system for preclinical 
immunotherapeutic trials, it likely does not reproduce the interactions that occur in the natural 
setting of cancer progression. 
 Very few laboratories have utilized conditional GEM as models to study T cell responses 
to tumors, potentially because of the relatively recent generation of these models. Examples to 
date have used Cre/LoxP technology to prevent the expression of model antigens until Cre is 
activated or introduced into cancer initiating cells, leading to the simultaneous expression of 
both oncogenes and model antigens (Cheung et al., 2008; Huijbers et al., 2006; Soudja et al., 
2010; Willimsky and Blankenstein, 2005; Willimsky et al., 2008). Although these systems are 
advantageous because they utilize the most sophisticated mouse models of cancer and can 
potentially provide a means for tumor-specific model antigen expression, in practice, it has been 
difficult to adequately control the expression of the model antigens in mice, leading to leaky 
expression in the thymus or other cells prior to tumor formation that may alter the phenotype of 
responding anti-tumor T cells (Cheung et al., 2008; Willimsky and Blankenstein, 2005). In 
Chapter 2, I will describe a novel method that utilizes conditional GEM in combination with 
lentiviral tumor-induction to introduce exogenous model tumor antigens into tumors, allowing the 
study of endogenous T cell responses to lung tumors expressing model neoantigens. 
 
Mouse cancer models alter anti-tumor T cell responses 
 A major divide exists between the phenotype of T cells responding to tumors that are 
transplanted versus those that arise endogenously. While T cell responses to transplanted 
tumors have been demonstrated to be effective, often leading to tumor regression or even 
complete tumor eradication, attempts to replicate these results using autochthonous cancer 
models have been unsuccessful. Evidence of cancer immunoediting, via antigen loss and other 
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mechanisms, is commonly found only in the context of tumor transplantation (Johnsen et al., 
2001; Shankaran et al., 2001; Spiotto et al., 2004; Urban et al., 1982). Almost universally, T cell 
tolerance, albeit in many different forms, is induced in response to autochthonous tumors and 
importantly, this is also what has been observed in cancer patients (Drake, 2010). This 
dichotomy may indicate that transplanted tumors induce more potent T cell responses that force 
the selective outgrowth of tumors that can evade the immune response. Autochthonous tumors, 
in contrast, may be ineffective at inducing potent T cell responses, making T cell tolerance the 
major mechanism of tumor evasion in these models. Significant evidence to support this 
hypothesis is provided in Chapter 2 of this thesis. In any case, these observations make it clear 
that careful consideration should be paid to the mouse cancer models used for investigations if 
we hope to learn valuable information about how to better treat the human disease. 
 
Goals for the next generation of mouse models of cancer 
Multiplicity, nature, and expression of tumor antigens 
Clearly the next generation of mouse models used to study T cell responses to cancer in 
the mouse should employ conditional GEM because these provide the most relevant 
representations of the human disease and allow for significant control of tumor development. A 
major hurdle for the next generation of cancer models will be to better recapitulate the T cell 
responses found in human cancers by modulating the tumor antigens that direct the T cell 
response. There are several key aspects to address. First, it is not clear whether the multiplicity 
of tumor antigens targeted by T cells alters the effectiveness of T cell responses. New methods 
that allow the introduction of multiple independent T cell antigens will allow investigators to 
determine the importance of tumor escape via the loss of multiple antigens, epitope spreading in 
promoting effective anti-tumor T cell responses, and CD4 T cell help in promoting CD8 T cell 
responses. Second, the nature of the tumor antigens targeted by T cells may be relevant to the 
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effectiveness of T cell responses. Though it has been argued that tumor-specific antigens 
(TSAs) would be better immunotherapeutic targets than tumor-associated antigens (TAAs) 
(Schietinger et al., 2008), T cells are found to be similarly tolerant in autochthonous models of 
cancer expressing TSAs or TAAs (see Chapter 2 and (Bai et al., 2008; Cheung et al., 2008; 
Willimsky and Blankenstein, 2005)). However, it is unclear whether true TSA expression has 
been achieved in these autochthonous models. In addition to the relevance of TSA versus TAA, 
the relevance of T cell responses targeting TSAs that are selected for by the tumor because 
they promote tumor progression versus TSAs that are bystander events during tumor 
progression is not known. The development of models that link tumor antigens to the “driving” 
(or oncogenic) event will be useful for investigating whether T cell responses to oncogenic 
antigens, whose expression in tumors cannot easily be downregulated to evade an immune 
response, instigate alternative mechanisms of tumor escape. Third, it is important to develop 
systems that allow the independent control of tumor antigen expression and tumor initiation. For 
instance, models that separate tumor initiation and the expression of tumor neoantigens can be 
used to determine whether T cell responses are different when the induction of neoantigen 
expression occurs in established tumors, where most mutated proteins likely arise in human 
cancers. In addition, the use of TRE promoters to control antigen expression could help 
elucidate the role of chronic antigen exposure in driving T cell tolerance by enabling 
investigators to reversibly turn on, and then turn off, the expression of the model tumor antigens 
and assess T cell function. 
 
T cell responses in different forms of cancer 
Finally, discoveries made in a particular model of cancer have often been accepted as 
broadly applicable to all immune-tumor interactions. However, there is a tremendous diversity of 
anti-tumor T cell responses that can be observed in different models of the disease. It is likely 
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that the immune response and tumor response can vary greatly depending on the originating 
tissue and the genetic pathology of different forms of cancer. In support of this concept, 
Chapters 2 and 3 of this thesis will describe two very different interactions between tumors and 
T cells in two different models of autochthonous cancer. Therefore, an important goal of the next 
generation of mouse cancer models will be to extend our analyses to other genetically 
engineered mouse models of cancer to discern whether T cell responses and tumor 
development change depending on the context of the disease. 
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ABSTRACT 
Neoantigens derived from somatic mutations in tumors may provide a critical link between the 
adaptive immune system and cancer. However, it has been difficult to properly recapitulate 
immune responses against tumor-specific neoantigens in models of the human disease. Here 
we describe a novel system to introduce exogenous antigens into genetically engineered mouse 
lung cancers to mimic tumor neoantigens. We show that endogenous T cells respond to and 
infiltrate tumors, resulting in a significant delay in malignant progression. Despite continued 
antigen expression, T cell infiltration does not persist and tumors ultimately escape immune 
attack. In contrast, transplantation of cell lines derived from lung tumors that express the 
antigens or prophylactic vaccination against autochthonous tumors, results in rapid tumor 
eradication or selection of tumors that lose antigen expression. These results provide insight 
into the dynamic nature of the immune response to naturally arising tumors and support clinical 
data that suggest a role for the immune system in cancer suppression rather than prevention. 
This model provides a valuable system for the optimization of immune therapies that can 
eradicate human cancers. 
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INTRODUCTION 
The potential for functionally important interactions between a developing tumor and the 
immune system has been appreciated for over a century (Balkwill and Mantovani, 2001). The 
association of tumor cells and lymphocytes has led researchers to postulate that the immune 
system actively inhibits the formation and progression of transformed cells and ultimately 
“shapes” nascent tumors by forcing the selective evolution of tumor cells that can evade the 
immune response, a phenomenon called tumor immunoediting (Dunn et al., 2002; Khong and 
Restifo, 2002; Schreiber, 2003). Significant numbers of T cells specific to mutated tumor 
proteins have been identified in cancer patients (Finn, 2008; Lee et al., 1999; Novellino et al., 
2005; Parmiani et al., 2007; Rubio et al., 2003) and several studies have correlated immune 
infiltration in tumors with improved prognosis (Buckanovich et al., 2008; Budhu et al., 2006; 
Finak et al., 2008; Galon et al., 2006; Molldrem et al., 2000; Pages et al., 2005; Piersma et al., 
2007). However, the persistence of malignant disease despite immune recognition presents an 
important medical and therapeutic question: how do tumors escape immune surveillance? 
Several mouse models have been used to gain insights into the mechanisms by which 
tumors may subvert immune responses, but each of these has critical limitations. 
Transplantation of primary or cultured tumor cells is commonly used, but these models are 
limited because they ectopically introduce large numbers of fully-developed tumor cells that 
grow rapidly, and transplantation can initiate proinflammatory responses or traffic tumor cells 
directly to lymphoid organs (Frese and Tuveson, 2007; Khong and Restifo, 2002; Ochsenbein et 
al., 1999; Ochsenbein et al., 2001; Spiotto et al., 2002). Carcinogen-induced mouse models of 
cancer have focused predominantly on sarcomas rather than cancers of epithelial origin and 
these tumors are expected to harbor large numbers of mutations that may lead to artificially 
robust immune responses (Dunn et al., 2002; Khong and Restifo, 2002). Transgenic mouse 
models of cancer that develop tumors spontaneously and express model tumor antigens 
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throughout the targeted organs fail to fully recapitulate immune responses against the human 
disease because antigen expression in normal tissues likely alters the T cell response, and 
thymic deletion of antigen-specific T cells typically prevents the study of endogenous T cell 
responses to tumors (Bai et al., 2008; Drake et al., 2005; Ercolini et al., 2005; Forster et al., 
1995; Getnet et al., 2009; Lyman et al., 2004; Muller-Hermelink et al., 2008; Nguyen et al., 
2002; Pellegrini et al., 2009; Savage et al., 2008; Smith et al., 1997; Speiser et al., 1997). 
Furthermore, as transgenic models rely on sporadic tumor-initiating events that can vary widely 
from tumor to tumor and mouse to mouse (Frese and Tuveson, 2007), it is difficult to follow the 
dynamics of the T cell response over time.  
In contrast, genetically engineered mouse models of many human cancers accurately 
recapitulate both the genetic and histopathologic progression of the human disease from its 
earliest lesions to metastasis and can provide spatiotemporal control of tumor onset (Frese and 
Tuveson, 2007). However, few studies have employed these models to elucidate the interplay 
between tumors and the immune system (Cheung et al., 2008; Clark et al., 2007; Huijbers et al., 
2006; Willimsky and Blankenstein, 2005). This is especially true in the context of lung cancer, 
which is responsible for more than one million deaths each year worldwide. 
In an effort to investigate the effect of T cell responses against tumor-specific 
neoantigens on tumor progression, we developed a system to induce potentially immunogenic 
autochthonous lung adenocarcinomas in a genetically engineered mouse model of the disease. 
This model allowed us to carefully compare tumors that originate in situ that lack or express 
model antigens in tumor cells, as well as to closely follow the immune response to tumors over 
the entire course of tumor progression. These studies reveal a dynamic relationship between 
the tumor and the immune system that ultimately influences tumor development. These data 
have clear implications for understanding the role of the immune system in controlling human 
lung cancer development. 
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RESULTS 
Autochthonous lung tumors expressing tumor antigens are infiltrated by lymphocytes 
early during tumor development 
To generate autochthonous lung tumors in a spatiotemporally controlled fashion, we 
utilized a model of human lung adenocarcinoma driven by the conditional expression of 
oncogenic K-rasG12D in combination with the loss of p53 (Figure S1) (DuPage et al., 2009; 
Jackson et al., 2005; Jackson et al., 2001). Tumor formation was initiated in K-rasLSL-G12D/+;p53fl/fl 
mice by inhalation of lentiviral vectors expressing Cre recombinase with or without additional 
antigens. To induce tumors that lack expression of model antigens, we used a lentiviral vector 
expressing Cre alone (Lenti-x, Figure 1A). These tumors exhibited little to no lymphocyte 
infiltration throughout their development as assessed by hematoxylin and eosin (H&E) staining 
and immunohistochemistry (Figure 1B-1E).  To induce tumors that express model tumor 
antigens, we engineered lentiviral vectors that, in addition to Cre, express the T cell antigens 
SIYRYYGL (SIY) and two antigens from ovalbumin – SIINFEKL (SIN, OVA257-264) and OVA323-339 
– fused to the C-terminus of luciferase (Lenti-LucOS, Figure 1A).  Fusing the antigens to 
luciferase enabled us to monitor antigen expression in tumors.  As shown in Figure 1, unlike 
tumors induced with Lenti-x, Lenti-LucOS-induced tumors had large numbers of infiltrating 
lymphocytes including both T and B cells at 8 weeks after tumor initiation (Figure 1B-1E). We 
did not observe any differences in innate immune cell infiltrates between tumor types (Figure 
S2). Based on the differences in immune cell infiltration, we designated Lenti-x-induced tumors 
as non-immunogenic and Lenti-LucOS-induced tumors as immunogenic (Figure 1A and Figure 
S1). 
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Figure 1. Induction of lung tumors using lentiviral vectors.  
(A) Design of Lenti-x and Lenti-LucOS constructs (SIN-LTR: self-inactivating long terminal 
repeat, ψ: HIV packaging signal, cPPT: central polypurine tract, PGK: phosphoglycerate kinase 
promoter, WRE: woodchuck post-transcriptional regulatory element, UbC: ubiquitin C promoter).  
(B) Lung tumors induced with Lenti-x or Lenti-LucOS were stained with H&E, anti-CD3, or anti-
B220, eight weeks after tumor initiation. Scale = 50µm (inset 10µm).  
(C and D) Quantification of immune infiltrates by IHC for CD3 and B220. P-values are ~10-8, and 
~10-3 for CD3 and ~10-15 and 0.02 for B220 at 8 and 16 weeks, respectively. n= 2-5 mice, 16-
100 tumors, per group, mean ± SEM. 
(E) Percent of lung tumors/ mouse containing infiltrating lymphocytes at 8, 16, and 24 weeks 
after tumor initiation. n= 9-22 mice, 49-1594 tumors, per group, mean ± SEM. 
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T cell responses against tumor antigens are generated but not maintained 
To examine the T cell response to LucOS expression in tumors over time, we assessed 
the degree of T cell infiltration at 16 and 24 weeks after tumor initiation. In contrast to the robust 
lymphocytic infiltration of immunogenic tumors at 8 weeks after tumor initiation, there was a 
dramatic reduction in tumor-infiltrating lymphocytes at the later time-points, indicating that the 
immune response was not sustained or tumors had escaped the immune response (Figure 1C-
1E). To determine whether the immune infiltrates in Lenti-LucOS tumors contained T cells 
specific for the antigens engineered into the tumors, we performed flow cytometry with MHCI/Kb 
DimerX reagents loaded with SIY or SIN peptides. To improve the sensitivity of the DimerX 
reagent, we utilized both PE and APC labeled dimers to co-stain CD8+ T cells. At several time 
points after tumor initiation with Lenti-LucOS, but not with Lenti-x, we detected CD8+ T cells 
reactive to SIY/Kb and SIN/Kb in the lungs and the mediastinal lymph nodes draining the lungs 
(DLN) (Figure 2A). As a positive control for a robust T cell response to the same antigens in the 
same organ, we infected mice with a recombinant influenza virus engineered to express SIY 
(WSN-SIY, Figure 2A). The antigen-specific T cell response to Lenti-LucOS tumors peaked 
between 4 and 8 weeks after tumor initiation but declined thereafter in the lungs and DLN, 
whereas T cells responding to SIY expressed by influenza expanded and contracted rapidly in 
the lungs (within 2-4 weeks) but persisted with increasing frequency in the DLN (Figure 2B, 2C, 
and Figure S3, S4A). We hypothesize that the delayed T cell response to tumors was due to 
relatively low levels of antigen produced and presented in the lung DLNs early during tumor 
development as well as a poor capacity for early-stage tumors to initiate a robust immune 
response. To further investigate the early response, we analyzed the T cell response after Lenti-
LucOS introduction into the lungs of mice that lacked the K-rasLSL-G12D allele, and could not form 
tumors (Figure S5A-G). We found that SIY and SIN-specific T cells were generated in the 
absence of tumor formation, presumably due to antigen expression in normal cells of the lung  
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Figure 2. T cell responses to tumor antigens are generated but not sustained.  
(A) Representative analysis of SIY and SIN specific CD8+ T cells in the lung and the draining 
mediastinal lymph node (DLN) of Lenti-x or Lenti-LucOS tumor-bearing mice or WSN-SIY 
infected mice. FACS plots are gated on PI-negative, CD8+ cells.  
(B and C) Percent of lymphocytes specific for SIN or SIY during Lenti-LucOS tumor progression 
in the lung or DLN. The percent of anti-SIN or anti-SIY reactive cells (of total lymphocytes) was 
determined as shown in Figure S3. n= 2-5 mice per time-point, mean ± SEM. 
(D) IFNγ and TNFα cytokine production in SIY and SIN-reactive T cells from the lungs of Lenti-
LucOS tumor-bearing mice at several time points after tumor initiation. The percentage of SIY 
and SIN-specific T cells from the lungs that were IFN-γ+TNF-α+ or IFN-γ+TNF-αneg in the 
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absence of stimulation (no peptide) or in the presence of SIY and SIN peptides (+ peptide) is 
shown. Percentages were determined by staining duplicate samples for either DimerX (as in A) 
or cytokine production as described in Figure S6A. n= 2-7 mice per time-point, mean ± SEM. 
(E) The percentage of SIY and SIN-specific T cells in the DLN that were IFN-γ+TNF-α+ 16 weeks 
after tumor initiation with Lenti-LucOS or 16 weeks after WSN-SIY infection. n= 4 mice per 
group, mean ± SEM.  
(F) PD-1 surface expression on anti-SIY/Kb+ and anti-SIN/Kb+ CD8+ cells (open histograms) or 
non-specific CD8+ cells (filled histograms) from the lungs of Lenti-LucOS tumor-bearing mice at 
several time-points after tumor initiation. n= 2-3 mice per group, mean ± SEM. 
 
 
 
 
 (Figure S5H-J). This indicates that while antigen expression is largely restricted to tumors in 
this system, the lentiviral infection can stimulate antigen-specific T cells that may contribute to 
the ensuing anti-tumor T cell response. Importantly, however, the T cell response in the 
absence of transformation was weak and short-lived when compared to mice that generated 
tumors (Figure S5A-F). This may indicate that the immune system responds differently to 
transformed cells or that tumor proliferation within the first several days following K-rasG12D 
activation leads to greater antigen production and, hence, more T cell activation. 
 
Endogenous tumor-reactive T cells are not fully functional and display traits of terminally 
differentiated effector cells 
To determine whether T cells specific to the tumor antigens were functional, we 
measured their capacity to produce IFN-γ and TNF-α at multiple time-points after tumor initiation 
(Figure 2D, 2E and Figure S6). Very few tumor-reactive T cells in the lungs had the capacity to 
produce both IFN-γ and TNF-α, and this activity was almost completely lost within the first five 
weeks of tumor development, whereas T cells maintained production of IFN-γ alone (Figure 
2D). This pattern of cytokine production during tumor progression may indicate an increase in 
terminally differentiated effector T cells (IFN-γ+TNF-αneg) that is accompanied by a progressive 
loss of high-quality, memory-like T cells (IFN-γ+TNF-α+) (Seder et al., 2008; Slifka and Whitton, 
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2000; Wherry et al., 2007). It is possible that persistent, non-productive, T cell engagement with 
tumor antigens drives T cells into an exhausted state (Bucks et al., 2009; Mueller and Ahmed, 
2009; Redmond and Sherman, 2005). Consistent with this, as tumors progressed, tumor-
reactive T cells showed increased expression of PD-1, a marker of T cell exhaustion, and low 
expression of CD127 (the IL-7Rα chain), a marker of long-lived memory cells (Figure 2F and 
not shown) (Wherry et al., 2007). Furthermore, during a productive T cell response against 
WSN-SIY, viral clearance was followed by a rapid decline in SIY-specific T cells that were IFN-
γ+TNF-αneg and the maintenance of IFN-γ+TNF-α+ cells (Figure 2E and Figure S4B). 
 
Adoptively transferred T cells primed by tumors rapidly lose activity 
To develop a more detailed view of the dynamics of the T cell response to established 
tumors from activation to effector function, we transferred naïve 2C or OT-I TCR transgenic T 
cells (which recognize SIY or SIN, respectively) into mice bearing Lenti-x or Lenti-LucOS 
tumors. As early as three days after transfer, 2C and OT-I T cells were activated and 
proliferated in the lung-draining lymph nodes (Figure 3A and 3B). By 12-14 days after transfer, 
the T cells could be detected in the lungs (Figure 3C). However, the activity of these T cells was 
significantly impaired in the DLN and lungs compared to T cells responding to the same 
antigens expressed in the context of infection with influenza (Figure 3D, Figure S4C). These 
results emphasize that although T cells can be stimulated to proliferate and migrate to tumors, 
few T cells retain the capacity to produce effector cytokines in response to tumors. 
Two potential mechanisms may explain the dysfunction of naïve T cells responding to 
antigens expressed by the Lenti-LucOS tumors: the presence of an immunosuppressive 
environment in tumor-bearing mice or the suboptimal priming of T cells by antigens expressed 
in tumors. To test whether the priming of T cells in the DLN is impaired, we assayed whether T 
cell activity in the lungs could be rescued by transferring effector T cells that were activated in  
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Figure 3. Adoptively transferred T cells are not fully functional in response to established 
tumors. 
(A) FACS analysis comparing the accumulation of SIN-reactive, OT-I T cells in the mediastinal 
draining lymph nodes (DLN) and the inguinal peripheral lymph nodes (PLN) three days after 
adoptive transfer of naïve OT-I cells into Lenti-x or Lenti-LucOS tumor-bearing mice 10 weeks 
after tumor initiation (similar results were observed when T cells were transferred four weeks 
after tumor initiation). Percent of total CD8+ cells that are anti-SIN/Kb+ is indicated. n≥ 3 mice for 
Lenti-LucOS or ≥1 mouse for Lent-x tumor-bearing mice in each of two independent 
experiments. 
(B) Histogram plots of CD8+anti-SIN/Kb+ gated cells for CFSE dilution or surface expression of 
CD44, CD62L, or CD69 from the DLN or PLN of Lenti-LucOS (open histogram) or Lenti-x (filled 
histogram) tumor-bearing mice. Undivided (CFSEhi) CD8+anti-SIN/Kb+ cells were examined in 
CD69 plots to detect initial T cell activation. n≥ 3 mice for Lenti-LucOS or ≥1 mouse for Lent-x 
tumor-bearing mice in each of two independent experiments. 
(C) FACS analysis for the presence of OT-I T cells in the lungs of Lenti-LucOS tumor-bearing 
mice 12 days after adoptive transfer of naïve CD45.1+ OT-I T cells (tumor-bearing mice were 
CD45.2+). n≥ 3 mice in at least three independent experiments. 
(D) Percent of CD8+CD45.1+ gated OT-I T cells producing IFNγ+TNFα+ or IFNγ+TNFαneg from 
the DLN or lung after transfer of naïve OT-I T cells. WSN-SIN represents analysis of OT-I T 
cells 7 days after WSN-SIN infection. Lenti-LucOS represents analysis of OT-I T cells 12 days 
!
!
"
#$
"
%
&'
$
(
&)
*
+%
"
',
#)
-
.
$
+%
/
'$
"
001
!
"
#$
"
%
&'
$
(
&)
*
+%
"
',
#)
-
.
$
+%
/
'$
"
001
23
3
23
2
23
4
23
5
23
6
23
3
23
2
23
4
23
5
23
6
23
3
23
2
23
4
23
5
23
6
23
3
23
2
23
4
23
5
23
6
23
3
23
2
23
4
23
5
23
6
23
3
23
2
23
4
23
5
23
6
23
3
23
2
23
4
23
5
23
6
23
3
23
2
23
4
23
5
23
6
23
3
23
2
23
4
23
5
23
6
3
43
63
73
83
233
9'):';<=
23
3
23
2
23
4
23
5
23
6
3
43
63
73
83
233
9'):';<=
23
3
23
2
23
4
23
5
23
6
3
43
63
73
83
233
9'):';<=
23
3
23
2
23
4
23
5
23
6
3
43
63
73
83
233
9'):';<=
23
3
23
2
23
4
23
5
23
6
3
43
63
73
83
233
9'):';<=
23
3
23
2
23
4
23
5
23
6
3
43
63
73
83
233
9'):';<=
>?@A >B66 >B74C >B7D
α
E@
FG
HI
J
>B8
C"%&+EC.$K@ C"%&+E=
B
C
G
!
C
G
B
C
G
!
C
G
26L5 2LM
2L32L3
23
3
23
2
23
4
23
5
23
6
23
3
23
2
23
4
23
5
23
6
>
B
6
N
L2
>B8
C
O
G
P
"
25LM
# $
B.!</"'!"#$%&Q'%&'()*+,
BCG COGP
23
3
23
2
23
4
23
5
23
6
3
43
63
73
83
233
9'):';<=
23
3
23
2
23
4
23
5
23
6
3
43
63
73
83
233
9'):';<=
9
')
:'
R
<
=
L
9
')
:'
R
<
=
L
P<&"S'>B8TαE@FGHIJT C"%&+EC.$K@ C"%&+E=
3
23
43
53
63
N3
!
"
#$
"
%
&'
$
(
&)
*
+%
"
',
#)
-
.
$
+%
/
'$
"
001
U@GE@FG C"%&+EC.$K@
V#<%1:"#'%<+W"'KVEF
U@GE@FG C"%&+EC.$K@
-
COGP
V#<%1:"#'<$&+W<&"-'KVEF
F?GγTVG?α'%"/F?GγTVG?αT>B6NL2T'KVEF
>B6NL4T'#"$+,+"%&1
BCG
U@GE@FG C"%&+EC.$K@ T2'-<( T24'-<(
C"%&+EC.$K@
!
"
#$
"
%
&'
$
(
&)
*
+%
"
',
#)
-
.
$
+%
/
'$
"
001
3
23
43
53
63
N3
73
M3
3
23
43
53
63
N3
3
23
43
53
63
N3
73
M3
  115 
after transfer into Lenti-LucOS tumor-bearing mice at time points between 12 and 16 weeks 
after tumor initiation. n= 6-7 mice per group, mean ± SEM. 
(E) Percent of CD8+CD45.1+ gated OT-I T cells producing IFNγ+TNFα+ or IFNγ+TNFαneg from the 
DLN or lung after transfer of in vitro-activated OT-I T cells. Lenti-LucOS represents analysis one 
day (lung only, n = 6 mice) and 12 days after transfer (n= 3 mice) into Lenti-LucOS tumor-
bearing mice at time points between 10 and 14 weeks after tumor initiation. WSN-SIN in the 
DLN represents analysis of OT-I T cells 14 days after WSN-SIN infection (n= 3 mice). Mean ± 
SEM. 
 
 
 
 
vitro. Indeed, tumor-specific T cells activated in vitro and then transferred immediately had the 
capacity to produce both IFN-γ and TNF-α and maintained this activity in the lungs of Lenti-
LucOS tumor-bearing mice (Figure 3D and 3E). Furthermore, transfer of activated T cells led to 
the generation of cells with comparable function to WSN-SIN-primed T cells in the DLN (Figure 
3E). T cell activity may also be exacerbated by interactions with cells or secreted factors in the 
tumor microenvironment. Foxp3+ T regulatory cells were found to specifically infiltrate Lenti-
LucOS tumors (Figure 2F and Figure S7). Nevertheless, T cell priming by tumor antigens is 
clearly suboptimal and contributes to the weak anti-tumor T cell response. 
 
Antigen expression and presentation is maintained in immunogenic tumors 
The loss of T cell infiltrates in tumors during tumor progression could also be due to the 
selection of tumors that lose antigen expression or antigen presentation to escape the immune 
response (Dunn et al., 2002; Khong and Restifo, 2002; Spiotto et al., 2004; Uyttenhove et al., 
1983; Ward et al., 1990; Zhou et al., 2004). To determine whether the T cell response was 
driving the outgrowth of tumors lacking antigen, we compared luciferase activity in Lenti-LucOS 
tumors generated in immune-competent and immune-compromised mice. At 16 and 20 weeks 
post tumor initiation, time-points associated with the dissipation of immune infiltrates in tumors, 
luciferase levels were comparable between normal and immune-compromised mice (Figure 
4A). The presentation of tumor antigens to T cells in the lung-draining lymph node was also 
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maintained during the latest stages of disease (24 weeks after tumor initiation), because tumor-
specific 2C T cells could still proliferate specifically in the draining lymph nodes of Lenti-LucOS 
tumor-bearing mice (Figure 4B). Additionally, Lenti-LucOS tumors maintained higher 
expression of MHC class I compared to Lenti-LucOS tumors that arose in Rag-2null mice or 
compared to Lenti-x tumors (Figure 4C, 4D). However, MHC class I expression decreased on 
Lenti-LucOS tumors between 16 and 24 weeks after tumor initiation (Figure 4D, 4E). Reduced 
MHC class I expression could contribute to tumor escape and may result from the waning anti-
tumor T cell activity and T cell infiltration into tumors. In support of this hypothesis we used cell 
lines derived from the model to show that MHC class I expression and SIN presentation on 
Lenti-LucOS tumor cells was regulated by IFNγ and that antigen-specific T cell recognition in 
vitro was sufficient to upregulate MHC class I and allow for the specific killing of Lenti-LucOS 
tumor cells (Figure S8). Therefore, the rapid decline in T cell infiltration into tumors may result 
from the combined effect of a reduced anti-tumor T cell response that results in lower MHC 
class I expression on tumor cells, ultimately reducing the potential for T cells to recognize tumor 
cells. We found further support for this model in vivo by testing whether in vitro-activated 2C T 
cells transferred into Lenti-LucOS tumor-bearing mice 16 weeks after tumor initiation, a time 
when few tumors have endogenous lymphocytic infiltrates, could be specifically retained in 
tumors. 2C T cells were specifically retained in Lenti-LucOS tumors but not in Lenti-x tumors 
(Figure 4F), and activated polyclonal T cells were not retained in Lenti-LucOS tumors (Figure 
4F). Furthermore, by staining tumor sections with the epithelial marker cytokeratin 8, we could 
observe tumor-infiltrating T cells making direct contacts with the epithelial cancer cells 
themselves rather than cytokeratin 8-negative stromal cells (Figure 4G, 4H). Thus, the 
dissipating T cell response to immunogenic tumors during the later stages of tumor progression 
was not due to the escape of tumors that had lost the capacity to present the tumor antigens. 
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Figure 4. Antigen expression and presentation is maintained in tumors.  
(A) Luciferase activity (RLU/ µg protein) in Lenti-LucOS tumor lysates from K-rasLSL-G12D/+;p53fl/fl 
or K-rasLSL-G12D/+;p53fl/fl;Rag-2-/- mice at 16 or 20 weeks after tumor initiation. n= 8-14 tumors per 
mouse per group.  
(B) FACS analysis comparing the accumulation of SIY-reactive, 2C T cells in the DLN three 
days after adoptive transfer of naïve 2C cells into Lenti-x (n= 1) or Lenti-LucOS (n= 3) tumor-
bearing mice 24 weeks after tumor initiation.  CFSE dilution of CD8+1B2+ cells in Lenti-LucOS 
(open histogram) or Lenti-x (filled histogram) mice. 
(C) Freshly isolated Lenti-LucOS tumors generated in Rag-2null (dashed line) and Rag-2+ mice 
(solid line) 20 weeks after tumor initiation were pooled and then compared by FACS analysis for 
H-2Kb surface expression after gating-out cells positive for CD45, CD31, Ter119, and IA/IE 
(MHCII). Plot is representative of three pooled tumor samples from Rag-2null or Rag-2+ mice. 
Filled histogram is a negative control stain for CD8. 
(D) Freshly isolated Lenti-LucOS (solid line) and Lenti-x tumors (dashed line) at 16 and 24 
weeks after tumor initiation were compared by FACS analysis for H-2Kb surface expression after 
gating-out cells positive for CD45, CD31, Ter119, and IA/IE (MHCII). Plots are representative of 
pooled and individual tumor samples from two independent experiments. Filled histograms are 
negative control stains for H-2Kd. 
(E) H-2Kb mean fluorescent intensity on Lenti-LucOS and Lenti-x tumors at 16 and 24 weeks 
after tumor initiation. n= 2-3 mice, 6-11 tumor samples per group per time point. Mean ± SEM. 
(F) Activated 2C T cells, or α-CD3/CD28 activated polyclonal CD8+ T cells, labeled with CFSE 
were transferred into Lenti-LucOS or Lenti-x tumor-bearing mice at 16 weeks post tumor 
initiation and tumors were analyzed for the presence of CFSE+ cells (green) 24 hours later. 
DAPI counter stained. Tumors are outlined and quantification of the number of CFSE+ cells/ 
tumor is indicated. Scale = 50µm. n= 2-4 mice, 21-38 tumors, per group, mean ± SEM. 
(G) Cytokeratin 8 (red) stained Lenti-LucOS tumors from (F) that received activated CFSE+ 2C 
T cells (green) 16 weeks after tumor initiation. Scale = 50µm. 
(H) High magnification of box outlined in (G). Scale = 10µm. 
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Immunogenic tumors exhibit delayed tumor progression 
Despite the suboptimal anti-tumor T cell response, it remained possible that the immune 
response might still affect the course of the disease. To understand the impact of the T cell 
response on tumor progression, we first compared the size of immunogenic Lenti-LucOS tumors 
to non-immunogenic Lenti-x tumors over the lifespan of tumor-bearing mice. As shown in Figure 
5, at each time point examined, immunogenic tumors were smaller than non-immunogenic 
tumors, with the differences in size being most significant at 8 and 16 weeks after tumor 
initiation, coincident with T cell infiltration into tumors (Figure 5A). Analysis of tumors 8 weeks 
after initiation revealed an increase in apoptosis in Lenti-LucOS compared to Lenti-x tumors but 
no difference in proliferation (Figure S9A-B). Importantly, the difference in size between Lenti-
LucOS and Lenti-x tumors required the presence of the adaptive immune system, because the 
expression of the LucOS antigens had no effect on tumor size when induced in immune-
compromised, Rag-2-deficient mice (Figure 5B). We also followed tumor progression by 
examining the histological tumor grades at each time-point. Interestingly, at 8 and 16 weeks 
after tumor initiation, Lenti-LucOS tumors were of lower grade compared to Lenti-x tumors 
(Figure 5C). By 24 weeks post tumor initiation, the primary lung tumor grades were similar; 
however, far fewer mice with immunogenic tumors had metastatic disease (Figure 5D).  Thus, 
early anti-tumor T cell responses can have long-lasting effects on tumor progression that delay 
the most deadly phase of the disease. Indeed, analysis of human lung adenocarcinoma gene 
expression datasets indicated that high expression of CD3 genes in tumor samples, as well as 
other genes expressed specifically in T and B cells, was predictive of better patient outcomes 
(Figure 5E and Figure S9C-F). 
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Figure 5. Immunogenic tumors have delayed tumor progression.  
(A) Tumor area, mean ± SEM, of Lenti-LucOS and Lenti-x lung tumors at 8, 16, and 24 weeks 
after tumor initiation. p-values are ~10-10, ~10-14, and ~0.108, respectively, from n= 9-15 mice, 
44-892 tumors, per group. 
(B) Tumor area, mean ± SEM, of Lenti-LucOS and Lenti-x lung tumors in K-rasLSL-
G12D/+;p53fl/fl;Rag-2-/- mice 16 weeks after tumor initiation. p ~0.561 from n= 6-7 mice, 45-223 
tumors, per group.  
(C) Tumor grades for Lenti-LucOS and Lenti-x lung tumors at 8, 16 and 24 weeks after tumor 
initiation. n= 9-22 mice, 49-1594 tumors, per group. Mean ± SEM. 
(D) The number of lung tumors/ mouse and metastatic index (number of mice with detectable 
metastases/ total examined, p < 0.02) in Lenti-LucOS and Lenti-x tumor-bearing mice 24 weeks 
after tumor initiation. n= 8-12 mice per group, mean ± SEM. 
(E) Kaplan-Meyer plot comparing the survival of Stage I/II (lymph node metastases free, N0) 
lung adenocarcinoma patients with high or low CD3 expression in tumors. Patients were ranked 
from highest to lowest based on CD3 expression in tumors (average expression of CD3δ, CD3γ, 
CD3ε, and CD247 (CD3ζ)) and the top versus bottom quartiles were compared, p < 0.02. 
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Loss of antigen expression in transplantable models of lung cancer 
Tumor antigen loss has been reported as a mechanism of tumor immune evasion in 
transplantable models of cancer (Spiotto et al., 2004; Uyttenhove et al., 1983; Ward et al., 1990; 
Zhou et al., 2004). Because the endogenously arising lung tumors described above did not lose 
antigen expression or presentation in the face of an anti-tumor immune response, we 
hypothesized that this may be the consequence of a weaker immune response against 
endogenous tumors compared to transplanted tumors. To compare immune responses in the 
context of transplantable or endogenously arising models of cancer, we transduced cell lines 
from the K-rasG12D-driven lung tumor model with lentiviral vectors to introduce either SIY fused 
to luciferase (LKR10-LucS) or ovalbumin (containing SIN and OVA323-339) and SIY fused to 
luciferase (LKR13-LucOS), and transplanted the cell lines subcutaneously into syngeneic 
immune-competent mice (Figure S8A). While the parental LKR10 and LKR13 cell lines 
produced tumors upon transplantation, the antigen-expressing LKR10-LucS and LKR13-LucOS 
were rejected or exhibited delayed growth (Figure 6A and 6B) and generated CD8+ T cells 
specific to SIN and/or SIY (Figure S10A-C). In stark contrast to the situation with 
autochthonous tumors, all the tumors that grew in immune-competent mice lost expression of 
the antigens (Figure 6C). Importantly, the parental and antigen-expressing cell lines were 
equally capable of forming tumors in immune-compromised mice (Figure 6A and Figure S10D). 
In addition, transferring naïve 2C or OT-I T cells into immune-compromised mice bearing 
established LKR10-LucS or LKR13-LucOS tumors led to reductions in tumor volume and 
antigen expression in an antigen-specific manner (Figure 6D and 6E). Thus, a T cell response 
to a single antigen expressed in transplanted lung tumor cell lines was sufficient to elicit tumor 
rejection or induce the selective outgrowth of tumors that had lost antigen expression.  
It has been reported that spontaneous tumors can induce a state of systemic tolerance 
toward tumor antigens such that T cells no longer respond to transplanted tumors expressing  
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Figure 6. Transplanted lung tumors induce strong T cell responses that force tumor 
elimination or tumor antigen loss.  
(A) Number of tumors rejected of the total transplanted subcutaneously into immune-competent 
or immune-compromised (Rag-2null) 129S4/SvJae mice (n.d.= not done). Results are cumulative 
from three independent experiments and transplantation of from 105 to 106 cells. 
(B) Size of LKR13 and LKR13-LucOS tumors eight and 27 days after subcutaneous 
transplantation into immune-competent 129S4/SvJae mice or LKR13-LucOS into Rag-2null 
129S4/SvJae mice. LKR13-LucOS tumors that were rejected are not included. Results are 
cumulative from three independent experiments. n= 2-5 mice per group. 
(C) Representative in vivo luciferase activity of LKR10-LucS or LKR13-LucOS tumors 
transplanted subcutaneously into Rag-2+ (n= 10 mice: 6 LKR10-LucS, 4 LKR13-LucOS) or Rag-
2null (n= 13 mice: 7 LKR10-LucS, 6 LKR13-LucOS) 129S4/SvJae mice.  
(D) Tumor growth after subcutaneous transplantation of LKR10-LucS or LKR13-LucOS into 
Rag-2null mice followed by transfer of naïve OT-I or 2C T cells (arrow) and measurement of 
luciferase activity (star) (OTI/2C = OT-I or 2C transfer). n= 3-4 mice per group.  
(E) Representative in vivo luciferase activity of LKR10-LucS tumors in Rag-2null mice that 
received OT-I or 2C T cells from (D). All LKR13-LucOS tumors lost detectable luciferase activity 
with transfer of OT-I or 2C T cells.  
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(F) Representative in vivo luciferase activity 7 and 14 days after subcutaneous transplantation 
of a Lenti-LucOS induced lung tumor cell line (KP-LucOS.3) into Rag-2null or Rag-2+ 
129S4/SvJae mice.  
(G) Similar to (D), Lenti-LucOS induced lung tumor cell lines (KP-LucOS.3 and KP-LucOS.2) or 
LKR13-LucOS were transplanted subcutaneously into Rag-2null mice, then OT-I, 2C, or no T 
cells were transferred and luciferase activity was measured in tumor cell lines generated from 
the tumors > 28 days after transplantation.  
(H) Lenti-LucOS induced lung tumor cell lines were orthotopically transplanted into 129S4/SvJae 
mice and luciferase activity in the grafted lung tumors was assayed and compared to the activity 
before transplantation (φ = not detectable). Mean ± SEM. 
 
 
 
 
 
the same antigens (Willimsky and Blankenstein, 2005). However, we found that even in the 
context of mice bearing autochthonous lung tumors expressing the tumor antigens, T cell 
responses were still effective against transplanted tumors expressing the same antigens 
(Figure S10E). We suspect that leaky expression of tumor antigens in normal tissues, rather 
than tumor-specific expression, may be responsible for the systemic tolerance to tumor antigens 
in these transgenic tumor models (Bai et al., 2008; Cheung et al., 2008; Drake et al., 2005; 
Willimsky and Blankenstein, 2005). 
Finally, we tested whether such T cell responses would also occur if we transplanted cell 
lines derived from our Lenti-LucOS-induced autochthonous lung tumors that had escaped the 
immune response in situ without losing antigen expression. Indeed, Lenti-LucOS cell lines 
transplanted subcutaneously into immune-competent mice lost antigen expression over time in 
a T cell-dependent manner (Figure 6F and 6G). Furthermore, Lenti-LucOS lung tumor cell lines 
lost antigen expression after orthotopic transplantation into the lung, indicating that 
transplantation, even into a tumor’s native site, can induce T cell responses that drive tumor 
antigen loss (Figure 6H). 
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Enhancing the anti-tumor T cell response with vaccination causes tumor elimination and 
tumor antigen loss 
Enhanced T cell priming in the context of transplanted tumors is a likely explanation for 
tumor elimination and tumor antigen loss in this setting. Therefore, we reasoned that priming by 
vaccination might elicit similar anti-tumor T cell responses against autochthonous tumors. To 
examine this possibility, we vaccinated mice prophylactically with a dendritic cell line engineered 
to express the model tumor antigens (DC2.4-LucOS) (Cheung et al., 2008) and subsequently 
induced Lenti-LucOS or Lenti-x tumors. Vaccination dramatically reduced the number of Lenti-
LucOS tumors but did not affect the number of Lenti-x tumors (Figure 7A and 7B). Furthermore, 
the majority of Lenti-LucOS tumors that did develop in vaccinated mice had dramatically 
reduced antigen expression (Figure 7C). This was likely due to an enlarged T cell response 
early during tumor development, as well as a functionally enhanced response characterized by 
increased secretion of effector proteins and the maintenance of CD127+ memory-like cells 
(Figure 7D-F). 
Despite the dramatic reduction of antigen expression in Lenti-LucOS tumors from 
vaccinated mice, there were still significant numbers of tumor-infiltrating lymphocytes 8 weeks 
after tumor initiation (not shown). This could be due to the capacity of T cells to recognize small 
amounts of antigen expressed in tumors that is below the level of detection by the luciferase 
assay. Indeed, T cells specific to the model antigens could still recognize Lenti-LucOS tumors in 
DC2.4-LucOS vaccinated mice because in vitro-activated SIY-specific T cells were still retained 
in tumors after adoptive transfer (Figure 7G). The maintenance of a T cell response to the 
tumor antigens in vaccinated mice led us to ask whether the progression of Lenti-LucOS tumors 
was altered in vaccinated compared to unvaccinated mice. Although Lenti-LucOS tumors in 
vaccinated mice appeared only modestly smaller 16 weeks after tumor initiation, the differences 
in tumor size between vaccinated and unvaccinated mice increased at 24 and 30 weeks after  
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Figure 7. Vaccination in autochthonous lung tumor model reduces tumor burden and 
promotes loss of antigen expression.  
(A and B) Tumor number on the lungs of mice with Lenti-x or Lenti-LucOS tumors 16 weeks 
after tumor initiation with or without prior DC2.4-LucOS vaccination. p-values are ~0.50 and 
~0.0008, respectively. 
(C) Freshly explanted Lenti-LucOS tumors were assayed for luciferase activity and the percent 
of tumors that were luciferase positive (> 50 RLU/µg protein) in unvaccinated and DC2.4-LucOS 
vaccinated mice is plotted. n= 5-6 mice, 27-34 tumors, per group. 
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(D) Representative FACS plots of SIY/Kb-specific T cells (gated on CD8) from the lung and DLN 
of unvaccinated or DC2.4-LucOS vaccinated mice, 9 days after tumor initiation with Lenti-
LucOS. n≥ 2 mice per group.  
(E) FACS for surface-exposed CD107a and captured IFNγ (gated on CD8) after stimulation of 
the DLN with SIY and SIN from unvaccinated or DC2.4-LucOS vaccinated, Lenti-LucOS or 
Lenti-x tumor-bearing mice (16 weeks post tumor initiation). Mean fluorescent intensities of 
CD107a and IFNγ on reactive T cells from Lenti-LucOS tumor-bearing mice with or without 
vaccination. n= 2-4 mice per group, mean ± SEM. 
(F) FACS analysis of CD8+ anti-SIY/Kb+- and anti-SIN/Kb+-specific T cells for CD127 and CD44 
surface expression from the lungs or DLN of unvaccinated or DC2.4-LucOS vaccinated Lenti-
LucOS or Lenti-x tumor-bearing mice (8 weeks post tumor initiation, n= 2-3 mice per group). 
The ratio of CD44+CD127+ (memory-like) to CD44+CD127- (effector-like) is shown below each 
FACS plot. 
(G) Lenti-LucOS tumors from unvaccinated or DC2.4-LucOS vaccinated mice 8 weeks after 
tumor initiation and 24 hours after transfer of SIY-reactive, CFSE-labeled activated T cells 
(green). DAPI counter stained. Tumors are outlined. Scale = 50µm. 
(H) Mean tumor area of Lenti-LucOS lung tumors at 16, 24 and 30 weeks after tumor initiation 
with or without DC2.4-LucOS vaccination. p-values are ~0.050, ~0.038, and ~0.027, 
respectively, from n= 3-10 mice, 70-506 tumors, per group at 16 and 24 weeks, and n= 1-2 
mice, 15-46 tumors, per group at 30 weeks. Mean ± SEM. 
(I) Percent of Lenti-LucOS tumors/ mouse containing infiltrating lymphocytes at 16, 24 and 30 
weeks after tumor initiation with or without DC2.4-LucOS vaccination (analysis of mice from part 
H). Mean ± SEM. 
 
 
 
 
tumor initiation (Figure 7H). Vaccination had no affect on Lenti-x tumor size (Figure S11A). The 
delayed tumor growth in vaccinated mice correlated with a prolonged retention of lymphocytic 
infiltrates into tumors (Figure 7I and Figure S11B), again highlighting the potential for tumor-
infiltrating lymphocytes to delay tumor progression. 
 
DISCUSSION 
Several important conclusions regarding immune-tumor interactions and their role in 
regulating tumor progression are evident from our study that could not be directly addressed 
using previous cancer models. Thus far, using genetically engineered mouse models, it has not 
been possible to compare tumors expressing or lacking tumor-specific antigens (Clark et al., 
2007; Huijbers et al., 2006; Willimsky and Blankenstein, 2005). With the recent sequencing of 
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several cancer genomes, including lung adenocarcinomas, it is clear that human tumors contain 
hundreds of mutated proteins and many of these have the potential to be presented on MHC 
molecules, thus providing a means for T cells to recognize tumors as distinct from their 
surrounding normal tissues (Ding et al., 2008; Segal et al., 2008; Sjoblom et al., 2006). Our 
ability to specifically control the induction of tumor formation and tumor antigen expression has 
allowed us to closely recapitulate the effects of T cell responses to tumor-specific neoantigens 
from inception to malignant transformation. 
In contrast to transgenic models of tumor-associated antigen expression, here we 
followed endogenous T cell responses against antigens expressed in autochthonous lung 
tumors in an attempt to model T cell responses to tumor neoantigens. By tracking the response 
of endogenous T cells as well as transferred T cells, we find that suboptimal T cell responses 
against tumors are not necessarily due to immune ignorance (Nguyen et al., 2002; Ochsenbein 
et al., 1999; Ochsenbein et al., 2001; Speiser et al., 1997; Spiotto et al., 2002). However, the 
expansion of T cells specific to the tumor antigens was markedly delayed, potentially allowing 
tumor escape (Hanson et al., 2000; Ochsenbein et al., 2001), and the T cell response eventually 
declined in both magnitude and quality as tumors progressed. Despite their ability to proliferate 
and migrate to tumors, T cells had an altered phenotypic state that was exemplified by a poor 
capacity to produce and secrete effector cytokines and a rapid loss of TNFα production in the 
lung. The reduced capacity of T cells to produce effector cytokines such as IFNγ and TNFα as 
tumors progressed may account for their inefficient migration to tumors over time (Calzascia et 
al., 2007; Muller-Hermelink et al., 2008). Our ability to precisely time tumor initiation allowed us 
to reveal a dynamic relationship between anti-tumor T cells and tumor cells. We provide 
evidence to suggest that a loss of T cell activity could lead to reduced MHC class I expression 
on tumor cells and contribute to the rapid decline in tumor-infiltrating lymphocytes. Tumor-
reactive T cells were also found to express high levels of PD-1 and low levels of CD127, 
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features that resemble T cell responses during chronic infections (Bucks et al., 2009; Seder et 
al., 2008; Wherry et al., 2007). Indeed, the T cell response to lung tumors was quite distinct 
from the response to the same antigens expressed by recombinant influenza virus after 
infection of the lung. It is important to note that blocking the function of the PD-1/PD-L1 pathway 
with the use of antibodies or PD-1-deficient T cells did not result in increased activity of tumor-
reactive T cells (not shown), indicating that signaling through the PD-1/PD-L1 pathway alone is 
not responsible for the loss of T cell reactivity against tumors in this model. Instead, T cell 
exhaustion might be exacerbated by an ineffective anti-tumor immune response that allows 
prolonged T cell exposure to antigens expressed from tumors. Chronic T cell stimulation with 
cognate antigen has been shown to be sufficient to drive exhaustion in several settings (Bucks 
et al., 2009; Drake et al., 2005; Mueller and Ahmed, 2009; Redmond and Sherman, 2005). We 
also found that T regulatory cells were recruited specifically to tumors expressing the LucOS 
antigens, and T regulatory cells have been shown to suppress anti-tumor responses in several 
cancer models (Clark et al., 2007; Ercolini et al., 2005; Pellegrini et al., 2009). Despite the 
evidence of an incomplete anti-tumor T cell response, the immune response still delayed tumor 
progression, indicating that suboptimal T cell responses that do not eliminate tumors are 
capable of slowing cancer progression (Koebel et al., 2007; Shankaran et al., 2001). This 
mirrors observations made here and in several retrospective studies of human cancer patients 
in which immune infiltration into tumors significantly correlated with improved patient outcomes 
(Buckanovich et al., 2008; Budhu et al., 2006; Dunn et al., 2002; Finak et al., 2008; Galon et al., 
2006; Molldrem et al., 2000; Pages et al., 2005; Piersma et al., 2007).  
Prophylactic vaccination provided substantial protection from autochthonous tumors, but 
it also led to prolonged immune infiltration into the Lenti-LucOS tumors that grew, delaying 
tumor progression even further. Interestingly, this occurred despite dramatically reduced levels 
of antigen expression in lung tumors from vaccinated mice. Delayed tumor progression despite 
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antigen loss may occur through direct targeting of tumor cells by T cells or via indirect 
elimination of tumor cells during T cell-mediated destruction of stromal cells that cross-present 
tumor antigens in the tumor microenvironment (Spiotto et al., 2004). This result has important 
implications for immunotherapy because it indicates that generating large numbers of highly 
functional, tumor-reactive T cells that persist long-term can effectively inhibit tumor progression 
even after the selective outgrowth of tumors that express very low levels of the targeted antigen. 
The majority of studies investigating immunity to cancer have focused on transplantable 
models of cancer (Dunn et al., 2002; Hanson et al., 2000; Khong and Restifo, 2002; Koebel et 
al., 2007; Ochsenbein et al., 2001; Schreiber, 2003; Shankaran et al., 2001; Spiotto et al., 2002; 
Street et al., 2002; Thomas and Massague, 2005). These studies have led to the discovery of 
several important mechanisms in both T cells and tumor cells that can modulate the 
effectiveness of anti-tumor T cell responses or allow for tumor escape. However, these models 
may not accurately reflect the human disease (Khong and Restifo, 2002; Ochsenbein et al., 
1999; Ochsenbein et al., 2001). Here we have used comparable models of transplantable and 
autochthonous lung cancer to show that transplantation induces anti-tumor T cell responses 
capable of driving tumor immunoediting. Even orthotopic transplantation of cell lines derived 
from Lenti-LucOS-induced tumors that had escaped immune surveillance in their autochthonous 
setting led to an adaptive immune response that forced the outgrowth of tumors with reduced 
antigen expression, a phenomenon that never occurred with autochthonous tumors expressing 
these antigens. This was due in part to suboptimal priming of T cells in the context of 
autochthonous tumors. T cells activated in vitro had enhanced activity compared to T cells 
stimulated in vivo and priming of T cells by vaccination led to responses against autochthonous 
tumors that were comparable to responses against transplanted tumors. It is possible that 
inefficient priming results from a lack of help from CD4+ T cells (Lyman et al., 2004). Indeed, 
CD4+ OT-II T cells specific for OVA323-339, proliferated only weakly in response to tumor initiation. 
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From our comparison of autochthonous and transplanted tumors, we conclude that the immune 
system recognizes tumors that originate from transformation of somatic cells in an inherently 
different way than transplanted tumor cell lines. 
Future experiments should address the diversity of anti-tumor immune responses that 
likely stem from subtle differences in the models used for the investigations. The development 
of models that link the tumor antigen to the driving oncogenic event will be useful for 
investigating whether T cell responses to oncogenic antigens, whose expression in tumors 
cannot easily be downregulated to evade an immune response, instigate alternative 
mechanisms of tumor escape (Willimsky and Blankenstein, 2005). It will also be informative to 
develop models in which tumor initiation and expression of tumor-specific antigens are 
temporally separable to discern whether T cell responses are different if the induction of antigen 
expression occurs in established tumors, where mutated proteins most likely arise in human 
cancers. Indeed, using these lentiviral vectors to initiate tumor development and introduce the 
antigens has some important limitations. Specifically, these lentiviruses require viral infection 
concomitant with tumor initiation, and they cannot completely restrict the expression of the 
antigens to tumor cells. However, preliminary experiments with lentiviral systems that can 
restrict the expression of the antigens to lung epithelial cells, as well as experiments in which we 
delayed antigen expression to several days after the lentiviral infection, indicate that inducing 
the expression of these antigens in lung epithelial cells is sufficient to generate antigen-specific 
T cell responses. Further investigation utilizing this system will be necessary to determine 
whether priming during tumor initiation in the context of the lentiviral infection alters the outcome 
of the anti-tumor immune response. Finally, discoveries made in a particular model of cancer 
have often been accepted as broadly applicable to all immune-tumor interactions. However, the 
immune response and tumor response are likely to vary greatly depending on the originating 
tissue and the genetic pathology of the disease. Therefore, it will be important to extend these 
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analyses to other genetically engineered mouse models of cancer to discern whether T cell 
responses and tumor development change depending on the context of the disease. 
 
MATERIALS AND METHODS 
Mice and tumor induction 
129S4/SvJae strains backcrossed 8 generations were used for all tumor transplant experiments 
and most autochthonous tumor studies. C57/BL6 mice backcrossed 5 generations were used 
when transgenic T cells from C57/BL6 mice were adoptively transferred (Figures 3 and 4B). 
Trp53fl mice were provided by A. Berns (Jonkers et al., 2001), K-rasLSL-G12D were generated in 
our laboratory (Jackson et al., 2001), and Rag-2-/- mice were purchased from The Jackson 
Laboratory (Bar Harbor, ME). Lung tumors were induced in K-rasLSL-G12D/+;p53fl/fl mice by 
intratracheal intubation and inhalation of viruses expressing Cre recombinase as reported 
previously (DuPage et al., 2009; Jackson et al., 2005). J. Chen provided the 2C, OT-I, and OT-II 
TCR transgenic mice that were C57/BL6 and crossed into Rag-2-/-. CCSP-rtTA mice (used in 
Figure S5H-J) specifically express the reverse tetracycline transactivator in lung epithelial cells 
using the clara cell secretory protein promoter described in (Meylan et al., 2009). All animal 
studies and procedures were approved by the Massachusetts Institute of Technology’s 
Committee for Animal Care. 
 
Lentiviral production 
Lentiviruses were produced by transfection of 293T cells with Δ8.2 (gag/pol), CMV-VSV-G, and 
the transfer vector expressing Cre as previously described (Tiscornia et al., 2006). TRELucOS 
(used in Figure S5H-J) is similar to Lenti-LucOS but uses a doxycycline-regulated promoter 
element (TRE) to control LucOS expression rather than the constitutive UbC promoter (Meylan 
et al., 2009). 
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Histology, tumor size, tumor grading 
Mice were killed at designated time-points and lung tissues were preserved by inflation and 
fixation with 3.6% formaldehyde solution or frozen in O.C.T. for experiments that followed 
migration of CFSE-labeled cells in tumors. Bioquant Image Analysis software was used to 
measure the area of individual tumors in histological sections from the lungs. Grading was 
performed by R.B. as described previously (DuPage et al., 2009). Briefly, Grade 1 lesions 
represent hyperplasias and small adenomas, Grade 2 lesions are large adenomas, Grade 3 
lesions are adenocarcinomas, Grade 4 lesions are invasive adenocarcinomas. Metastasis to 
distant organs was monitored by gross examination of mice during necropsy followed by 
histological examination of metastases observed, whereas lung-draining lymph nodes were 
always examined by histological analysis for local metastases. 
 
Immunohistochemistry 
We performed immunohistochemical analysis on formalin-fixed paraffin sections after heat-
mediated antigen retrieval in sodium citrate (see Abcam protocol) (Johnson et al., 2001). We 
used α-CD3 (1:100, Dako), α-B220 (1:50, RA3-6B2), α-Mac-3 (1:10, M3/84) (BD Pharmingen), 
α-Foxp3 (1:25, FJK-16s) (eBioscience), α-cytokeratin 8 (1:25) primary antibodies and 
Vectastain ABC secondary reagents followed by DAB substrate detection (Vector Laboratories). 
 
Flow cytometry 
Cell suspensions from lymphoid organs were prepared by mechanical disruption between 
frosted slides. Cell suspensions from lungs were generated by mincing and digesting the tissues 
for ~1 hour at 37°C in 125 U/ml Collagenase Type I (Gibco) and 60 U/ml Hyaluronidase 
(Sigma). Single cell suspensions were stained with the specified antibodies for 20-30 min after 
treatment with FcBlock (BD Pharmingen). α-CD8α (53-6.7), α-CD45.1 (A20), α-mouse IgG1 
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(X56), α-PD-1 (J43), α-IFNγ (XMG1.2), α-TNFα (MP6-XT22), α-CD107a (ID4B), α-CD44 (IM7), 
α-CD62L (MEL-14), α-CD69 (H1.2F3), and DimerX I (Dimeric Mouse H-2Kb:Ig) were from BD 
Pharmingen. α-CD127 (A7R34) was from eBioscience. J. Chen provided the 1B2 antibody 
recognizing the 2C TCR (Kranz et al., 1984). H. Eisen provided the 25-D1.16 antibody that 
recognizes SIN-loaded Kb/MHCI (Porgador et al., 1997). All antibodies were used at 1:200. 
Peptide-loaded DimerX reagents were prepared as specified by manufacturer and used at 1:75. 
Staining cells with the same ligand labeled with PE or APC for improved sensitivity has been 
reported (Stetson et al., 2002; Townsend et al., 2001). Propidium iodide was used to exclude 
dead cells when appropriate. Cells were read on a FACSCalibur or LSR II (BD Biosciences) and 
analyzed using Flowjo software (Tree Star). 
 
Cytokine production 
Single cell suspensions from lungs or lymphoid organs were resuspended in the presence or 
absence of SIYRYYGL and/or SIINFEKL peptides in OPTI-MEM I (Gibco) supplemented with 
GolgiPlug (BD Pharmingen) for ~4 hours at 37°C, 5% CO2. Cells were then fixed and stained for 
intracellular cytokines using the Cytofix/Cytoperm kit (BD Biosciences). Alternatively, for IFNγ-
capture, cells were stained with the capture and detection antibodies according to the 
manufacturer’s protocol (Miltenyi Biotec). 
 
Luciferase detection 
Freshly explanted tumors or cell lines were lysed in Cell Culture Lysis Reagent, mixed with 
Luciferase Assay Reagent according to manufacturer’s instructions (Promega), and relative light 
units (RLU) were detected using the Optocomp I luminometer (MGM Instruments). RLUs were 
standardized based on the total number of cells or total protein (Bio-Rad Protein Assay) used in 
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each assay. In vivo bioluminescence images were obtained using the NightOWLII LB983 
(Berthold Technologies) after intraperitoneal injection of 1.5 mg Beetle Luciferin (Promega). 
 
CFSE-labeling and adoptive transfer 
Naïve and activated T cells were labeled with 5µM CFSE (Molecular Probes) for 10 min at 
37°C. Naïve TCR transgenic T cells were harvested from lymphoid organs, stained, and 5x105-
106 CD8+ cells were transferred intravenously. Alternatively, freshly harvested TCR transgenic T 
cells were stimulated in vitro with cognate peptide for 16-20 hours and then grown in complete-
RPMI supplemented with 5 ng/ml IL-2 (R&D Systems) for 6-7 days to generate activated T cells. 
~107 in vitro-activated T cells were then transferred intravenously either unstained or stained 
with CFSE depending upon the experiment. 
 
Tumor cell lines and transplantation 
LKR10 and LKR13 are cell lines derived from K-rasG12D-driven mouse lung tumors from 
129S4/SvJae mice (Johnson et al., 2001; Kumar et al., 2007). LKR10-LucS and LKR13-LucOS 
were generated by lentiviral infection with LucS or LucOS constructs (no Cre). KP-LucOS.2, KP-
LucOS.3 cell lines were generated from Lenti-LucOS-induced lung tumors from 129S4/SvJae 
mice. KP-x.1 was generated from a Lenti-x-induced lung tumor from a129S4/SvJae mouse. 
From 105-106 cells were used for transplantations either subcutaneously or intravenously 
(“orthotopic”) depending on the particular experiment. Immune-competent 129S4/SvJae mice 
receiving transplants came from the same mouse strains used to generate the autochthonous 
tumors. Immune-compromised recipients were Rag-2-deficient. Subcutaneously transplanted 
tumor volumes were calculated by multiplying the (length x width x height) of each tumor. 
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DC2.4-LucOS vaccination 
DC2.4-LucOS cells were generated from the dendritic cell line (DC2.4) (Shen et al., 1997) after 
infection with lentivirus that expresses LucOS (no Cre). Mice were vaccinated with an 
intraperitoneal injection of 5x105 cells  >1 month prior to lung tumor initiation. 
 
Influenza 
WSN-SIY and WSN-SIN influenza strains were provided by J. Chen (Bai et al., 2008). Mice 
were infected with 20 pfu of virus/ mouse by intratracheal intubation and inhalation. 
 
Statistical analyses 
P-values from unpaired two-tailed student’s T-tests were used for all statistical comparisons with 
the following exceptions: Figure 7F we utilized Welch’s correction because the variance in 
vaccinated and unvaccinated mice differed significantly, Figure 5D we utilized the Fischer exact 
probability test, and Figure 5E we utilized the logrank test. 
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Figure S1. The K-rasLSL-G12D/+;p53fl/fl mouse model of human lung adenocarcinoma.  
The K-rasLSL-G12D allele allows for the conditional expression of oncogenic K-rasG12D from its 
endogenous locus by the engineering of a transcriptional and translational stop element flanked 
by LoxP sites in front of the first coding exon of the mutant gene. The p53fl allele (generated by 
the laboratory of A. Berns) contains LoxP sites surrounding exons 2-10 of the endogenous p53 
gene. After lentiviral introduction of Cre (Lenti-x), non-immunogenic tumors are formed due to 
the removal of the stop element in front of the oncogenic K-rasG12D allele and the deletion of 
nearly all of the p53 coding exons. Immunogenic tumors are generated after the introduction of 
exogenous antigens contained on the lentivirus (Lenti-LucOS). 
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Figure S5. Lenti-LucOS infection initiates a small and transient T cell response against 
the OVA and SIY antigens. 
(A) FACS analysis for the presence of anti-SIY T cells from bronchoalveolar lavage (BAL) 7 
days after infection of K-rasLSL-G12D/+ or K-ras+/+ mice with WSN/SIY or Lenti-LucOS (gated on PI 
negative cells). Percent of CD8+ T cells specific for SIY is shown. Data is representative of 
infections from at least three different lentiviral preparations. 
(B) Quantification of the number of CD8+ T cells in the BAL of K-rasLSL-G12D/+ or K-ras+/+ mice 
infected with Lenti-LucOS or Lenti-LucS. Representative of infections from at least three 
different lentiviral preparations. 
(C) Quantification of the number of anti-SIY or anti-SIN T cells in the BAL of K-rasLSL-G12D/+ or K-
ras+/+ mice infected with Lenti-LucOS or Lenti-LucS. Data is representative of infections from at 
least three different lentiviral preparations. 
(D) Percent of lymphocytes specific for SIN or SIY in the lungs of mice after infection with Lenti-
LucOS. Solid lines show the percent of lymphocytes in K-rasLSL-G12D/+ mice that form tumors (Tu) 
while dashed lines show the percent of lymphocytes in K-ras+/+ mice that do not form tumors 
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(WT). Percent of lymphocytes is calculated as shown in Figure S3. n= 2-5 mice per time-point, 
mean ± SEM. 
(E) FACS analysis comparing CFSE dilution (top) in naïve 2C or OT-I cells (gated: 
CD8+CD45.1+) from the mediastinal DLN five days after transfer of 2x105 CFSE-labeled naïve 
2C cells into K-rasLSL-G12D/+;p53fl/fl or K-ras+/+ mice followed by intratracheal administration of 
Lenti-LucOS lentivirus or three days after transfer of 2x105 CFSE-labeled naïve OT-I T cells 
followed by intratracheal administration of 10-5 µmol Ovalbumin + 1µg LPS (as a positive 
control). The percent of cells fully diluted of CFSE is shown. Grey histograms represent DLN 
cells transferred into uninfected control mice. FACS analysis comparing the percentage of 
CD8+CD45.1+ transferred 2C cells of the total CD8+ in the DLN of K-rasLSL-G12D/+;p53fl/fl or K-ras+/+ 
mice five days after Lenti-LucOS infection (bottom). FACS plots are representative of results 
from 2-3 mice per group. 
(F) FACS analysis for the persistence of transferred naïve OT-I T cells after infection with Lenti-
LucOS in K-rasLSL-G12D/+ or K-ras+/+ mice. 5x105 naïve OT-I T cells were transferred into mice 
prior to infection with Lenti-LucOS and the presence of OT-I T cells (gate: CD8+CD45.1+) was 
analyzed after 6 weeks (n= 2 mice per group) or 5 days after i.p. injection of 5x105 DC2.4-
LucOS cells (8 weeks after infection, n= 2 mice per group). As a positive control, mice were 
inoculated intratracheally with 10-5 µmol Ovalbumin + 1µg LPS. 
(G) FACS analysis comparing CFSE dilution in OT-II cells (gated: CD4+CD45.1+) from the 
mediastinal DLN or inguinal PLN three or five days after transfer of 2x105 CFSE-labeled naïve 
OT-II cells into K-rasLSL-G12D/+ or K-ras+/+ mice followed by intratracheal administration of 10-5 
µmol Ovalbumin + 1µg LPS (as a positive control) or Lenti-LucOS lentivirus. The percent of 
undivided cells in the DLN is shown. Representative results from three mice per group. 
(H) FACS analysis for the presence of anti-SIN T cells from the lungs of wild-type or K-rasLSL-
G12D/+;p53fl/fl;CCSP-rtTA+ (KPR) mice five days after infection with TRELucOS and Dox feeding. 
Percent of PI-negative, CD8+ cells is shown in the FACS plots and the total number of anti-SIN 
cells per lung from 3 mice in each group is shown (the approximate limit of detection is indicated 
by the dashed line). 
(I) FACS analysis for the presence of anti-SIN T cells from the lungs of K-rasLSL-
G12D/+;p53fl/fl;CCSP-rtTA+ (KPR) mice infected with TRELucOS and then fed Dox food for 7 days 
beginning 5 days after infection (days 6-13). Percent of PI-negative, CD8+ cells is shown in the 
FACS plots and the total number of anti-SIN cells per lung from 3 mice is shown (the 
approximate limit of detection is indicated by the dashed line). Three uninfected wild-type mice 
served as controls. 
(J) The total number of anti-SIN cells per DLN from the experiments described in panels H and I 
(the approximate limit of detection is indicated by the dashed line). 
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ABSTRACT 
Cancer immunosurveillance and immunoediting have largely been defined using carcinogen-
driven models of sarcomagenesis. However, the heterogeneity and tractability of these models 
is often complex, making it difficult to pinpoint key aspects of these processes. Here we use a 
genetically engineered mouse model of sarcomagenesis to investigate cancer immunoediting. 
This system allowed us to conditionally induce tumors harboring similar genetic and 
histopathological characteristics that either did or did not express potent antigens recognizable 
by endogenous T cells. We show that the process of immunoediting requires the presence of 
potent T cell antigens and that lymphocytes drive the evolution of less immunogenic, or “edited,” 
tumors by selecting for tumor cells that epigenetically silence the expression of the targeted 
antigens. 
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INTRODUCTION 
 Cancer immunosurveillance is a mechanism by which immune cells, particularly 
lymphocytes of the adaptive immune system, protect the host from the de novo development 
and progression of cancer (Dunn et al., 2002; Schreiber, 2003). To understand this process, 
investigations have relied heavily on the use of mouse models of cancer in which carcinogens, 
primarily methylcholanthrene (MCA), are used to induce the development of tumors (Dunn et 
al., 2006). Using these models, various immune-compromised mice lacking particular 
populations of immune cells or harboring deficiencies in key immune effector pathways have 
been shown to have an increased susceptibility to MCA-induced sarcoma formation, providing 
experimental evidence to support cancer immunosurveillance (Kaplan et al., 1998; Shankaran 
et al., 2001; Swann et al., 2008). Furthermore, as a consequence of the selective pressures 
imposed on cancers during immunosurveillance, anti-tumor immune responses can also drive 
the outgrowth of tumor cells with decreased sensitivity to immune attack, or decreased 
“immunogenicity,” through a process called cancer immunoediting (Dunn et al., 2002; 
Shankaran et al., 2001). Cancer immunoediting by the adaptive immune system was revealed 
experimentally when tumors induced with MCA in lymphocyte-deficient mice were demonstrated 
to be more immunogenic in transplantation assays than tumors induced in immune-competent 
mice (Engel et al., 1997; Koebel et al., 2007; Shankaran et al., 2001; Svane et al., 1996). 
Therefore, tumors that arise in immune-competent animals are susceptible to immune-mediated 
destruction and those tumors that are not eradicated by immune attack, represent escape 
variants that were shaped, or “edited,” by the immune system during tumor evolution. Despite 
the evidence that cancer immunoediting occurs in these settings, as well as in human cancers, 
we still lack a clear understanding of the mechanisms by which tumors are edited by immune 
cells during this process. 
  159 
Recognition of tumor-specific antigens (TSAs) by lymphocytes may be critical for 
immunosurveillance of cancers. Evidence to support the role of TSAs in cancer immunity comes 
from the fact that effective immunization against MCA-induced sarcomas is often restricted to an 
individual tumor, that is, immunization with one tumor rarely provides cross-reactive protection 
against other independently derived tumors (Prehn, 1968; Prehn and Main, 1957). However, 
these experiments only reveal an important role for TSAs in the context of prior immunization 
and transplantation, not in the context of primary tumor development. In addition, the molecular 
identification of TSAs from carcinogen-induced tumors can be laborious and difficult owing to 
their unique existence in individual tumors. In a few studies of long-term-cultured tumor cell 
lines, TSAs capable of mediating tumor regression were characterized, and the antigens were 
found to be somatically mutated normal genes (Dubey et al., 1997; Monach et al., 1995; Stauss 
et al., 1986). Therefore, a plausible mechanism by which the process of immunoediting may 
occur is by enforcing the selective outgrowth of tumors that do not express specific antigens that 
can be targeted by T or B lymphocytes. Immunoediting by selective antigen loss is supported by 
the observation that serial passage of immunogenic tumors in immune-competent animals can 
lead to the reduced immunogenicity of tumors (Prehn, 1968). In several examples, reduced 
immunogenicity upon transplantation of tumor cell lines has been demonstrated to occur by the 
selective outgrowth of tumor cells that no longer express the TSAs targeted by lymphocytes 
(Stauss et al., 1986; Urban et al., 1982; Uyttenhove et al., 1983; Zhou et al., 2004). However, 
these types of investigations, while feasible with transplantable cell line models of cancer, are 
extremely difficult to perform in the context of spontaneous or carcinogen-induced primary 
tumorigenesis because the antigens targeted by T cells are unknown. Therefore, it is still 
unclear whether T cell responses directed against TSAs and subsequent tumor antigen loss 
during the evolution of primary tumors in their natural setting are critical features of the 
immunoediting process. The investigation of these key issues would be simplified with a more 
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tractable system in which primary tumors could be initiated that harbored defined tumor 
antigens. 
To investigate the role of tumor-specific antigens targeted by endogenous T cells in the 
process of immunoediting, we utilized a genetically engineered mouse model of 
sarcomagenesis (Kirsch et al., 2007). This model allowed us to induce the in situ transformation 
of genetically and histopathologically defined sarcomas that could be engineered to express 
model tumor antigens. The capacity to induce sarcoma formation with defined tumor antigens 
provided a significant improvement over carcinogen-induced primary sarcomas because it 
allowed us to monitor antigen-specific T cell responses to tumors, track the expression of the 
antigens in tumors, and compare the immunogenicity of tumors in the presence or absence of 
these tumor antigens. We find that the process of cancer immunoediting requires the presence 
of TSAs that can be recognized by T lymphocytes. Furthermore, cancer immunoediting can 
occur through the selective outgrowth of tumor cells that have epigenetically silenced TSA 
expression. 
 
RESULTS 
Sarcoma formation with increased penetrance and reduced latency in Rag-2-/- immune-
compromised mice 
 To investigate whether T lymphocytes could prevent the formation of tumors in an 
autochthonous mouse model of sarcomagenesis, we utilized a recently described model to 
induce the formation of sarcomas by intramuscular injection of viral vectors expressing Cre in K-
rasLSL-G12D/+;p53fl/fl;Rag-2+/- (KP) or K-rasLSL-G12D/+;p53fl/fl;Rag-2-/- (KPR) mice (Kirsch et al., 2007). 
To induce sarcomas with potentially immunogenic antigens we used lentiviral vectors that 
express Cre alone (Lenti-x) or vectors that, in addition to Cre, express the T cell antigens 
SIYRYYGL (SIY) and two antigens from ovalbumin – SIINFEKL (SIN, OVA257-264) and OVA323-339 
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– fused to the C-terminus of luciferase (Lenti-LucOS), as recently described (DuPage et al., 
Chapter 2). Fusion of the T cell antigens to luciferase provided a means to assay for the 
maintenance of antigen expression in sarcomas.  
 KP mice that were induced to express strong T cell antigens with Lenti-LucOS formed 
tumors later (85.7 ± 6.2 days) than KPR mice (73.6 ± 4.3 days) (Figure 1A,B). In addition, 
whereas only 28% of KP mice developed sarcomas within the first 180 days after tumor 
induction via Lenti-LucOS injection, 100% of KPR mice developed sarcomas after Lenti-LucOS 
injection (Figure 1A,C). A comparable difference in sarcoma latency and penetrance was also 
observed in KP compared to KPR mice injected with Lenti-x (Figure 1B,C). Therefore, tumor 
immunosurveillance in this model of sarcomagenesis may act independently of the presence of 
exogenous antigens. Alternatively, it is possible that Cre is immunogenic in the context of 
sarcoma development, although Cre was not found to be immunogenic in previous studies 
investigating lung adenocarcinoma development (DuPage, et al., Chapter 2). Interestingly, 
sarcomas also developed with significantly delayed onset (beyond 180 days) in immune-
competent mice. In KP mice injected with Lenti-LucOS, 4/13 mice monitored beyond 180 days 
developed tumors at 186, 278, 359, or 525 days after intramuscular injection. Only 1/6 mice 
injected with Lenti-x developed a tumor after 180 days. It is possible that the late onset of 
tumors seen in KP mice, but not KPR mice, is due to the activity of adaptive immune responses 
that maintain small tumors in an equilibrium state (Dunn et al., 2002; Koebel et al., 2007). 
To further investigate the importance of the expression of experimentally delivered T cell 
antigens in mediating these phenotypes, we used K-rasLSL-G12D/+;p53fl/fl;R26LSL-LSIY/+ (KPL-SIY) 
mice which are tolerant to luciferase and the SIY antigen due to thymic deletion of reactive T 
cells (Supplementary Figure 1 and (Cheung et al., 2008)). We compared sarcoma 
development KP versus KPL-SIY mice after the injection of Lenti-LucS, a lenti-vector that 
expresses SIY fused to luciferase. Thus, we were able to directly compare tumor induction  
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Figure 1. Sarcoma formation in Rag-2-/- mice occurs with reduced latency and increased 
penetrance. 
(A) 25 K-rasLSL-G12D/+;p53fl/fl;Rag-2+/- mice (KP) and 11 K-rasLSL-G12D/+;p53fl/fl;Rag-2-/- mice (KPR) 
were injected intramuscularly with equivalent doses of Lenti-LucOS and the development of 
palpable sarcomas was monitored twice a week for at least 180 days. The percentage of mice 
in each group with sarcomas is depicted over the first 120 days (no tumors developed between 
120-180 days). Cumulative data from at least three independent experiments is shown (A-C).  
(B) Time after intramuscular injection of Lenti-LucOS, Lenti-x, or Ad-Cre in which sarcomas first 
became palpable in KP (triangles) or KPR (circles) tumor-bearing mice. Data only includes 
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sarcomas that arose within the first 180 days, see text for data relating to tumors arising after 
180 days. 
(C) Percentage of KP and KPR mice with sarcomas of the total (n) injected intramuscularly with 
Lenti-LucOS, Lenti-x, or Ad-Cre within the first 180 days (see text for data relating to tumors 
arising after 180 days). 
(D) 5 KP and 6 KP-LSIY (K-rasLSL-G12D/+;p53fl/fl;R26LSL-LSIY/+) littermates received intramuscular 
injection of Lenti-LucS and the percentage of mice with sarcomas within the first 180 days is 
plotted. See text for a comparison of the latency of tumor development in these mice. 
 
 
 
 
utilizing the same lentiviral vector (Lenti-LucS) in immune-competent mice versus mice that 
were specifically tolerant only to the LucS antigens introduced into the tumors. KPL-SIY mice 
had an enhanced susceptibility to sarcoma formation with Lenti-LucS and the sarcomas became 
palpable much sooner than in KP littermates (89.5 ± 17.4 versus 139 days) (Figure 1D). Thus, 
protection from sarcoma formation depends on the presence of strong antigens in tumors that 
can be recognized by T cells. Furthermore, although Cre may be immunogenic in this setting, 
expression of Luciferase and SIY are clearly influential in preventing sarcoma formation. 
 
Functional T cell responses are generated against antigens expressed in sarcomas 
 An advantage of this genetically engineered and conditional cancer model is that we can 
examine the endogenous antigen-specific T cell response to engineered tumor antigens. We 
used MHCI/Kb DimerX reagents loaded with SIY and SIN peptides to track tumor-reactive CD8+ 
T cells in Lenti-LucOS-induced sarcoma-bearing mice by flow cytometry. To improve the 
sensitivity of the DimerX reagent, we utilized both PE- and APC-labeled dimers to co-stain CD8+ 
T cells. Mice bearing Lenti-LucOS sarcomas, but not mice bearing Lenti-x sarcomas, harbored 
CD8+ T cells specific to SIY and SIN in the inguinal lymph nodes nearest to the tumors as well 
as in the spleen (Figure 2A,B). To look at the functional activity of these T cells, we 
restimulated lymphocytes harvested from the lymphoid organs of tumor-bearing mice with SIY 
and/or SIN peptides in vitro and performed intracellular cytokine staining (ICCS) for IFN-γ and 
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TNF-α production. CD8+ T cells specific for the tumor antigens were completely functional as 
evidenced by the fact that all of the cells could produce large quantities of both IFN-γ and TNF-α 
upon in vitro restimulation (Figure 2A-D). This is in complete contrast to the dramatically 
reduced activity of T cells responding to lung adenocarcinomas that expressed the same 
antigens (DuPage et al., Chapter 2). Interestingly, we consistently found slightly increased 
percentages of antigen-specific T cells in the inguinal lymph node closest to the tumor 
compared to the contralateral lymph node (Figure 2A). This may indicate an increased 
concentration of the antigens in the proximal lymph node due to ongoing antigen production in 
the tumors. 
We also analyzed KP mice injected with Lenti-LucOS that did not develop sarcomas for 
antigen-specific T cells. We hypothesized that such T cell responses could be protecting these 
mice from sarcoma formation. Indeed, we detected fully functional antigen-specific T cells in 
these mice as well (Figure 2C,D). Importantly, intramuscular lentiviral injection of p53fl/fl mice 
with Lenti-LucOS that cannot initiate tumor formation also generated fully functional antigen-
specific T cells (Supplementary Figure 1). Therefore, antigen-specific T cell responses 
induced after intramuscular injection of Lenti-LucOS are functional and likely provide protection 
from the formation of sarcomas that express these antigens. 
 
Cancer immunoediting phenotypes require the presence of potent T cell antigens 
 To assay whether autochthonous sarcomas become “edited” (i.e. less susceptible to 
rejection) when derived in immune-competent animals, we compared the growth of multiple 
sarcomas independently derived in KP or KPR mice after transplantation into either wildtype or 
Rag-2-/- immune-compromised mice. While Lenti-LucOS-induced tumors derived in KP mice 
grew similarly upon transplantation into both wildtype or Rag-2-/- mice, many of the Lenti-LucOS-
induced tumors derived in KPR mice were completely rejected (1/7) or had stunted growth (4/7)  
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Figure 2. Functional T cell responses are generated against antigens expressed in 
sarcomas. 
(A) Top: FACS analysis using SIY- and SIN-loaded DimerX reagents to detect tumor antigen 
specific CD8+ T cells in the inguinal lymph nodes either draining (DLN) or peripheral to (PLN) 
the tumors of Lenti-x-induced or Lenti-LucOS-induced tumor-bearing mice. FACS plots are 
gated on PI-negative, CD8+ cells. Bottom: IFN-γ and TNF-α cytokine production in CD8+ T cells 
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from the lymph nodes of mice depicted in (A) after restimulation in vitro with both SIY and SIN 
peptides. FACS plots are representative of at least three mice per group. 
(B) Similar to analyses in (A) except with cells harvested from spleens of tumor-bearing mice. 
To detect tumor-specific CD8+ T cells in the spleens of Lenti-LucOS tumor bearing mice FACS 
was performed with DimerX reagents loaded either with SIY or SIN. 
(C and D) The percent of SIY and SIN-specific T cells that were IFN-γ+TNF-α+ from lymph 
nodes (C) or spleens (D) of KP mice infected with Lenti-LucOS that developed a “sarcoma” or 
were “tumor-free” at the time of analysis. Percentages were determined by comparing the 
fraction of CD8+ cells in duplicate samples stained for DimerX or cytokine production. As a 
positive control, mice were infected with an influenza strain engineered to express the SIY 
antigen (WSN-SIY) and endogenous T cells reactive to SIY were analyzed after four months. 
Data is the mean ± SEM from 3-4 mice per group. 
 
 
 
 
upon transplantation into wildtype mice compared to Rag-2-/- mice (Figure 3A,B). These results 
closely recapitulate previous experiments performed in a similar manner using a MCA-induced 
model of sarcomagenesis (Shankaran et al., 2001). 
 Next we wanted to determine whether similar results could be observed after the 
transplantation of Lenti-x-induced sarcomas that lacked the strong T cell antigens. Surprisingly, 
Lenti-x-induced sarcomas derived in KP and KPR mice grew equally well when transplanted 
into wildtype and Rag-2-/- mice, regardless of their origin (Figure 3C,D). Therefore, unlike Lenti-
LucOS-induced sarcomas derived in KPR mice, Lenti-x-induced sarcomas derived in KPR mice 
were not susceptible to lymphocyte-mediated anti-tumor responses. We hypothesize that a lack 
of potent T cell antigens in Lenti-x-induced sarcomas may be responsible for the failure of 
lymphocytes to impede tumor growth upon transplantation, and that tumor antigen expression is 
a prerequisite for the lymphocyte-mediated immunoediting process. The previously reported 
immunogenicity of MCA-induced sarcomas derived in immune-compromised mice may be due 
to the de novo generation of potent tumor neoantigens as a consequence of the mutagenic 
activity of MCA (Khong and Restifo, 2002; Prehn and Main, 1957). However, we found that 
MCA treatment of non-immunogenic Lenti-x-induced sarcoma cell lines in vitro, very rarely 
produced clones with increased immunogenicity (Supplementary Figure 2). This may not be  
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Figure 3. Cancer immunoediting phenotypes require the presence of potent T cell 
antigens. 
Results plotted in A-D are the mean tumor volume ± S.E.M. of tumors transplanted into 3-5 
wildtype or 1-2 Rag-2-/- recipients. Transplant experiments were repeated for many of the tumor 
lines in A-D with similar results. 
(A) Lenti-LucOS-induced sarcomas derived independently in KPR mice (n = 6, different color 
lines) were transplanted into wildtype mice (solid lines) or Rag-2-/- mice (dashed lines) and 
tumor growth was measured. One additional tumor line exhibited delayed growth in wildtype 
mice but was excluded from this plot due to its rapid growth beyond the scale of the tumors 
depicted. 
(B) Similar to (A) except Lenti-LucOS-induced sarcomas were derived in KP mice. 
(C) Similar to (A) except sarcomas were induced in KPR mice with Lenti-x. 
(D) Similar to (C) except sarcomas were induced in KP mice with Lenti-x. 
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surprising since experiments with fibroblasts transformed with MCA in vitro have shown that 
immunogenicity and tumorigenicity are linked, meaning that the immunogenicity of tumor cell 
lines was the result of mutations that were likely to be both antigenic and oncogenic (Embleton 
and Heidelberger, 1972; Mondal et al., 1971). 
 
Immunoediting occurs by antigen loss 
 If it is true that cancer immunoediting by lymphocytes requires the presence of potent 
tumor antigens, we hypothesized that Lenti-LucOS-induced tumors that appear edited after 
forming in KP mice, may result from the selection of tumor cells that have lost the expression of 
these potent antigens. We analyzed the expression of the tumor antigens by measuring the 
levels of luciferase activity in tumors. Whereas tumors derived in KPR mice were universally 
luciferase positive, tumors derived in KP mice had reduced luciferase activity in all but one out 
of six sarcomas tested (Figure 4A,B). Interestingly, we discovered that the sarcoma that had 
retained luciferase activity also had significantly reduced H-2Kb expression, the MHC class I 
allele responsible for presenting the SIY and SIN antigens, when compared to a panel of other 
sarcomas, even after prior treatment with IFN-γ (Supplementary Figure 3). Therefore, cancer 
immunoediting appears to proceed by the selective outgrowth of tumors that either do not 
express potent antigens or cannot present the antigens on their cell surface. 
 Lenti-LucOS-induced sarcomas derived in KPR mice that grew out after transplantation 
into wildtype mice, also lost the expression of tumor antigens (Supplementary Figure 4). 
Importantly, the growth of tumors that lost antigen expression after being passaged through 
wildtype mice grew comparably upon secondary transplantation into wildtype and Rag-2-/- mice, 
whereas sarcomas passaged through Rag-2-/- mice did not (Supplementary Figure 4), thus 
mirroring the results of de novo sarcomagenesis in this transplantable system. To test whether 
antigen loss in edited tumors was sufficient to provide a means of escape for Lenti-LucOS- 
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Figure 4. Immunoediting occurs by the selection of tumor cells that have epigenetically 
silenced antigen expression. 
(A) Representative in vivo luciferase activity of Lenti-x-induced or Lenti-LucOS-induced 
sarcomas derived in K-rasLSL-G12D/+;p53fl/fl;Rag-2+/- (KP) or K-rasLSL-G12D/+;p53fl/fl;Rag-2-/- (KPR) 
mice demonstrates antigen loss in KP-derived sarcomas. Note: “POS CTRL” sarcoma was 
luciferase positive because it was induced in a K-rasLSL-G12D/+;p53fl/fl;R26LSL-LSIY/+ (KPL-SIY) 
mouse. 
(B) Luciferase expression from Lenti-LucOS-induced sarcoma cell lines derived in KPR or KP 
mice. 
(C) Two independent tumors (3919 and 4070) that lost antigen expression (AgLoss) upon 
passage through immune-competent mice were transplanted into wildtype (solid blue line) or 
Rag-2-/- (dashed blue line) 129S4/SvJae mice and tumor growth was monitored. Alternatively, 
the antigens were reintroduced by lentiviral infection with a LucOS-expressing construct (AgLoss-
LucOS) and then transplanted into wildtype (solid red line) or Rag-2-/- (dashed red line) 
129S4/SvJae mice and tumor growth was monitored. Tumor volumes represent the mean ± 
SEM of transplants into three wildtype mice or one Rag-2-/- mouse as a control. 
(D) Cell lines from three independent Lenti-LucOS sarcomas induced in KPR mice (Primary, 
black columns), and then passaged through Rag-2-/- mice (Tx->Ragnull, grey columns), or 
passaged through wildtype mice (Tx->Rag+) were treated for three days with 1µM of 5-aza-2’-
deoxycytidine (Aza) and then analyzed for luciferase activity (luciferase activity from untreated 
cell lines is also shown). Mean ± SEM from two experiments. 
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induced sarcomas derived in KP mice, we reintroduced the LucOS antigens into sarcomas that 
had lost expression of the antigens after passage in wildtype mice (called AgLoss tumors). Re-
expression of LucOS in these tumors led to severely stunted tumor growth, indicating that loss 
of antigen expression was the primary means of tumor escape in this setting (Figure 4C). 
 
Tumor antigens expression is impeded by hypermethylation 
 To test whether epigenetic silencing of tumor antigen expression via DNA methylation 
was responsible for antigen loss and tumor escape, we treated cell lines that had lost luciferase 
expression with 5-aza-2’-deoxycytidine (Aza) and monitored the cells for the induction of 
luciferase activity. In several independent lines that lost luciferase expression after 
transplantation into immune-competent mice, luciferase activity could be completely restored 
with Aza treatment (Figure 4D). Therefore, in the context of T cell responses targeting potent 
antigens that are not required for tumor maintenance, tumors can escape through the selection 
of cells that have epigenetically silenced the expression of the tumor antigens. 
 
DISCUSSION 
 Using an autochthonous, genetically engineered model of sarcomagenesis we show that 
T lymphocyte-driven tumor antigen loss is a critical means by which cancer immunoediting 
occurs in a primary tumor setting. While tumor antigen loss has been shown in multiple 
transplantable models of cancer, it has not been demonstrated in tumors that arise 
endogenously. This is primarily due to the fact that carcinogen-induced models of primary 
sarcomagenesis generate different antigens in each individual tumor, making it impossible to 
track their expression during primary tumor development. Furthermore, identifying such 
antigens from progressively growing tumors may not be possible if antigen expression is lost 
during the natural progression of these tumors due to the pressures of immunoediting. The 
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presence of such antigens could have been inferred by the fact that sarcomas derived in 
lymphocyte-deficient mice are often rejected upon transplantation into immune-competent mice, 
but such antigens have yet to be identified. In addition, a multitude of alternative mechanisms, 
besides antigen loss, could provide a means for the escape of carcinogen-induced sarcomas in 
immune-competent mice (Dunn et al., 2006; Smyth et al., 2001; Zitvogel et al., 2006). By 
inducing sarcomas that express model tumor antigens, we were able to obviate these 
complications, enabling us to track tumor-reactive T cells as well as the expression of model 
tumor antigens in tumors. 
 Just as MCA-induced sarcomas do not form as readily in immune-competent compared 
to immune-compromised mice, we found that autochthonous tumors arose less frequently in 
immune-competent mice (KP) compared to Rag-2-/- mice (KPR). Protection seemed to be at 
least partially dependent on the expression of tumor-specific antigens (TSAs) in the primary 
tumors. Only tumors induced with integrating lentiviruses that provide stable gene expression in 
infected cells showed differences in tumor penetrance in KP compared to KPR mice. Tumors 
induced in wildtype mice with Ad-Cre viruses, that only express Cre protein transiently, did not 
have reduced susceptibility to tumor formation (as demonstrated here and previously in (Kirsch 
et al., 2007)). However, the titer of Ad-Cre and lentiviral-Cre vectors is difficult to compare 
directly, and it is possible that the dose of Ad-Cre administered causes the transformation of a 
much greater number of tumor-initiating cells, thus overwhelming the capacity of the immune 
system to regulate the development of sarcomas. In addition, we found that tumor-specific 
antigen expression was critical to immune surveillance when R26LSL-LSIY/+ mice, that are tolerant 
to the luciferase and SIY antigens, were more susceptible to tumor formation with Lenti-LucS 
than R26+/+ littermates. Although this model may be complicated by the use of viral vectors to 
initiate the tumorigenesis process, all inducible models of cancer may be problematic due to 
effects on the immune system during tumor induction. The effect of MCA-injection on the 
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immune system and tumor development has also been debated (Hewitt et al., 1976; Qin and 
Blankenstein, 2004; Scott, 1991). Nevertheless, using a new model of sarcomagenesis, we find 
evidence to support the hypothesis that lymphocyte responses can act early to eliminate 
sarcomas prior to their progression to palpable tumors. 
 Using this autochthonous model of sarcomagenesis we also found evidence of an 
equilibrium state waged between lymphocytes and tumors during the process of cancer 
immunoediting. Although we have not provided direct evidence that lymphocytes actively 
restrain tumor progression in this model, this was elegantly shown previously with the use of 
antibodies to deplete specific immune cell populations (Koebel et al., 2007), it is evident that the 
onset of overt disease is delayed in immune-competent KP mice compared to lymphocyte-
deficient KPR mice. It is possible that the equilibrium state may be partially dependent upon the 
presence of tumor-specific antigens, because significantly delayed tumor onset (after 180 days) 
occurred more frequently in mice with Lenti-LucOS-induced sarcomas (30.7%, n = 13) than 
mice with Lenti-x-induced sarcomas (16.7%, n = 6). It would be interesting to detect very early 
stage tumors that are held in an equilibrium state to determine whether the maintenance of 
antigen expression is required for this phase of immunoediting, however, it has not been 
possible to detect such early lesions in this model. This may indicate that the equilibrium phase 
occurs at a stage of tumor development that is not detectable by histological analysis. Depleting 
CTLs with anti-CD8 antibodies following tumor-induction could serve as an alternative means to 
examine tumors in equilibrium. CD8-depletion may release tumors to grow progressively so that 
they could be harvested and analyzed for antigen expression (Koebel et al., 2007). 
 Ultimately, autochthonous tumors escape immune regulation by losing expression of 
TSAs. The absence of TSAs in sarcomas arising in immune-competent mice coincides with the 
capacity of these tumors to grow progressively upon serial transplantation into other immune-
competent mice. Re-introduction of the same tumor antigens into sarcomas that had escaped 
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immunosurveillance, was sufficient to make the sarcomas susceptible to lymphocyte-mediated 
regulation, making it unlikely that alternative means of immune evasion were acquired in these 
tumors. The mechanism of antigen loss in these tumors was epigenetic in nature because 
antigen expression in tumor cell lines could be restored by blocking the incorporation of 
methylated DNAs with 5-aza-2’-deoxycytidine treatment. However, it is possible that the 
expression of model TSAs from genomically integrated lentiviral vectors might make the 
antigens more susceptible to gene silencing by methylation. It will be important to examine 
whether TSAs expressed from endogenous loci are silenced by a similar mechanism to evade 
immunosurveillance. 
Most importantly, we found that inducing sarcomas in the absence of potent TSAs (using 
Lenti-x), significantly reduced the immunogenicity of transplanted sarcomas. Lenti-x-induced 
sarcomas derived in Rag-2-/- mice were able to grow without inhibition after transplantation into 
immune-competent hosts. This may indicate that the immunogenicity of MCA-induced sarcomas 
is a consequence of the generation of carcinogen-mediated mutations that serve as TSAs in 
these tumors (Embleton and Heidelberger, 1975; Khong and Restifo, 2002; Prehn and Main, 
1957). In contrast to carcinogen-induced cancer models, cancers that arise spontaneously in 
mice have typically been found to be weakly immunogenic (Embleton and Heidelberger, 1972, 
1975; Hewitt et al., 1976; Prehn and Main, 1957; Scott, 1991). Therefore, expression of TSAs 
may be a critical prerequisite for the establishment of immunosurveillance and the process of 
immunoediting. The identification and characterization of such TSAs in human cancers may 
also be a critical prerequisite for the generation of effective anti-cancer immunotherapies in 
patients suffering with this disease. 
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MATERIALS AND METHODS 
Mice and tumor induction 
129S4/SvJae strains backcrossed 8 generations were used for all experiments. Trp53fl mice 
were provided by A. Berns (Jonkers et al., 2001), K-rasLSL-G12D were generated in our laboratory 
(Jackson et al., 2001), and Rag-2-/- mice were purchased from The Jackson Laboratory (Bar 
Harbor, ME). Sarcomas were induced in KP and KPR mice by intramuscular injection of the left 
hind limb with replication-incompetent viruses expressing Cre recombinase as reported 
previously (Kirsch et al., 2007). Mice were monitored twice a week for palpable sarcoma 
formation beginning 50 days after intramuscular injection. All animal studies and procedures 
were approved by the Massachusetts Institute of Technology’s Committee for Animal Care. 
 
Lentiviral production 
Lentivirus production by transfection of 293T cells with Δ8.2 (gag/pol), CMV-VSV-G, and various 
transfer vectors expressing Cre was performed as previously described (Tiscornia et al., 2006). 
 
Preparation, culture, and transplantation of primary sarcomas 
Primary sarcomas were explanted and single cell suspensions were generated by mincing and 
digesting the tissues for ~1 hour at 37°C in 125 U/ml Collagenase Type I (Gibco), 60 U/ml 
Hyaluronidase (Sigma), and 2 mg/ml Collagenase/Dispase (Roche), followed by passage 
through a 70 µm filter. In most experiments, 2x105 cells were used for immediate subcutaneous 
transplantation of the freshly isolated single cell suspensions. Alternatively, cell lines were 
generated from the primary autochthonous tumors and subsequently 2x105 cells were 
transplanted after trypsinization and three washes in plain DME medium. Immune-competent or 
Rag-2-/- mice on the 129S4/SvJae background were used for all transplants. These recipient 
mice came from the same mouse strains used to generate the autochthonous tumors. 
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Subcutaneously transplanted tumor volumes were calculated by multiplying the length x width x 
height of each tumor. 
 
Flow cytometry 
Cell suspensions from lymphoid organs were prepared by mechanical disruption between 
frosted slides. Single cell suspensions were stained with the specified antibodies for 20-30 min 
after treatment with Fc Block (BD Pharmingen). α-CD8α (53-6.7), α-IFNγ (XMG1.2), α-TNFα 
(MP6-XT22), and DimerX I (Dimeric Mouse H-2Kb:Ig) were from BD Pharmingen. All antibodies 
were used at 1:200. Peptide-loaded DimerX reagents were prepared as specified by 
manufacturer and used at 1:75. Staining cells with the same ligand labeled with PE or APC for 
improved sensitivity has been previously reported (Stetson et al., 2002; Townsend et al., 2001). 
Propidium iodide was used to exclude dead cells when cell were not fixed. Cells were read on a 
FACSCalibur and analyzed using Flowjo software (Tree Star). 
 
Cytokine production 
Single cell suspensions from lymphoid organs were resuspended in the presence or absence of 
SIYRYYGL and SIINFEKL peptides in OPTI-MEM I (Gibco) supplemented with GolgiPlug (BD 
Pharmingen) for ~4 hours at 37°C, 5% CO2. Cells were then fixed and stained for intracellular 
cytokines using the Cytofix/Cytoperm kit (BD Biosciences).  
 
Luciferase detection 
Freshly explanted tumors or cell lines were lysed in Cell Culture Lysis Reagent, mixed with 
Luciferase Assay Reagent according to manufacturer’s instructions (Promega), and relative light 
units (RLU) were detected using the Optocomp I luminometer (MGM Instruments). RLUs were 
standardized based on the total number of cells or total protein (Bio-Rad Protein Assay) used in 
  176 
each assay. In vivo bioluminescence images were obtained using the NightOWLII LB983 
(Berthold Technologies) or the IVIS Spectrum (Xenogen Corp.) bioluminescent imaging systems 
after intraperitoneal injection of 1.5 mg Beetle Luciferin (Promega). 
 
5-aza-2’-deoxycytidine treatment 
Tumor cell lines were plated at low confluency (2x105 cells/ well of 6-well plate), and treated with 
1µM of 5-aza-2’-deoxycytidine replaced daily for three consecutive days. Cells were then 
analyzed for luciferase activity. 
 
Influenza 
The WSN-SIY influenza strain was provided by J. Chen. Mice were infected with 20 pfu of virus/ 
mouse by intratracheal intubation and inhalation. FACS analyses presented here were 
performed four months after infection. 
 
Statistical analyses 
P-values for statistical comparisons were generated using unpaired two-tailed Fisher exact 
probability tests or student’s T-tests. 
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Supplementary Figure 1. T cell responses are specific to exogenously introduced 
neoantigens expressed in lentiviruses and tumors. 
(A) KP (left) or wildtype mice (right) were infected intramuscularly with Lenti-LucOS and 
analyzed five weeks later (no tumors were apparent in KP infected mice). Top: FACS analysis 
using SIY- and SIN-loaded DimerX reagents to detect antigen specific CD8+ T cells in the 
spleen. FACS plots are gated on PI-negative, CD8+ cells. Bottom: IFN-γ and TNF-α cytokine 
production in CD8+ T cells from the spleens of mice depicted in (A) after restimulation in vitro 
with both SIY and SIN peptides or left unstimulated with peptides. Representative of the 
analysis of three mice per group. 
(B) Comparison of KP (left) or KPL-SIY mice (right) infected intramuscularly with Lenti-LucOS 
shows a lack of SIY-specific T cells in mice with the R26LSL-LSIY allele. Top: FACS analysis using 
SIY- or SIN-loaded DimerX reagents to detect antigen specific CD8+ T cells in the spleen. FACS 
plots are gated on PI-negative, CD8+ cells. Bottom: IFN-γ and TNF-α cytokine production in 
CD8+ T cells from the spleens of mice depicted in (A) after restimulation in vitro with either SIY 
or SIN peptides. Representative of the analysis of at least 2 mice per group. 
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Supplementary Figure 2. MCA treatment in vitro may enhance the immunogenicity of 
Lenti-x-induced sarcomas. 
Examples from two Lenti-x-induced sarcoma cell lines treated with 40 µg/ml of MCA for six days 
before single clones were picked and grown by limiting-dilution. Only two clones of 20 total 
MCA-treated clones that were transplanted, showed a modest increase in immunogenicity 
compared to the parent (4044, left) or other MCA-treated clones (4042, right). However, 
because it was such a rare occurrence to find clones that had increased immunogenicity after 
treatment with MCA, it is possible that these clones represent variants already present within 
the primary tumor cell population that were naturally more immunogenic, and their 
immunogenicity may not be a direct effect of MCA treatment. 
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Supplementary Figure 3. Reduced expression of H-2Kb on the surface of a KP-derived 
Lenti-LucOS-induced sarcoma that maintained expression of the LucOS antigens. 
Freshly harvested sarcomas were cultured 20-24 hours in the presence of 10 units of IFN-γ 
(solid line) or left untreated (dashed line) and then stained with anti-H-2Kb antibodies and 
analyzed by flow cytometry (shaded histogram are negative controls stained with anti-CD8 
antibodies). All sarcomas were induced with Lenti-LucOS. 10143 was derived in a KPR mouse 
and retained luciferase expression, while 8377, 9912, and 10077 were derived in KP mice and 
were luciferase negative (see Figure 4B). 10015 was derived in a KP mouse but retained 
luciferase expression. 
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Supplementary Figure 4. Reduced antigen expression and immunogenicity of KPR-
derived tumors passaged through immune-competent mice. 
(A) Antigen expression in primary Lenti-LucOS-induced tumors derived in KPR mice was lost 
after transplantation into wildtype mice but not Rag-2-/- mice (as determined by luciferase activity 
in vivo). Luciferase-negative tumor in wildtype recipient is outlined. Results are representative of 
the transplantation of four independent Lenti-LucOS-induced sarcomas derived in KPR mice. 
(B) Comparison of the relative tumor growth (mean final tumor volume in wildtype versus  
Rag-2-/-) of Lenti-LucOS-induced sarcomas derived in KPR mice after passage through wildtype 
(Rag+) or Rag-2-/- mice (Ragnull). Note that upon the 2nd transplantation, tumors passaged 
through wildtype animals grew more similarly in wildtype and Rag-2-/- mice than tumors 
passaged through Ragnull mice, indicating a reduction in immunogenicity coincident with a loss 
in tumor antigen expression (A). 
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ABSTRACT 
Immunotherapeutic strategies to boost anti-tumor T cell responses have been largely ineffective 
in treating cancer patients. New experimental models of cancer in mice more accurately 
recapitulate the human disease and provide new opportunities to test immunotherapeutic 
strategies and understand these inconsistent clinical results. Several investigations have shown 
that therapeutic vaccination against tumor-associated antigens can provoke anti-tumor T cell 
responses, but that T cells rapidly lose activity within the context of the tumor microenvironment. 
Here we show that vaccination against specific antigens expressed in autochthonous mouse 
lung adenocarcinomas using engineered strains of influenza can stimulate anti-tumor T cell 
responses that retain activity and can eradicate recently initiated tumors. In addition, therapeutic 
vaccination can act to stimulate anti-tumor T cell responses in an antigen-independent fashion, 
enhancing the expansion and the activity of T cells that recognize antigens whose expression is 
confined to tumors. Understanding the mechanism by which the T cell response is enhanced 
under the conditions of live viral infection could reveal new strategies to boost anti-tumor T cell 
responses to treat human lung cancer. 
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INTRODUCTION 
Vaccination strategies can generate strong memory responses to specific antigens that 
can protect individuals from subsequent infection by pathogens that produce the antigen 
(Dermime et al., 2004; Pardoll, 2002). Such strategies are effective because the vaccine 
preparations are formulated to provide optimal conditions for immune cell activation, providing 
signals to facilitate enhanced antigen presentation and co-stimulation to responding T cells. A 
critical issue with cancer vaccination, however, is that it is rarely prophylactic (Lollini and Forni, 
2002). Patients with cancer have instead been treated therapeutically with “vaccines” when the 
cancers have already formed and frequently after the disease has already significantly 
progressed (Goldman and DeFrancesco, 2009). Therefore, cancer vaccines are really a form of 
active immunotherapy to boost immune responses against tumors rather than protect patients 
from the development of cancer. As such, cancer vaccines more closely resemble 
immunotherapies against persistent infections (Kim and Ahmed, 2010; Pardoll, 2002). 
Nevertheless, cancer immunotherapy is an attractive strategy to enhance immunity to cancer by 
stimulating new, or greater numbers of T cells specific for tumor antigens. In these techniques, 
tumor antigens, in the form of DNA, peptides, or killed tumor cells, can be administered with 
adjuvants, such as cytokines or Toll-like receptor agonists, or antigens can be engineered into 
attenuated pathogens, such as bacteria or viruses, to enhance immune cell activation towards 
antigens expressed in tumors (Bocchia et al., 2000). The use of adjuvants or pathogens in 
vaccines may also facilitate the effector function of T cells by promoting an inflammatory 
environment at the tumor site (Laheru et al., 2005). Some of these methods have demonstrated 
efficacy in the clinic, but the results are highly variable (Goldman and DeFrancesco, 2009; 
Morse et al., 2005; Rosenberg et al., 2004). With the development of new experimental models 
of cancer in mice that more accurately recapitulate the human disease, we may gain new 
insights into the reasons behind this inconsistent clinical data.   
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We previously explored the role of endogenous immune responses to autochthonous 
lung adenocarcinomas that expressed potent T cell antigens (DuPage et al., Chapter 2). T cell 
responses against these tumors could delay the malignant progression of the cancer, but 
ultimately the anti-tumor T cells lost activity and the tumors escaped this immune response. 
Prophylactic vaccination with a dendritic cell line could provide protection from lung tumor 
development and further delay malignant progression of the cancers. However, it is likely 
impossible to recapitulate such results in human cancer patients because the tumor antigens to 
target for prophylactic vaccination cannot be predicted (Bocchia et al., 2000; Lollini and Forni, 
2002). In this study we wanted to understand how autochthonous lung tumors respond to 
therapeutically generated T cell responses as these types of responses might mimic immune-
tumor interactions in cancer patients after immunotherapy. 
Several previous investigations using endogenous mouse models of cancer have shown 
that various forms of vaccination against tumor-associated antigens can either generate or 
enhance anti-tumor T cell responses to pancreatic, mammary, and prostate cancers (Anderson 
et al., 2007; Ercolini et al., 2005; Speiser et al., 1997; Verdeil et al., 2008). Here we describe a 
vaccination approach against endogenous mouse lung cancers that utilizes a recombinant 
influenza virus engineered to express the SIY peptide, WSN-SIY (Bai et al., 2008; Cheung et 
al., 2008). Influenza is an ideal candidate vaccine against lung cancer because it naturally 
infects the lung, generating a robust cytotoxic T cell response within the same environment that 
tumors develop. We reveal that vaccination can stimulate anti-tumor T cell responses both 
directly and indirectly by modifying the expansion and the activity of tumor-specific T cells. 
Vaccination can be effective early during tumor progression, but as tumors progress, 
vaccination is less effective because it does not induce as many anti-tumor T cells and tumor 
growth may allow tumors to escape more readily via antigen loss. These data have clear 
 189 
implications for understanding the pitfalls of vaccination therapies and provide important insights 
into additional ways that vaccines may be harnessed to treat human lung cancer. 
 
RESULTS 
Infection with an influenza engineered to express tumor antigens at tumor initiation 
protects mice from tumor development 
We previously showed that prophylactic vaccination of mice with a dendritic cell line 
(DC2.4-LucOS) engineered to express the same antigens expressed in lung adenocarcinomas 
induced with Lenti-LucOS could generate memory T cells that provided substantial protection 
from the development of these lung tumors (DuPage, et al., Chapter 2). Here we wanted to 
examine the effect of therapeutic vaccination with strains of influenza engineered to express the 
SIY antigen (WSN-SIY) that is also expressed in Lenti-LucOS tumors. To first determine the 
effect of a strong effector T cell response directed against a single antigen (SIY) at tumor 
initiation (as opposed to a memory T cell response), we infected mice with a control influenza 
that does not express SIY (WSN) or the SIY-expressing influenza (WSN-SIY) by intratracheal 
inhalation of 20 pfu of virus concomitantly with the inhalation of Lenti-LucOS to initiate lung 
tumor formation. As shown in Figure 1A, simultaneous influenza infection had a significant 
effect on tumor burden, but only when the influenza expressed the SIY antigen also present in 
the initiated tumors.  These data suggest that the expression of antigens in lung tumors 
themselves do not sufficiently prime T cells to respond to and eliminate tumors. In addition, 
simply creating an inflammatory environment with influenza infection during tumor initiation is 
not sufficient to enhance the priming of tumor antigen-specific T cell responses that can control 
tumor development. 
The reduced tumor burden after WSN-SIY infection at tumor initiation correlated with an 
increased frequency of SIY-specific CD8+ T cells in the lymph nodes draining the lungs (DLN)  
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Figure1. Infection with an influenza engineered to express tumor antigens at tumor 
initiation protects mice from tumor development. 
(A) The number of tumors on the surface of the lungs of mice bearing Lenti-LucOS tumors 
analyzed 16 weeks after tumor initiation that received no influenza (ctrl), WSN, or WSN-SIY 
simultaneously with tumor initiation. Each data point represents a mouse. *p<0.05, ***p<0.001. 
(B) Representative FACS analysis for SIY-specific CD8+ T cells in the lung tumor draining lymph 
nodes (DLN) and spleens of Lenti-x or Lenti-LucOS tumor-bearing mice from (A) that received 
WSN-SIY at the time of tumor initiation (ctrl did not receive influenza). FACS plots are gated on 
PI-negative cells and the percent of SIY/Kb+ cells of total CD8+ cells is indicated. Adjacent plots 
to right are gated on the SIY/Kb+CD8+ cells to show CD127 expression on SIY-specific cells. 
The percent of cells that are CD127+CD8+ and CD127-CD8+ is indicated. N.D. (None Detected) 
indicates that the percent of SIY/Kb+ cells is below the reliable limit of detection with the DimerX 
reagent. 
(C) Graphs of the percent of SIY-specific (left) or SIN-specific (right) CD8+ T cells detected in 
the DLN from mice in (A). n = 3-6 mice per group, mean ± SEM. 
(D) The number of tumors on the surface of the lungs of mice bearing Lenti-LucOS tumors 
analyzed 16 weeks after tumor initiation that received no influenza (ctrl) or WSN-SIY eight 
weeks after tumor initiation. 
(E) Graph of the percent of SIY-specific CD8+ T cells detected in the DLN from mice in (D). n = 
4-7 mice per group, mean ± SEM. *p<0.05. 
 192 
(Figure 1B,C). In contrast, the SIN-specific T cell response was unaffected or potentially even 
reduced by WSN-SIY vaccination, and SIY-specific T cells were only detected in the spleens of 
mice that had received WSN-SIY (Figure 1B,C). We examined the expression of CD127 (IL-
7Rα) on the surface of SIY-specific T cells to determine the differentiated state of the T cells 
(Kaech et al., 2003). We found that while Lenti-x tumor-bearing mice infected with WSN-SIY 
had high expression of CD127 on the majority of SIY-specific cells, indicative of a resting central 
memory phenotype, SIY-specific T cells in Lenti-LucOS tumor-bearing mice were largely CD127 
negative, indicative of effector T cells (Figure 1B). Lenti-LucOS tumor-bearing mice that 
received WSN-SIY had SIY-specific T cells with an intermediate CD127 phenotype, indicating 
that while memory cells may have been generated, an ongoing effector response was still 
engaged due to the expression of the SIY antigen in the lung tumors (compare the fraction of 
CD127 positive cells in the DLN versus the spleen) (Figure 1B). Regardless of WSN-SIY 
infection, between 70-80% of SIN-specific T cells in Lenti-LucOS tumor-bearing mice had low 
expression of CD127, similar to SIY-specific T cells in the unvaccinated Lenti-LucOS tumor-
bearing mice (not shown). Therefore, effective vaccination at tumor initiation requires viruses 
that express shared antigens also expressed in tumors to induce the differentiation of antigen-
specific memory T cells against the virus that can cross-react with tumors. 
 
Therapeutic vaccination against established tumors does not reduce the lung tumor 
burden 
 We have established that early infection at tumor initiation can protect mice from tumor 
development, next we wanted to determine whether established tumors could be eradicated by 
WSN-SIY vaccination. In this regimen we allowed Lenti-LucOS tumors to develop for eight 
weeks before challenging mice with WSN-SIY. Unlike, the results with WSN-SIY infection at 
tumor initiation, vaccination at eight weeks after tumor initiation did not reduce the tumor 
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burden, despite significantly increasing the fraction of SIY-specific T cells in the DLN and spleen 
(Figure 1D,E, and not shown). Therefore, tumor elimination with WSN-SIY vaccination is only 
possible when challenging mice very early during tumor development. 
 
A narrow window of time exists after tumor initiation for effective therapeutic vaccination 
with influenza 
Next we wanted to determine if therapeutic vaccination with WSN-SIY could be effective 
in reducing the tumor burden at any point after tumors had been initiated. We vaccinated mice 
with WSN-SIY simultaneously, two weeks, or six weeks after tumor initiation and assessed the 
tumor burden as well as the magnitude of the SIY-specific T cell response 16 weeks after the 
tumors were induced (Figure 2A). Vaccination simultaneously or at two weeks post tumor 
initiation reduced the number of tumors in Lenti-LucOS tumor-bearing mice, but vaccination at 
six weeks after tumor initiation did not reduce the tumor burden (Figure 2B). WSN-SIY 
vaccination at any time during the course of Lenti-x tumor progression did not affect the tumor 
burden, indicating that the effectiveness of influenza vaccination depended upon shared antigen 
expression in the viruses and tumors (Figure 2C). We also analyzed luciferase activity in 
explanted tumors to assess the maintenance of LucOS antigen expression. We found that Lenti-
LucOS tumors in WSN-SIY vaccinated mice selectively lost antigen expression, but in a manner 
dependent on the time of vaccination (Figure 2D). Mice vaccinated simultaneously or at two 
weeks after tumor initiation lost antigen expression in 80-90% of tumors, whereas only 30% of 
tumors lost antigen expression in mice vaccinated six weeks after tumor initiation. In addition, 
the level of luciferase activity in tumors that did not completely lose antigen expression was 
quantifiably reduced compared to unvaccinated mice (not shown). Therefore, although there 
was no reduction in tumor number in mice vaccinated six weeks after tumor initiation, there was 
a reduction in the number of tumors that maintained high antigen expression. 
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Figure 2. Therapeutic vaccination early after tumor initiation can reduce the lung tumor 
burden. 
(A) Scheme of therapeutic vaccination regimen. 
(B) The number of tumors counted in ten histological sections of lungs (two sections per lobe) of 
mice bearing Lenti-LucOS tumors analyzed 16 weeks after tumor initiation that received no 
influenza (ctrl) or WSN-SIY at tumor initiation or two weeks or six weeks after tumor initiation. 
Each data point represents the tumor number from one mouse. *p<0.05, **p<0.01. 
(C) Same scheme as in (B) but with Lenti-x tumors. Tumor numbers were not significantly 
different between any of the groups. 
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(D) Freshly explanted tumors were assayed for luciferase activity and the percent of tumors that 
were luciferase positive (> 50 RLU/µg protein) in unvaccinated and WSN-SIY vaccinated mice is 
plotted. n = 2-7 mice, 8-28 tumors, per group. 
(E) Graph of the percent of SIY-specific CD8+ T cells detected in the spleen from mice in (B) 
and (C). Lenti-x + WSN-SIY represents combined data from WSN-SIY infection at different time 
points because the percent of SIY-specific cells was unchanged. n = 4-13 mice per group, mean 
± SEM. *p<0.05, ***p<0.001. 
(F) Comparison of tumor number versus the percent of SIY-specific T cells in the spleens (log 
scale) from Lenti-LucOS tumor-bearing mice vaccinated with WSN-SIY. 
 
 
 
 
To understand why vaccination as early as six weeks after tumor initiation did not lead to 
significant tumor eradication, we assessed the capacity of the differentially timed vaccinations to 
generate memory T cells. The fraction of SIY-specific T cells found in the spleens of mice 
vaccinated six weeks after tumor initiation was significantly reduced compared to mice 
vaccinated at the earlier time points (Figure 2E). Indeed, we could observe an inverse 
correlation between the fraction of SIY-specific T cells found in the spleens of WSN-SIY 
vaccinated mice and their lung tumor burden (Figure 2F). Thus, the capacity to generate 
memory cells in mice bearing six week-old established Lenti-LucOS tumors is reduced and may 
account for the lack of a reduced tumor burden in these mice. 
 
Epitope spreading to the tumor-expressed SIN antigen with influenza vaccination 
 During the various therapeutic vaccinations with WSN-SIY, in addition to following the 
SIY-specific response, we continued to monitor the response of T cells specific for SIN. 
Interestingly, we noticed that unlike infection at initiation, in which the SIN-specific T cell 
response seemed unaltered, the SIN-specific T cell response appeared to be enhanced with 
WSN-SIY infection at time points well after tumors were initiated. Eight days after WSN-SIY 
infection of mice bearing established Lenti-LucOS tumors, most SIY-specific T cells in the DLNs 
and lungs had the capacity to produce IFN-γ and TNF-α (Figure 3A-C). This activity was much  
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Figure 3. Influenza vaccination with WSN-SIY can enhance T cell responses to tumor 
antigens not expressed in the virus. 
(A) Top: FACS analysis using SIY- or SIN-loaded DimerX reagents to detect tumor antigen 
specific CD8+ T cells in the lung-draining lymph nodes (DLN) of Lenti-LucOS tumor-bearing or 
wild-type mice infected with WSN-SIY. FACS plots are gated on PI-negative, CD8+ cells. 
Bottom: IFN-γ and TNF-α cytokine production in CD8+ T cells from the DLN of the same mice 
shown above after in vitro stimulation with SIY, SIN, or no peptides. Tumor-bearing mice were 
infected with WSN-SIY 15 weeks after tumor initiation. FACS plots are representative of two 
mice per group. 
(B and C) Graphs of the percent of SIN-specific or SIY-specific T cells from the mice depicted in 
(A) capable of producing both IFN-γ and TNF-α (black bars) or IFN-γ alone (white bars) in the 
DLN (B) or the lung (C). 
(D) FACS analysis using SIY- (left) or SIN-loaded (right) DimerX reagents to detect tumor 
antigen specific CD8+ T cells in the DLN of Lenti-LucOS or Lenti-x tumor-bearing mice left 
untreated or infected with WSN-SIY. FACS plots are gated on PI-negative, CD8+ cells. The 
arrow indicates the concomitant increase in SIN-specific T cells in the DLN after WSN-SIY 
infection of Lenti-LucOS tumor-bearing mice. 
(E) To determine whether the population of SIN-specific T cells was increased in mice receiving 
WSN-SIY, we divided the percent of SIN-specific T cells in vaccinated mice by the percent of 
SIN-specific T cells in unvaccinated littermate pairs. The fold increase in SIN-specific T cells 
with WSN-SIY infection is shown for five different littermate pairs. 
 
 198 
greater than that of endogenous T cells responding to SIY when produced from Lenti-LucOS 
tumors in the absence of WSN-SIY infection (DuPage, et al., Chapter 2). This indicates that the 
failure of therapeutic vaccination beyond six weeks after tumor initiation is not due to SIY-
specific T cells lacking effector function. The surprising finding, however, was that SIN-specific T 
cells also had enhanced activity similar to that of the SIY-specific T cells (Figure 3A-C). This 
was unexpected because only SIY-specific T cells could be directly primed by the engineered 
influenza, and therefore, the increased activity of SIN-specific T cells must have been through 
some different and indirect means. We hypothesized that the enhanced activity of SIY-specific T 
cells primed by WSN-SIY would increase anti-tumor cytotoxicity, and in the context of a viral 
infection in the lung, this could lead to increased presentation of the SIN antigen in the DLN by 
virally matured antigen-presenting cells. This phenomenon by which a productive response to 
one antigen leads to a stronger response to a second antigen, is known as “epitope spreading” 
(Lally et al., 2001; Markiewicz et al., 2001; Vanderlugt and Miller, 2002). By comparing 
littermates that either did or did not receive WSN-SIY, we found that in four of five pairs 
examined, mice that received WSN-SIY had equal or greater numbers of SIN-specific T cells in 
their DLN (Figure 3D,E). Thus, the expansion of SIN-specific T cells with increased functional 
activity may be due to epitope spreading after a cytotoxic anti-tumor response by SIY-specific T 
cell primed directly by WSN-SIY. 
 
Influenza infection without shared tumor antigen expression can boost anti-tumor T cell 
responses against established tumors 
To further investigate whether epitope spreading was boosting the SIN-specific T cell 
response after WSN-SIY vaccination, we examined the response of naïve OT-I T cells that were 
transferred a day after infecting mice harboring established Lenti-LucOS tumors with influenza 
viruses that either did (WSN-SIY) or did not (WSN) express common antigens present in the 
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lung tumors (Figure 4A). Indeed, OT-I T cells had increased activity when transferred into mice 
receiving WSN-SIY compared to mice that did not receive virus (Figure 4B,C). However, we 
were surprised to find that mice infected with the WSN influenza, that does not express any 
common tumor antigens, also resulted in the increased activity of the transferred OT-I T cells 
(Figure 4B,C). In addition, mice receiving the WSN infection had an enhanced recruitment of 
OT-I T cells into the lungs compared to mice that didn’t receive any virus (Figure 4D). Most 
importantly, however, mice receiving naïve OT-I T cells after WSN infection had reduced 
luciferase activity in their lungs that was nearly equivalent to the luciferase activity of WSN-SIY 
infected mice (Figure 4E). This indicates that the combination of OT-I transfer and WSN 
infection had the functional consequence of either inducing the death of antigen-expressing 
tumor cells or selecting for tumor cells with reduced expression of the antigens. To look more 
specifically at the tumors themselves, we repeated the therapeutic regimen shown in Figure 4A, 
but waited several months to allow tumors to grow large enough for individual tumor analysis. 
Whereas the transfer of naïve OT-I T cells or WSN infection alone did not result in the outgrowth 
of tumors that had lost antigen expression, the combination of OT-I T cell transfer and WSN 
infection led to a significant number of tumors that lost antigen expression, though not to the 
extent obtained with WSN-SIY infection (Figure 4F). Further investigation will be needed to 
determine how WSN infection enhances the response of naïve OT-I T cells. Understanding the 
mechanism by which the T cell response is enhanced under these conditions will be important 
for therapeutic strategies. 
 
DISCUSSION 
 Several important insights can be gleaned from these experiments that may help to 
guide better strategies for the treatment of patients with cancer using T cell-based 
immunotherapies. Although it is clear that early vaccination of the tumor site with influenza  
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Figure 4. Influenza vaccination boosts anti-tumor T cell responses against established 
tumors even without expressing shared tumor antigens. 
(A) Scheme of therapeutic vaccination and adoptive T cell transfer regimen. 
(B and C) Graphs of the percent of transferred OT-I T cells (identified as CD8+CD45.1+) capable 
of producing both IFN-γ and TNF-α (black bars) or IFN-γ alone (white bars) in the DLN (B) or the 
lung (C) after transfer into Lenti-LucOS tumor-bearing mice that had not received an influenza 
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vaccine (ctrl) or had received WSN or WSN-SIY one day prior to the adoptive transfer of naïve T 
cells. As a control, 2C T cells were transferred into Lenti-x tumor-bearing mice following 
infection with WSN-SIY. n = 3 mice per group, mean ± SEM.  
(D) The size of the OT-I population in the DLN (top) and the lung (bottom) in the absence (white 
bars) or presence (grey bars) of WSN infection prior to the adoptive transfer of naïve T cells. 
The size of the OT-I population is represented as the fraction of total lymphocytes (based on 
FSC/SSC characteristics) that were CD8+CD45.1+. n = 3 mice per group, mean ± SEM. 
(E) Luciferase activity (RLU/µg protein) from whole lung lysates of mice 12 days after receiving 
naïve 2C or OT-I T cells after prior infection with WSN or WSN/SIY or without prior influenza 
infection (ctrl) as depicted in (A). Lung tissues samples came from mice shown in B-D. n = 3 
mice per group, mean ± SEM. 
(F) Freshly explanted tumors were assayed for luciferase activity and the percent of tumors that 
were luciferase positive (> 50 RLU/µg protein) of the total in each group is plotted. The total 
number of tumors (n) analyzed from at least two mice per group is indicated. 
 
 
 
 
viruses that express antigens shared with the tumors can be effective in reducing the 
subsequent tumor burden, it is unlikely that this can have any direct application in a clinical 
setting because of the need to identify the tumor antigens and begin treatment so early. 
However, despite the fact that viruses that did not express shared tumor antigens were not 
efficacious when given at tumor initiation, the treatment of established tumors with such viruses 
did markedly improve the recruitment and function of tumor-specific T cells. This indicates that 
direct priming against specific tumor antigens may not be necessary for effective 
immunotherapy. 
Therapeutic vaccination two weeks after tumor initiation with WSN-SIY could also 
significantly reduce the overall tumor burden in mice. However, WSN-SIY infection as early as 
six weeks after tumor initiation did not reduce the lung tumor burden. Previous studies have 
indicated that advanced tumors can create an immunosuppressive microenvironment that 
directly suppresses anti-tumor T cell responses (Rabinovich et al., 2007; Zou, 2005). While 
vaccination in several mouse cancer models could produce large numbers of T cells specific to 
tumor antigens, the cells rapidly became unresponsive to the antigens after entering the tumor 
microenvironment (Anderson et al., 2007; Bai et al., 2008; Cheung et al., 2008; Willimsky et al., 
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2008). This did not appear to be the case in this system, however, because SIY-specific (and 
even SIN-specific) T cells retained activity in the lungs following vaccination. In addition, 
reduced levels of antigen expression in the tumors of vaccinated mice indicated that a 
productive T cell response was generated that could drive the outgrowth of tumor cells with 
reduced antigen expression. Similar results have been documented after the treatment of 
patients with melanoma in which tumors had reduced or lost expression of antigens targeted by 
the vaccines (Khong and Restifo, 2002).  
A key difference in mice vaccinated with WSN-SIY at later time points after tumor 
initiation was the size of the responding SIY-specific T cell population detected in the spleen. 
Mice vaccinated six weeks after tumor initiation had significantly fewer SIY-specific T cells 
compared to mice vaccinated earlier with WSN-SIY. Not surprisingly, smaller populations of 
SIY-specific T cells in the spleen correlated with increased numbers of tumors in the lungs. The 
persistence of greater numbers of tumor-reactive T cells in patients receiving adoptively 
transferred tumor-specific T cells has also been correlated with improved clinical responses 
(Morgan et al., 2006). Therefore, quantitatively weaker T cell responses with vaccination at the 
later time points during tumor progression may underlie their reduced efficacy. It is not clear 
what is responsible for the reduced T cell response in the context of established tumors, but we 
speculate that it could paradoxically be the result of the endogenous SIY-specific T cells 
responding to SIY expressed from the tumors that helps to more rapidly eradicate virus-infected 
cells, consequently reducing the effectiveness of the vaccine. In support of this, we find that the 
number of bulk CD8+ T cells recruited to the lungs of mice infected with WSN-SIY compared to 
WSN is reduced in Lenti-LucOS tumor-bearing mice (not shown). In addition to the generation 
of a smaller pool of tumor-reactive T cells, the greater tumor burden encountered at progressive 
states of the disease may present too large of a burden for cytotoxic T cells to completely 
eradicate entire tumor masses. 
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Interestingly, we found that infection with WSN-SIY or even WSN, can enhance the 
expansion and activity of T cells responding to the SIN tumor antigen. We suspect that influenza 
infection may improve the priming of T cells against tumor antigens by inducing tissue damage 
in the lungs that increases tumor antigen release and enhances the activity of the antigen-
presenting cells that stimulate naïve T cells in the tumor draining lymph nodes (Vanderlugt and 
Miller, 2002). However, influenza infection of the lung may also modulate the anti-tumor T cell 
response by changing the tumor microenvironment in the lung such that T cells are recruited 
more efficiently and retain activity upon encounter with tumors expressing cognate antigen 
(Laheru et al., 2005). Understanding the mechanism by which the T cell response is enhanced 
under these conditions could reveal new strategies to boost anti-tumor T cell responses. We 
have begun to further examine how influenza infection may indirectly boost anti-tumor T cell 
responses by trying to recapitulate these results using various TLR ligands in place of influenza 
vaccination. Other investigations have shown that the administration of TLR ligands, such as 
poly(I:C), can increase the accumulation and function of anti-tumor T cells in tumors (Verdeil et 
al., 2008). Preliminary experiments indicate that the intratracheal introduction of poly(I:C), but 
not LPS, can significantly improve the recruitment of CD8+ T cells to the lungs of tumor-bearing 
mice (not shown). Vaccination with influenza in different anatomical locations in tumor-bearing 
mice could potentially separate the role of priming versus augmentation of the tumor 
microenvironment in boosting the anti-tumor T cell response. Although the results presented 
here are sobering because we define only a very short window of time for effective immune 
therapy, we have also provided hope that continued investigation of autochthonous mouse 
models of cancer may provide for the discovery of new and unanticipated approaches to 
effectively treat cancer by harnessing the immune system. 
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MATERIALS AND METHODS 
Mice and tumor induction 
129S4/SvJae strains backcrossed 8 generations were used for the experiments in Figures 1-3. 
C57/BL6 mice backcrossed 11 generations were used for experiments in Figure 4 in which 
transgenic T cells from C57/BL6 mice were adoptively transferred. Trp53fl mice were provided 
by A. Berns (Jonkers et al., 2001), K-rasLSL-G12D were generated in our laboratory (Jackson et al., 
2001), and Rag-2-/- mice were purchased from The Jackson Laboratory (Bar Harbor, ME). Lung 
tumors were induced in K-rasLSL-G12D/+;p53fl/fl mice by intratracheal intubation and inhalation of 
viruses expressing Cre recombinase as reported previously (DuPage et al., 2009; Jackson et 
al., 2005). J. Chen provided the 2C, OT-I, and OT-II TCR transgenic mice and transgenic T cells 
for adoptive transfers came from 2C;Rag-2-/- or OT-I;Rag-2-/- mice on a pure C57/BL6 
background. All animal studies and procedures were approved by the Massachusetts Institute of 
Technology’s Committee for Animal Care. 
 
Lentiviral production 
Lentivirus production by transfection of 293T cells with Δ8.2 (gag/pol), CMV-VSV-G, and various 
transfer vectors expressing Cre was performed as previously described (Tiscornia et al., 2006). 
 
Influenza 
The WSN-SIY and WSN influenza strains were provided by J. Chen. Mice were infected with 20 
pfu of virus/ mouse by intratracheal intubation and inhalation. 
 
Flow cytometry 
Cell suspensions from lymphoid organs were prepared by mechanical disruption between 
frosted slides. Cell suspensions from lungs were generated by mincing and digesting the tissues 
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for ~1 hour at 37°C in 125 U/ml Collagenase Type I (Gibco) and 60 U/ml Hyaluronidase 
(Sigma). Single cell suspensions were stained with the specified antibodies for 20-30 min after 
treatment with Fc Block (BD Pharmingen). α-CD8α (53-6.7), α-CD45.1 (A20), α-mouse IgG1 
(X56), α-IFNγ (XMG1.2), α-TNFα (MP6-XT22), and DimerX I (Dimeric Mouse H-2Kb:Ig) were 
from BD Pharmingen. α-CD127 (A7R34) was from eBioscience. All antibodies were used at 
1:200. Peptide-loaded DimerX reagents were prepared as specified by manufacturer and used 
at 1:75. Staining cells with the same ligand labeled with PE or APC for improved sensitivity has 
been previously reported (Stetson et al., 2002; Townsend et al., 2001). Propidium iodide was 
used to exclude dead cells when cell were not fixed. Cells were read on a FACSCalibur and 
analyzed using Flowjo software (Tree Star). 
 
Cytokine production 
Single cell suspensions from lungs or lymphoid organs were resuspended in the presence or 
absence of SIYRYYGL and SIINFEKL peptides in OPTI-MEM I (Gibco) supplemented with 
GolgiPlug (BD Pharmingen) for ~4 hours at 37°C, 5% CO2. Cells were then fixed and stained for 
intracellular cytokines using the Cytofix/Cytoperm kit (BD Biosciences).  
 
Luciferase detection 
Freshly explanted tumors or whole lungs were lysed in Cell Culture Lysis Reagent, mixed with 
Luciferase Assay Reagent according to manufacturer’s instructions (Promega), and relative light 
units (RLU) were detected using the Optocomp I luminometer (MGM Instruments). RLUs were 
standardized based on the total number of cells or total protein (Bio-Rad Protein Assay) used in 
each assay. 
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Adoptive T cell transfer 
Naïve TCR transgenic T cells from OT-I or 2C mice were harvested from lymphoid organs, then 
counted and enumerated by FACS analysis before 2x105 CD8+ cells were transferred 
intravenously. 
 
Statistical analyses 
P-values for statistical comparisons were generated using unpaired two-tailed student’s T-tests. 
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CHAPTER 5 
 
 
DISCUSSION AND FUTURE DIRECTIONS
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In this thesis research, I used tractable and reproducible models of autochthonous 
mouse cancers that accurately recapitulate the stepwise progression of human cancer, both 
histopathologically and genetically, to study cancer immune surveillance. This led to several key 
observations that were not possible with previous technologies. I show that TSA expression, 
along with the origin of the disease and the type of model used to study immune responses to 
tumors, can all influence the dynamics of immune-tumor interactions, driving T cells to become 
tolerant or forcing tumors to escape. Thus, this research emphasizes the considerable 
contextual diversity in immune responses to cancer that should be further explored. Lessons 
learned from our attempts to improve immune responses against cancer utilizing therapeutic 
vaccines have also revealed important insights into immune-tumor interactions. Finally, I will 
end by proposing that the regulated timing of adaptive immunity may provide a unifying theme 
to rationalize the range of immune responses and tumor phenotypes we and others have 
observed while investigating the processes of cancer immune surveillance. 
 
I. Tumor antigens in immunotherapy: TAA versus TSA 
 The presence of antigens expressed in tumors that are recognizable by T cells is 
essential for the detection and the potential regulation of cancer. However, the type of antigens 
targeted by an immune response may be antigens specific to cancer cells or antigens also 
present in normal host tissues. Whether or not the type of antigen targeted by T cells alters the 
effectiveness of the immune response against cancer has long been debated, and a clear 
answer is still elusive.  
 Transgenic mouse models of cancer that express tumor-associated antigens (TAAs) 
indicate that T cells responding against these types of tumor antigens routinely become tolerant 
(Pardoll, 2003). Several groups have shown that immune tolerance toward tumors occurs due to 
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immune ignorance – T cells are not stimulated to respond to the TAAs expressed by tumors 
(Ochsenbein et al., 1999; Speiser et al., 1997). Ignorance likely occurs in these scenarios as a 
direct consequence of the actions of central and peripheral tolerance mechanisms that lead to 
the deletion of T cells capable of recognizing these types of antigens (Cheung et al., 2008; 
Ohashi et al., 1991). Therapeutic vaccinations can often bolster endogenous T cell responses 
against the autochthonous tumors, but the responses are not sustained. This has important 
implications for human cancer, as T cells directed against TAAs may require special conditions, 
not only to become activated, but also to persist in a host environment that naturally removes 
these cells. If ignorance or deletional tolerance can be overcome in these models, ultimately 
anergy or the loss of the functional activity of TAA-specific T cells seems to universally occur 
(Anderson et al., 2007; Cheung et al., 2008; Drake et al., 2005; Lyman et al., 2004). 
 Transplantable models have provided the only means to express true tumor-specific 
antigens (TSAs) in cancer models, and interestingly, these tumors can be routinely rejected 
after transplantation (Schreiber, 2003). This has led many investigators to speculate that T cells 
targeting TSAs are critical for productive T cell responses against cancer (Parmiani et al., 2007; 
Schietinger et al., 2008). However, it is unclear whether transplantation faithfully recapitulates 
the human disease, leading many to believe that the importance of TSAs is exaggerated due to 
the artificial nature of these models (Khong and Restifo, 2002; Scott, 1991). Several attempts 
have been made to create endogenous mouse models of cancer that express TSAs (Cheung et 
al., 2008; Soudja et al., 2010; Willimsky and Blankenstein, 2005). Interestingly, systemic T cell 
tolerance toward the tumor antigens was found to inhibit productive anti-tumor immune 
responses in all of these systems. Leaky expression of the putative TSAs in normal tissues or 
prior to tumor formation may be responsible for the systemic tolerance in these models (Cheung 
et al., 2008; Getnet et al., 2009; Willimsky et al., 2008). Therefore, TSA expression from 
autochthonous mouse models of cancer may be difficult to achieve. 
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 In an effort to investigate the effect of T cell responses against TSAs expressed from 
endogenously arising tumors, I developed a novel system to introduce exogenous antigens into 
spatiotemporally controlled autochthonous mouse cancers (Chapters 2 and 3). By mimicking 
TSA expression in lung tumors and sarcomas, I found that endogenous T cell responses to 
tumors are generated that can persist for long periods of time. Therefore, tumor antigens are not 
ignored in the context of TSA expression, and T cells targeting TSAs, as opposed to TAAs, are 
not rapidly deleted. In the setting of TSA expression in lung cancer, T cells ultimately became 
tolerant. This could be overcome by vaccination with dendritic cells or therapeutic influenza 
infection, indicating that priming by autochthonous tumors in vivo was suboptimal even in 
response to TSAs. In addition, in autochthonous lung-tumor-bearing mice, T cell responses 
against transplanted tumors expressing the same TSAs were unaltered. Therefore, T cell 
tolerance against TSAs expressed from autochthonous tumors was specific to the endogenous 
tumors, and unlike TAAs, TSA expression from endogenous tumors did not induce a systemic 
state of T cell tolerance. 
 These results indicate that TSAs may serve as better targets for human cancer 
immunotherapy because T cells directed against these antigens do not need to overcome host 
tolerance networks that can remove or suppress T cells specific for TAAs. Furthermore, T cells 
targeting TSAs will only target tumors, reducing the risk of inducing autoimmune reactions. 
Indeed, many cancer immunotherapies in animal models and human clinical trials result in 
autoimmune side-effects (Caspi, 2008). These side-effects may be the result of the generalized 
blockade of immune tolerance networks, such as with CTLA-4 antibodies, or the 
immunotherapeutic targeting of TAAs. These risks could potentially be minimized if the 
therapies were tailored against TSAs. Lastly, TSAs may originate from mutations in proto-
oncogenes or tumor suppressors that are necessary for driving the disease, whereas TAA 
expression may not be essential to the cancer’s etiology (Schietinger et al., 2008). Therefore, 
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selection for tumor cells with reduced expression of TAA may provide an easy mechanism of 
immune escape that is not viable for tumors expressing oncogenic TSAs.  
In our model, the TSAs were not oncogenic in nature and thus mimicked so called 
“passenger mutations.” Not surprisingly, lung tumors that grew in mice vaccinated against the 
TSAs or sarcomas that developed in immune-competent mice, lost expression of the model 
TSAs. Nevertheless, the expression of these TSAs still provided significant protection from 
tumor initiation and progression in both types of cancer. Models that link TSAs to the driving 
oncogenic event need to be developed to investigate whether T cell responses to oncogenic 
antigens can be even more effective. We are developing new lentiviral vectors that will express 
model TSAs fused directly to an oncogenic K-ras allele to study the T cell response to such 
oncoantigens. In addition, our lab is screening multiple oncogenic mutations in K-ras to 
determine whether novel peptides are generated that can be presented on MHC class I 
molecules from mice with different H-2 backgrounds.  
Models in which tumor initiation and expression of TSAs are temporally separable are 
also needed to discern whether T cell responses are different if the induction of antigen 
expression occurs in established tumors, where mutated proteins likely accumulate in human 
cancers. We are developing lentiviral systems that utilize a tetracycline operon to control TSA 
expression, allowing TSAs to be turned on after tumors are initiated (see Chapter 2). The 
combined use of ligand-regulatable Cre and Flp recombinases may also provide a means to 
separate the genetic induction of cancer from the expression of model TSAs (see Introduction, 
Figure 4). 
 Despite the advantages of TSAs, these antigens may be more difficult to target with 
current immunotherapeutic techniques because they are different in each cancer. However, if 
targeting TSAs provides the best therapeutic option, greater focus needs to be placed on 
methods to tailor therapies to individual patients. The post-genomic era provides us with a new 
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means to rapidly identify mutations in individual tumors and computationally predict which 
peptides will prompt the best T cell responses in these patients (Segal et al., 2008). Streamlined 
methods to harvest tumor-infiltrating T cells from patients and selectively expand T cells 
recognizing TSAs for reinfusion back into patients has already proven to be quite successful 
against some forms of cancer (Rosenberg et al., 2008). Alternatively, utilizing patients’ own 
resected tumors as the basis for tailored vaccinations may also provide a means to target TSAs 
without prior identification of the targeted antigens. 
 
II. Different models of cancer have altered T cell responses 
 The models of cancer used to draw conclusions about immune responses to tumors are 
seldom emphasized in cancer immunology investigations. This has led to an acceptance in the 
field that discoveries made using a particular cancer model actually reveal important 
mechanisms underlying all immune-tumor interactions. However, there may be tremendous 
diversity in how T cells respond to tumors in different settings – TAA or TSA expression, 
autochthonous or transplanted, carcinogen-induced or arising spontaneously, or originating in 
different tissues (see next section). In this thesis research, I provide evidence to suggest that 
the cancer model significantly influences immune-tumor interactions. 
In Chapter 2, I compared homologous forms of lung cancer in autochthonous and 
transplantable settings to determine whether immune-tumor interactions differed. We 
discovered that while autochthonous lung tumors expressing TSAs had delayed malignant 
progression but always retained antigen expression, transplanted tumors expressing TSAs were 
either rejected or tumors that did grow always lost expression of TSAs. Orthotopic 
transplantation of cell lines back into the lung by intravenous injection also led to the outgrowth 
of tumors that lost expression of TSAs. Tumor protection and antigen loss only occurred in the 
autochthonous tumor setting after the transfer of in vitro activated TSA-specific T cells or 
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vaccination against the TSAs. This indicates that priming in response to endogenous lung 
tumors is less efficient than priming against transplanted tumors. Using mouse models of 
pancreatic cancer, another study also found that autochthonous tumors grew progressively 
while transplanted cell lines derived from these tumors were rejected (Garbe et al., 2006). In 
contrast to our results, all the cell lines generated from the autochthonous pancreatic tumors 
were immunogenic upon transplantation, whereas the immunogenicity of lung tumors from our 
model required the introduction of model TSAs. The investigators were hindered by a lack of 
knowledge about the tumor antigens targeted by T cells, making it impossible to compare T cell 
priming in both contexts. Instead they found that CD8+ T cells could not infiltrate the 
endogenous tumors as efficiently as transplanted tumors. Additional mechanisms by which 
transplanted tumors may artificially promote anti-tumor T cell responses are detailed in section 
five of the Introduction. These results indicate that immune responses and their effect on tumor 
development may be the direct result of the cancer models used for the investigation. 
To understand cancer immunoediting, investigators have relied heavily on the use of 
mouse models of cancer in which carcinogens, primarily methylcholanthrene (MCA), are used to 
induce the development of tumors. However, the immunogenicity of carcinogen-induced 
sarcomas has been questioned as artificial because spontaneously arising tumors are rarely 
immunogenic (Hewitt et al., 1976). The mutagenic activity of carcinogens may generate tumor-
specific neoantigens in experimentally induced tumors that grossly exceed the number of 
neoantigens harbored in human cancers (Khong and Restifo, 2002). By utilizing genetically 
engineered mouse models of sarcomagenesis that could be conditionally induced to express or 
lack TSAs, we provide evidence to suggest that TSA expression is required for the process of 
immunoediting against sarcomas (Chapter 3). Only sarcomas derived in lymphocyte-deficient 
mice that express model TSA antigens are rejected upon transplantation into immune-
competent mice. Thus tumor immunogenicity is not a necessary byproduct of the tumorigenic 
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process. The sarcomas induced to express TSAs in immune-competent mice lost expression of 
the antigens during their development, indicating that immunoediting during tumor development 
acts by selecting for tumor cells that have lost the expression of potent antigens. Both of these 
results could potentially explain the reduced immunogenicity of spontaneous tumors derived in 
immune-competent mice. Therefore, these data provide a missing link between the discordant 
results found using either carcinogen-induced or spontaneously arising tumors. 
  
III. Tumor origin affects the T cell response and a tumor’s immunogenicity  
Over four decades ago, R.T. Prehn speculated that the tissue in which a cancer arises 
could influence how the immune system responds to cancer (Prehn, 1968). However, this issue 
has scarcely been addressed experimentally. By comparison of autochthonous models of lung 
cancer and sarcomagenesis described in Chapters 2 and 3, it is clear that the tissue in which a 
tumor originates can significantly modulate the ensuing T cell response. Importantly, both 
models contained the same genetic alterations to initiate the cancers, by using K-rasLSL-
G12D/+;p53fl/fl mice, and expressed the same model TSAs, by using Lenti-LucOS to induce tumor 
formation. Only the site of tumor formation and the type of cancers generated were distinct. 
 In both scenarios, T cell responses directed against the model TSAs could be detected, 
however, only T cells generated in the sarcoma model were fully functional, providing protection 
from sarcoma formation or driving TSA loss in palpable sarcomas. T cells responding to TSAs in 
lung tumors led to a delay in the malignant progression of the cancers, but were not completely 
functional and ultimately dissipated from tumors despite maintained expression of the TSAs in 
tumors. It is not clear what underlies these divergent immune responses to the same TSAs in 
the context of these two forms of cancer, but it is enticing to speculate that different immune 
environments surrounding the tumors may dictate the anti-tumor immune response.  
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Disruption or damage to tissues underlying the surface of the skin, such as during an 
abrasion, can lead to the introduction of pathogens that require rapid and effective immune 
responses for host protection. This has perhaps led to the evolution of fewer regulatory 
requirements for activating cells of the adaptive immune system in these tissues, making most 
disturbances in this environment immune stimulatory (Strid et al., 2009). Indeed, this has made 
skin the tissue of choice for vaccination regimens and may also explain why primary sarcomas, 
induced either by carcinogens or genetically, and sub-cutaneously transplanted tumors are so 
susceptible to anti-tumor immune responses. The relatively rare encounter with external 
elements in tissues underneath the skin contrasts with the epithelial cells of the lung, which are 
perturbed constantly by the external environment (Strid et al., 2009). This has led to the 
evolution of an immune-tolerant environment in the lung, which prevents inappropriate (and 
potentially detrimental) immune responses to innocuous encounters (Holt et al., 2008). Thus the 
immune environment of the lung maintains a more stringent threshold for adaptive immune 
activation. In this context, T cell responses to autochthonous lung tumors may be driven to 
inactivity and tolerance because of unique immune-regulatory networks that have specifically 
evolved in the lung. In fact, early investigations found that carcinogen-induced lung adenomas 
were less immunogenic than carcinogen-induced sarcomas. However, Prehn predicted at the 
time (perhaps incorrectly), that stronger immune responses were actually induced in lung 
tissues, which led to the outgrowth of lung tumors with reduced immunogenicity compared to 
sarcomas. An important next step for cancer immunologists should be to embrace the diversity 
of immune environments that likely shape immune responses to cancers that arise in different 
tissues by broadening our investigations to encompass a greater diversity of cancer models. 
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IV. Cancer vaccination 
 The weak and incomplete endogenous T cell response generated in our autochthonous 
model of lung cancer recapitulates many of the features of T cell responses against human 
cancers, making it an ideal system to test immunotherapeutic strategies. Successful therapeutic 
vaccination has proven to be very difficult in patients with cancer as well as in many 
experimental mouse cancer models (Drake, 2010; Goldman and DeFrancesco, 2009). Similar to 
other investigations in mouse models of cancer that express TAAs, work from our lab has also 
found that it is impossible to sustain T cell responses against model TAAs expressed in our 
model of lung cancer after vaccination with a strain of influenza expressing the same TAA 
(Cheung et al., 2008). However, in Chapter 4, we showed that by targeting TSAs in lung tumors 
with the same strains of influenza, we could generate fully functional T cell responses against 
the tumor antigens that were sustained, again providing support for the use of TSAs in vaccine 
strategies rather than TAAs. 
 Nevertheless, the tumors in these mice were not eradicated. Potential explanations for 
tumor escape after therapeutic vaccination include lost or reduced expression of TSAs and a 
decreased magnitude of the T cell response after vaccination in mice with established tumors. 
However, it is still not clear why vaccination did not more dramatically reduce the tumor burden 
since antigen expression was clearly maintained in some tumors and functionally competent T 
cells did persist. Understanding the ineffectiveness of the vaccine in this context may provide 
insights into the failures of therapeutic vaccines in cancer patients.  
A kinetic argument has often been used to describe the failure of immune responses to 
eradicate cancers (Hanson et al., 2000). It is possible that immune responses can only control a 
limited tumor burden due to a limited cytotoxic capacity of T cells and the rapid growth of 
tumors. This could explain why adoptive cell transfer therapy (ACT) has proven to be more 
effective than vaccination therapies. The tremendous number of anti-tumor T cells generated 
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and transferred during ACT (on the order of 1011 cells) may exceed the productive capacities of 
vaccine-induced immune responses. Yet the generation of a sustained memory T cell response 
in our vaccination scheme would seem to eventually overcome this problem by providing a 
limitless supply of T cells to attack the relatively slow-growing lung tumors. Although employing 
the immunoediting hypothesis provides limitless potential explanations for tumor evasion, 
antigen loss would seem to provide the easiest mode of escape in the context of functional anti-
tumor T cells. One potential explanation is that antigen-expressing tumor cells within the core of 
the tumors are sheltered or protected from T cell recognition by tumor cells that have lost 
antigen expression. Other investigations have shown that impeded access into the tumor can 
allow tumors to escape (Buckanovich et al., 2008). Alternatively, the T cell response against 
tumors may end with the clearance of the influenza infection because T cell activity may require 
reencounter with tissue-resident, antigen-presenting cells (APCs) that are only active during 
infections (Woodland and Kohlmeier, 2009). If this were the case, repeated stimulation of APCs 
at the site of tumors might prolong T cell responses against tumors. In section VI, I will discuss 
the implications of a temporally regulated immune response in productive immune responses 
against cancer. 
 
V. Immune tolerance or immunoediting? 
 Whether cancers progress because of the induction of anti-tumor immune tolerance or 
the evolution of tumor-escape mechanisms has been a topic of great debate and has 
unfortunately forged the development of two opposing ideological camps in the field of cancer 
immunology (Qin and Blankenstein, 2004). However, by examination of different forms and 
models of cancer in Chapters 2 and 3, we find support for both mechanisms of tumor evasion. 
As described in sections I, II and III of this Discussion, the immune response and its outcome on 
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tumor development are affected by the types of tumor antigens expressed, the models used, 
and the types of cancers studied. 
 Interestingly, evidence for both immunoediting and immune tolerance occurring within 
the progression of a single cancer has even been documented. In this particular study, 
investigators found that T cell tolerance to a tumor antigen was preceded by reduced 
expression of the antigen in tumors (Zhou et al., 2004). It is interesting to speculate that both 
mechanisms may complement, rather than exclude, one another. For example, if strong 
immune responses arise in response to tumors naturally, or by induction with vaccines, 
immunoediting may be required for tumors to escape. Indeed, we found evidence of decreased 
TSA expression in sarcomas and also lung tumors in the context of vaccination. Evidence of 
immunoediting can also be found in the clinic, particularly after therapeutic vaccination against 
specific tumor antigens (Khong and Restifo, 2002). However, prolonged interactions between 
immune cells and tumors would seem to naturally drive immune tolerance (Kim and Ahmed, 
2010). This might occur in the context of relatively weak immune responses that are unable to 
rapidly eradicate the tumors. In this way, autoregulatory tolerance mechanisms may provide an 
alternative route for “unedited” tumors (or tumor cells) to progress by outlasting the functional 
immune response. 
 
VI. Timing in adaptive immune responses: a unifying theme? 
 In closing, it is interesting to speculate about the role of the immune system in regulating 
cancer from the perspective of its clear evolutionary role in fighting pathogenic infections. 
Foremost, it is important to consider that perhaps the most critical aspect of the evolution of the 
immune system was the generation of appropriate checks and balances to regulate this 
powerful weapon, rather than the creation of a more effective killer of infectious agents. Just by 
considering that 25% of deaths worldwide each year are due to infection (from W.H.O.), while 
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the prevalence of autoimmune disease is only perhaps 4% (from Cureresearch.com), one may 
infer that the immune system has evolved to err on the side of tolerance rather than immunity. A 
key mechanism for preventing autoimmune reactions may be the evolution of systems that 
restrict adaptive immune responses to a defined period of time. This is not a new idea, as it has 
long been understood that both intrinsic and extrinsic factors contribute to the natural 
contraction of responding adaptive immune cells after infections (Badovinac et al., 2004; 
Jameson and Masopust, 2009). However, the natural cessation of immune responses after an 
acute infection is rarely considered in the context of immune responses to cancer. 
Transplantable tumors are the only cancers that have been cured by an adaptive 
immune response. More importantly, these tumors have always been rejected within a short 
window of time between 10 and 14 days after transplantation or following various immune 
priming protocols. When tumors grow for extended periods of time, immune responses may 
delay the growth of tumors, but never reject them (Hanson et al., 2000). In a similar manner to 
transplanted tumors, acute viral infections are always cleared within the first two weeks after 
infection (Wherry and Ahmed, 2004). Viral infections that are not cleared ultimately go on to 
become chronic infections that are essentially tolerated by the immune system. In contrast to 
transplanted tumors, autochthonous tumors have never been eradicated in any setting, but 
therapeutic treatments have always begun very late during cancer progression. Immunity 
against autochthonous tumors has only come in the form of protection after prophylactic 
vaccination or very early therapeutic vaccination as evidenced in Chapters 2 and 4 of this 
thesis. All of these results seem to emphasize that there is an inherent clock that controls the 
timing of active T cell responses, whether it’s against viruses or cancers. What is responsible for 
maintaining this “leash” on the immune response is unclear. As pointed out in the previous 
section, the presence of activating signals at the sites of T cell function (potentially provided by 
activated APCs) may be necessary to license T cell activity. Alternatively, persistent encounters 
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with antigens may drive T cells to lose function (Bucks et al., 2009). Perhaps activated T cells 
are only permitted to retain effector function for limited periods of time after initial priming, and 
paradoxically, antigen withdrawal is required for T cells to ultimately retain function. Antigen 
withdrawal would normally occur with the clearance of pathogens. However, antigen withdrawal 
would not occur if T cell responses were directed against self antigens. Thus, T cells may be 
hard-wired to lose function in the context of persistent antigen exposure as a means to prevent 
inappropriate responses to self. 
In any case, for the immune system to effectively treat cancer, it may be important to 
consider that the immune system works best in an acute fashion. Indeed, considering the acute 
timing of the immune response can provide a unifying explanation for the diversity of results 
from many investigations using different cancer models. From the perspective of the immune 
system, however, cancer may more accurately be viewed as a chronic disease. Therefore, 
immune therapy against cancer must not only act to boost T cell responses to tumors, but also 
attempt to counteract the many, as yet unidentified, regulatory networks that likely restrict the 
timing of active immune responses. Autoimmune diseases represent rare breakdowns in these 
regulatory systems that enable immune responses to continue indefinitely and may provide 
clues as to how to better treat cancer immunotherapeutically. 
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ABSTRACT 
The development of animal models of lung cancer is critical to our understanding and treatment 
of the human disease. Conditional mouse models provide new opportunities for testing novel 
chemopreventatives, therapeutics and screening methods that are not possible with cultured 
cell lines or xenograft models. This protocol describes how to initiate tumor formation in two 
conditional genetic models of human non-small cell lung cancer (NSCLC) utilizing the activation 
of oncogenic K-ras and the loss of function of p53. We discuss methods for sporadic expression 
of Cre in the lungs via engineered adenovirus or lentivirus and provide a detailed protocol for 
the administration of the virus by intranasal inhalation or intratracheal intubation. The protocol 
requires 1-5 minutes per mouse with an additional 30-45 minutes to set-up and allow for the 
recovery of mice from anesthesia. Mice may be analyzed for tumor formation and progression 
starting 2-3 weeks after infection. 
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INTRODUCTION 
Lung cancer is the leading cause of cancer deaths worldwide with non-small cell lung 
cancer (NSCLC) being the most prevalent form of lung cancer (Sun et al. 2007; Jemal et al. 
2008; Herbst et al. 2009). Progress within the last decade has led to the sophisticated 
engineering and application of advanced preclinical models of human cancer in the mouse (Van 
Dyke and Jacks 2002; Frese and Tuveson 2007). These models are critical to our 
understanding of the human disease because they shed light on events and processes that 
cannot be easily studied using transplantable or chemically-induced cancer models (Meuwissen 
and Berns 2005; Shaw et al. 2005; Frese and Tuveson 2007). Several laboratories have 
constructed genetically engineered mouse models of NSCLC that mimic the genetic and 
histopathological features of the human disease (Fisher et al. 2001; Jackson et al. 2001; 
Johnson et al. 2001; Meuwissen et al. 2001; Meuwissen and Berns 2005; Ji et al. 2006; Dankort 
et al. 2007). The development of Cre recombinase-controlled (Cre/LoxP) tumor models has 
allowed for the generation of autochthonous tumors derived from a limited number of somatic 
cells that become transformed in their natural location, surrounded by a normal tissue 
microenvironment (Frese and Tuveson 2007). By engineering LoxP DNA elements into the 
mouse genome that either surround (‘flox’) exons critical to a tumor suppressor gene’s function 
or surround a synthetic ‘stop’ element (‘LSL’) inserted in front of an oncogene, investigators can 
‘turn-off’ tumor suppressors or ‘turn-on’ oncogenes with delivery of Cre recombinase to the 
appropriate cell types (Supp. Fig. 1 and see reference 5 for a review of Cre/LoxP-controlled 
genetically engineered mouse models of cancer). With this technology, investigators can not 
only recapitulate the genetic alterations found in the human disease, but also the timing of onset 
and potentially the cellular origin of the disease. 
Common mutations in human NSCLC are activating mutations in K-RAS (10-30%) and loss 
of function point mutations in p53 (50-70%) (Herbst et al. 2009). Our laboratory has modeled an 
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oncogenic mutation in K-ras by changing a glycine to aspartic acid at codon 12 in the gene’s 
endogenous locus. To control the expression of K-rasG12D, a lox-stop-lox (LSL) cassette was 
engineered into the first intron of the K-ras gene. The LSL cassette consists of transcriptional 
and translational stop elements flanked by LoxP sites that prevents the expression of the mutant 
allele until the stop elements are removed by the activity of Cre recombinase (Jackson et al. 
2001; Tuveson et al. 2004). The LSL cassette thus creates a null version of the gene. It is 
important to note that K-ras null mice are embryonic lethal (Johnson et al. 1997); therefore, mice 
can only be heterozygous for the K-rasLSL-G12D allele. To mimic the loss of p53 function in our K-
rasLSL-G12D-driven tumor model, we have utilized a conditional p53 allele from the laboratory of 
Anton Berns. This ‘floxed’ p53 allele (p53fl) has LoxP sites flanking exons two through ten of p53 
that are deleted after Cre-mediated recombination, abolishing p53 function (Jonkers et al. 2001) 
(Supp. Fig. 1). Prior to Cre-mediated recombination, the p53 locus is maintained in its wildtype 
state and p53 activity is normal. To more accurately recapitulate the p53 loss of function 
mutations commonly observed in human NSCLC, our laboratory has generated two conditional 
point mutant (mt) versions of p53 (R172H, R270H) that are engineered into the endogenous 
p53 locus, but silenced by a LSL cassette in the absence of Cre (Olive et al. 2004). We use 
mice that are p53LSL-mt/fl or p53LSL-mt/+ to specifically express mutant p53 alone or with wildtype 
p53 (respectively) in tumors upon Cre-mediated recombination (Olive et al. 2004; Jackson et al. 
2005). Importantly, as with the K-rasLSL-G12D allele, the LSL cassette in p53LSL-mt alleles blocks 
p53 expression in the absence of Cre, effectively creating a p53 null allele. Therefore, p53LSL-mt/fl 
or p53LSL-mt/+ mice are heterozygous for wildtype p53 and phenocopy p53+/- mice. To specifically 
express either of these mutant p53 alleles sporadically in cells of the lung, mice inhale viruses 
engineered to express Cre either by intranasal instillation or intratracheal intubation.  
 
 
  231 
Additional Cre recombinase controlled animal models of lung cancer 
In addition to the models of NSCLC utilized in this protocol, other conditional lung cancer 
models have been described which may be initiated with inhalation of viruses expressing Cre. 
The activation of oncogenic K-ras along with loss of p16Ink4a or Ink4a/Arf tumor suppressors, 
which are mutated in 20-50% of human cases, have been described (Fisher et al. 2001; Ji et al. 
2007). In another mouse model, two other subtypes of NSCLC, squamous cell and large cell 
carcinoma, develop following the combined activation of oncogenic K-ras and loss of the LKB1 
tumor suppressor, which is mutant in 10-30% of human cases (Ji et al. 2007). NSCLC models 
driven by conditionally activated mutations in Braf or EGFR, mutated in 3% or 10-40% 
(respectively) of human lung cancers, have also been generated (Ji et al. 2006; Dankort et al. 
2007) (and unpublished, K. Lane). A model of small cell lung cancer (SCLC) has been created 
in which tumors arise following the loss of both the p53 and Rb tumor suppressors (Meuwissen 
et al. 2003). 
 
Limitations of viral delivery of Cre recombinase 
Although these Cre/LoxP models provide the most sophisticated means to sporadically 
control genetic events at their endogenous loci, they are also limited by the difficult requirement 
to introduce Cre into an initiating cancer cell. In this protocol, investigators cannot restrict the 
genetic events exclusively to initiating cells of the disease because of the inherently non-specific 
nature of the viruses used to deliver Cre to cells of the lung. However, this has in fact been 
beneficial in our laboratory because it does not require that investigators identify and target Cre 
specifically to the cell of origin of the disease. Perhaps the best system to deliver Cre 
specifically to the cells that give rise to the disease are next generation regulatable Cre alleles, 
such as the tamoxifen-inducible Cre-estrogen receptor (CreERT) fusion protein (Frese and 
Tuveson 2007). By expressing a CreERT transgene under the control of a cell type-specific 
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promoter, investigators can induce Cre activity specifically in the cells of a given tissue by 
injecting animals with tamoxifen. With proper dosing of tamoxifen, investigators can in theory 
control the penetrance of Cre activity and therefore the multiplicity of the disease. However, 
various promoter-driven CreERT alleles are not yet available and CreERT models succumb to 
problems encountered with many transgenic models in that the expression and activity of these 
alleles are often leaky and do not provide tight control of tumor initiation in the organ of interest  
(Frese and Tuveson 2007). Therefore, despite the drawback of using potentially hazardous 
viruses, this technique is the most effective means to sporadically deliver Cre to cells of the lung 
to initiate lung tumor formation. 
 
Alternative animal models of lung cancer 
There are several alternative lung cancer models to those described here that do not require 
viral delivery of Cre to the lungs to generate tumors (see reference 6 for a comprehensive 
review of mouse models of NSCLC). Transgenic models have been created that utilize lung 
tissue specific promoters to drive expression of viral oncoproteins, such as E6/E7 and large T 
antigen, or cellular oncogenes, such as c-myc, c-Raf-1 and v-H-ras (Meuwissen and Berns 
2005). However, these models are limited in recapitulating the human disease because the 
oncogenic transgene is expressed in all of the cells of a targeted organ beginning early in the 
organ’s development. To overcome this limitation, our laboratory has engineered a latent 
oncogenic allele of K-ras that is expressed spontaneously in only a limited number of cells in the 
lung to initiate lung tumor formation (Johnson et al. 2001). However, the stochastic nature of this 
allele does not allow investigators to control tumor onset or multiplicity. Double transgenic 
models that rely on doxycycline-regulated transcriptional transactivators have allowed for the 
induction of oncogene expression in adult animals, making it possible to control tumor initiation 
(Meuwissen and Berns 2005). However, these models still fail to provide sporadic oncogene 
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expression at physiological levels due to the use of doxycyline-regulated transcription factors. 
Furthermore, these transgenic systems make it difficult to control tumor multiplicity and require 
continuous doxycycline dosing to maintain oncogene expression. 
 
Applications of intranasal and intratracheal delivery methods 
The intranasal and intratracheal infection techniques described in this protocol are not 
restricted to tumor-initiating studies. Investigators may theoretically probe the role of any 
Cre/LoxP-controlled genes in various cells of the lung using this protocol to deliver Cre. 
Alternatively, the intranasal or intratracheal delivery methods can be used in applications other 
than the viral delivery of Cre recombinase. The viral delivery systems may be adapted to 
express cDNAs or shRNAs in cells of the lung by infection with lentiviruses (Marumoto et al. 
2009). Viruses, such as the influenza virus, can be delivered for pathological studies (Shen et 
al. 2008). siRNAs can be delivered as therapeutic agents for disease (Ge et al. 2004). While 
either the intranasal or intratracheal techniques can be utilized for the aforementioned studies, 
only intratracheal intubation is recommended for the orthotopic transplantation of lung tumor 
cells or lung tumor cell lines to the alveolar space of the lungs (unpublished, C. Kim and T. 
Jacks). Certain chemical injurants, such as bleomycin, can be delivered intratracheally to study 
repair mechanisms in the lung and the effect of injury on tumor development (Daly et al. 1997). 
Therefore, there are a number of uses of this technique for a variety of studies involving the 
mouse lung. Here we describe the use of the intranasal and intratracheal delivery methods to 
introduce viruses expressing Cre to initiate the K-rasLSL-G12D/+ (K) and the K-rasLSL-G12D/+;p53fl/fl 
(KP) conditional mouse models of NSCLC (Supp. Fig. 1). 
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EXPERIMENTAL DESIGN 
After deciding to utilize autochthonous tumor models, investigators must consider the 
genetic tumor model, the viral system to express Cre recombinase, and the viral delivery 
method when initiating an experiment. Each option has certain advantages and limitations that 
are highlighted in the text and the Tables. 
 
Genetic Model 
Although both the K-rasLSL-G12D/+ (K) and the K-rasLSL-G12D/+;p53fl/fl (KP) NSCLC models induce 
tumors that resemble the human disease histopathologically, they have distinct features that 
make them more suitable for different applications (Table 1). In our laboratory’s mouse models 
of NSCLC, the activation of an oncogenic allele of K-ras is sufficient to initiate the tumorigenesis 
process, while the additional deletion or point mutation of p53 significantly enhances tumor 
progression, leading to a more rapid development of adenocarcinomas that have features of a 
more advanced disease. K-ras and p53 mutant tumors exhibit a greater incidence of cellular 
and nuclear pleomorphism, desmoplasia, and a high frequency of metastases to the mediastinal 
lymph nodes and the pleural spaces of the thoracic cavity, and less frequently to the liver and 
kidneys. 
 
 
 
 
 
 
 
 
Table 1: Choosing a tumor model 
K-rasLSL-G12D/+ (K) K-rasLSL-G12D/+;p53fl/fl (KP) 
Limited tumor progression 
(modifier screens) 
Rapid tumor progression 
No metastases Metastatic disease 
Local: draining lymph node, pleural cavity 
Distant: liver, kidney 
Long survival Short survival 
Single allele 
(easy to breed) 
Multiple alleles 
Small tumors 
(limited tumor tissue) 
Large tumors 
(more tumor tissue for DNA, RNA, protein) 
(easier to track with live imaging, microCT) 
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Cre System 
To generate tumors sporadically in the lungs of K-rasLSL-G12D/+ mice, our laboratory initially 
used replication-deficient adenoviruses expressing Cre (Ad-Cre) to deliver transient Cre 
expression to infected cells of the lung (Jackson et al. 2001; Meuwissen et al. 2001). Prior to 
administration, Ad-Cre is precipitated with calcium phosphate (see procedure) to improve the 
delivery of Cre by increasing the efficiency of viral infection of the lung epithelium (Fasbender et 
al. 1998). Recently, we have used lentiviruses to deliver Cre to the lung (Lenti-Cre) (Kumar et 
al. 2008). Lentiviruses are beneficial because they integrate into the genome of infected cells 
(Naldini et al. 1996), allowing for further modification of the tumors by simultaneously 
introducing Cre recombinase and stable expression of cDNAs to overexpress, or short-hairpin 
RNAs to silence, genes of interest (Table 2). 
In order to control for the number of tumors generated, viruses are titered prior to use in 
experiments. Ad-Cre is titered at the University of Iowa, while Lenti-Cre is titered in our 
laboratory by assaying for Cre activity after infection of the 3TZ reporter cell line, a mouse 
fibroblast cell line modified to express β-galactosidase after Cre-mediated recombination 
(Psarras et al. 2004). We infect mice with 2.5x107 infectious particles of Ad-Cre (titered at Univ. 
Iowa) or approximately 104-105 infectious particles of Lenti-Cre (3TZ titered in-house). It is 
important to note that Ad-Cre and Lenti-Cre are titered differently, and as a result, the titers 
cannot be directly compared.  
 
Table 2: Choosing the Cre system 
Adenovirus Cre (Ad-Cre) Lentivirus Cre (Lenti-Cre) 
High, reproducible titer 
(typically produces a greater number of 
tumors, shorter survival) 
Variable titer 
Titered virus is commercially available In-house production may be required 
Cannot introduce cDNAs or shRNAs with 
Cre recombinase 
Potential to modify tumors by introduction of 
cDNAs or shRNAs in lentivirus 
(gain-of-function or loss-of-function experiments) 
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Viral Administration Method 
While we initially delivered Cre to the lungs of anesthetized mice using intranasal (IN) 
instillation of the virus, we now prefer to deliver the virus to the lungs by intratracheal (IT) 
intubation. IT delivery provides the most direct and consistent method for the virus to reach the 
lungs. Reproducible delivery of the virus is critical because it directly affects the number of 
tumors generated in the mice. However, intratracheal intubation requires additional equipment 
and practice to perform it correctly and in a timely manner (Table 3). Therefore, it may be easier 
to begin with the IN delivery method to assess the tumor model and practice the IT method 
while continuing to breed animals for future experiments. 
 
 
Anesthesia 
We recommend using avertin (2-2-2 Tribromoethanol) to anesthetize the mice. The amount of 
avertin administered to the mice is crucial to the success of the procedure. Mice administered 
too much avertin are more likely to stop breathing during the infection procedure, and recover 
poorly from the anesthesia. Conversely, mice administered too little avertin may struggle to 
inhale the virus and should be given more avertin before continuing. Therefore, we recommend 
using the smallest volume of avertin required to keep mice anesthetized during the procedure. 
Table 3: Choosing the viral administration method 
Intranasal (IN) Intratracheal (IT) 
No training required 
(can implement rapidly) 
Technique requires practice 
for proficiency 
No additional equipment necessary Requires catheters, light 
source, platform 
Indirect and variable delivery of virus to lungs 
• virus displaced in nasal passage, mouth or 
esophagus/stomach 
• low penetrance sinonasal adenocarcinomas in KP 
infected mice (Jackson et al. 2005) 
Direct delivery of virus to 
lungs 
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Following the procedure, mice will recover better if they are kept warm to maintain their normal 
body temperature after anesthesia.  
 
Age of Mice 
Our laboratory has utilized mice between 6 and 12 weeks of age for tumor initiation by IN or IT 
delivery of viruses expressing Cre. Mice of this age are old enough to recover from the 
anesthetic, the volume of virus administered to the lung, and the intubation of the trachea with 
the catheter. 
 
Volume of virus 
Mice can be infected with a volume ranging from 50-125 µl per mouse, but we recommend 
using a total volume of 75 µl per mouse. Although a volume of 125 µl can be administered, it is 
not recommended for very young mice (6 weeks of age or younger). If 125 µl is administered, 
then the mice should receive two doses of 62.5 µl each, with a 1-5 minute break in between the 
doses, to allow the mice to recover a normal breathing pattern before receiving the second 
dose. 
 
MATERIALS 
REAGENTS 
CRITICAL The following list of reagents represents our laboratory’s preference. All reagents, 
with the exception of Ad-Cre, can be modified according to investigator preference. 
• Mice: LSL-KrasG12D (Mouse Models of Human Cancers Consortium (MMHCC) Strain 
01XJ6, Jackson Laboratory #008179 (B6), #008180 (129)); p53fl (MMHCC Strain 01XC2, 
Jackson Laboratory #008462 (B6)); p53 LSL-R270H (MMHCC Strain 01XM3, Jackson 
Laboratory #008651 (129svj)); p53LSL-R172H (MMHCC Strain 01XM2, Jackson Laboratory 
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# 008652 (129svj)). Researchers in industry can obtain these mice by contacting the MIT 
Technology Licensing Office (http://web.mit.edu/tlo/www/industry/).  
CAUTION All experiments should be done in accordance with protocols approved by the 
Institutional Animal Care and Use Committee. 
• K-rasLSL-G12D (LSL K-ras G12D) and p53 mutant genomic targeting vectors are available 
from Addgene (http://www.addgene.org/pgvec1?f=c&cmd=showcol&colid=171). Koch 
Institute Core Facilities can perform chemotherapeutic testing and small animal imaging 
(http://web.mit.edu/ki/facilities/core.html)  
CAUTION Mice should be kept under specific pathogen-free conditions during 
experiments.  
Protocols to genotype the mouse strains listed above can be found on the Jacks Lab 
website (http://web.mit.edu/jacks-lab/protocols_table.html) 
• Protocols to determine the recombination efficiency of the KrasLSL-G12D and p53fl alleles 
can be found on the Jacks Lab website (http://web.mit.edu/jacks-
lab/protocols_table.html) 
• 2-2-2 Tribromoethanol (Avertin, Sigma Aldrich T48402) 
• 2-methyl-2-butanol (Tert-amyl alcohol, Sigma Aldrich 152463) 
• Phosphate Buffered Saline (PBS) 
• Minimal Essential Media (MEM, Sigma, M4655) 
• CaCl2 (Mallinckrodt, Catalog #4160) 
• Bleach 
• Adenovirus-Cre (University of Iowa, Gene Transfer Vector Core, 
http://www.uiowa.edu/~gene/; Jacks Lab website http://web.mit.edu/jacks-
lab/protocols/AdenovirusCre.html) 
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CAUTION Preparation and administration of viruses should occur in a biosafety hood 
and follow all guidelines for biosafety level 2 research.  
• Lentivirus-Cre (Three plasmid transfection system of CMV-VSV-G (Addgene plasmid 
8454), Δ8.2 (gag/pol) (Addgene plasmid 8455), and transfer vector expressing Cre 
(modified from Addgene plasmid 17408)) (Naldini et al. 1996; Pfeifer et al. 2001; Lois et 
al. 2002; Stewart et al. 2003; Tiscornia et al. 2006; Kumar et al. 2008) 
CAUTION Preparation and administration of viruses should occur in a biosafety hood 
and follow all guidelines for biosafety level 2 research. Research with lentiviruses 
pseudotyped with VSV-G containing known or putative oncogenes or short hairpin RNAs 
to silence tumor suppressor genes should abide with all institute safety practices. 
 
EQUIPMENT 
• Bottle top vacuum filter (.22 µM, 150 ml, Corning, cat. no. 430624) 
• Scale (Ohaus, cat. no. HH120D) 
• Needles (30 gauge, ½ inch, Becton Dickinson, cat. no. 305106) 
• Syringes (1 ml, Becton Dickinson, cat. no. 309602) 
• Flat forceps (Roboz, cat. no. RS-8260) 
• Exel Safelet IV catheters (22 gauge, 1 inch, Fisher, cat. no. 14-841-20) 
• Intubation platform (Steve Boukedes, labinventions@gmail.com) 
• Fiber-Lite Illuminator (Dolan-Jenner Industries, Inc., Model 3100-1)  
• Heat lamp (or latex gloves filled with warm water) 
 
REAGENT SETUP 
Avertin Stock (1.6 g ml-1) Add 15.5 ml tert-amyl alcohol to 25 g of avertin. Stir overnight to 
dissolve. Stable at room temperature (18-25 °C) for approximately 1 year. 
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CRITICAL Seal bottle tightly and protect from light. Discard the solution if it yellows. 
Avertin Working Solution (20 mg ml-1) Dilute avertin stock in PBS, stir overnight, and protect 
from light. Sterilize by passing solution through a 0.22 µm filter. Aliquots may be safely stored at 
4 °C in the dark for approximately 4 months. 
2 M CaCl2 Dissolve in distilled water and store at 4 °C for up to 5 years. 
Virus Ad-Cre should be prepared fresh each time and used within one hour of preparation. For 
extended storage times, Lenti-Cre should be stored at -80 °C or alternatively, at 4 °C for periods 
of a few days. Keep viruses on ice prior to infection. 
 
EQUIPMENT SET-UP 
Biosafety hood To set-up for either IN or IT administrations, arrange the virus, a heat lamp (or 
gloves filled with warm water), and a beaker filled with 50% bleach (to disinfect catheters and 
pipette tips that have contacted the virus) in a biosafety hood.  
Intubation platform and light source For IT administration, set up the platform and light 
source on a flat surface near the biosafety hood (Fig. 1a). Insert the catheter into the trachea 
outside of the hood, and then move the mouse into the biosafety hood to inhale the virus. A 
sharps waste container is also required for the proper disposal of the needles from the Exel 
Safelet IV Catheter. 
 
PROCEDURE 
Virus Preparation TIMING 30 min 
1 For infection with Lenti-Cre, proceed to step 5. For Ad-Cre, prepare the adenovirus-precipitate 
mixture. Determine the number of mice that you will infect and pipette the appropriate volume of 
MEM into a tube. Refer to the Experimental Design Section to determine the volume of virus to 
administer per mouse. 
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CAUTION Preparation and administration of viruses should occur in a biosafety hood and follow 
all guidelines for biosafety level 2 research. Research with lentiviruses pseudotyped with VSV-G 
containing known or putative oncogenes or short hairpin RNAs to silence tumor suppressor 
genes should abide with all institute safety practices. 
CAUTION All experiments should be done in accordance with protocols approved by the 
Institutional Animal Care and Use Committee. 
CRITICAL STEP The adenovirus-precipitate mixture should be used within one hour of 
preparation. If many mice will be infected, precipitates should be prepared sequentially.  
2 After the adenovirus thaws on ice, pipette the adenovirus directly into the MEM to obtain a 
final titer of 2.5x107 PFU per mouse. Flick the tube to mix.  
CRITICAL STEP Do not freeze/thaw the adenovirus as this reduces the titer of the virus 10 fold 
with each thaw. 
3 Add 2M CaCl2 into the MEM mix to obtain a final CaCl2 concentration of 10 mM. Flick the tube 
to mix. 
4 Incubate at room temperature for 20 min to allow for the formation of calcium phosphate 
precipitates.  
 
Delivery of Ad-Cre or Lenti-Cre using the intratracheal or intranasal infection method  
5 Avertin Administration TIMING 5 min per mouse 
Anesthetize mice via intra-peritoneal injection of room temperature 20 mg ml-1 avertin (use 0.4 
mg g-1 body weight for females and 0.45 mg -1 body weight for males). Confirm the mice are fully 
anesthetized by ensuring that they lack a toe reflex.  
CRITICAL STEP Administering the correct amount of avertin is crucial to successfully delivering 
the virus.  
TROUBLESHOOTING 
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6 Delivery of Ad-Cre or Lenti-Cre can be carried out using Option A the intratracheal infection 
method or Option B the intranasal infection method 
A. Intratracheal infection method TIMING 1-5 min per mouse 
i. Place mouse on the platform so that it is hanging from its top front teeth on 
the bar (Fig. 1b, c). 
ii. Push the mouse towards the bar so that the chest is vertical underneath the 
bar (perpendicular to the platform) (Fig. 1b). 
iii. Direct the Fiber-Lite Illuminator to shine on the mouse’s chest, in between the 
front legs (Fig. 1c). 
iv. Prepare the Exel Safelet IV catheter for the infection procedure. To ensure 
that the needle does not become exposed and impale the mouse, hold the 
square part of the needle with one’s thumb and index finger, and using one’s 
middle finger, push the catheter over the end of the needle completely and 
continue to hold the catheter in place during the infection protocol (Supp. Fig. 
2 a, b).  
TROUBLESHOOTING 
v. Using the Exel Safelet IV catheter, open the mouth and gently pull out the 
tongue with the flat forceps (Fig. 1d).  
vi. Locate the opening of the trachea by peering into the mouth and looking for 
the white light emitted from the trachea (Fig. 1e). 
TROUBLESHOOTING  
vii. While holding the Exel Safelet IV catheter vertically, position the catheter over 
the white light emitted from the opening of the trachea, and allow the catheter 
to slide into the trachea until the top of the catheter reaches the mouse’s front 
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teeth (Fig. 1f). There should be no resistance while inserting the catheter into 
the trachea. 
viii. While stabilizing the Exel Safelet IV catheter with one hand, remove the 
needle from the mouth (Fig. 1g). 
CRITICAL STEP Prior to removing the needle, the mouse cannot breathe 
through the catheter. Once the Exel Safelet IV catheter has been inserted 
into the trachea, promptly remove the needle to allow the mouse to breathe 
through the catheter.  
ix. The proper placement of the catheter in the trachea can be confirmed by 
visualizing the white light shining through the opening of the catheter in the 
mouth (Fig. 1h). 
x. Move the platform, mouse, and catheter into the biosafety hood.  
xi. Pipette the virus directly into the opening of the catheter to ensure the entire 
volume is inhaled (Fig. 1i). 
xii. If the catheter is correctly inserted into the trachea, the mouse will begin 
inhaling the virus immediately. Once the virus is no longer visible in the 
opening of the catheter, wait a few seconds for the entire volume to travel 
down the catheter before removing the catheter from the trachea and 
disposing of it in 50% bleach.  
TROUBLESHOOTING  
B. Delivery of Ad-Cre or Lenti-Cre using the intranasal delivery method TIMING 2-5 min 
per mouse 
i. In the biosafety hood, lay the mouse in your hand, ventral side up. Tilt the 
mouse so that the head is positioned above its feet (Fig. 2a).  
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CRITICAL STEP Do not grasp the mouse tightly as this will inhibit the 
mouse’s breathing 
ii. Hold the end of a pipet tip over the opening of one nostril and dispense the 
virus dropwise until the entire volume of virus has been inhaled (Fig. 2b, c). 
CRITICAL STEP Do not attempt to insert the pipet tip into the nostril. 
TROUBLESHOOTING 
Animal Recovery TIMING 10-15 min 
7 Place the mouse under a heat lamp (Supp. Fig. 3a) or on a latex glove filled with warm water 
(Supp. Fig. 3b) to recover in the biosafety hood. 
TROUBLESHOOTING 
 
TIMING  
Steps 1-4 Virus Preparation (Ad-Cre only): 30 min 
Step 5 Avertin Administration: 5 min per mouse 
Step 6A Intratracheal Infection: 1-5 min per mouse after an initial training phase 
Step 6B Intranasal Delivery: 2-5 min per mouse 
Step 7 Animal Recovery: 10-15 min 
 
TROUBLESHOOTING 
Troubleshooting advice can be found in Table 4. 
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Table 4: Troubleshooting advice 
Step 
Number Problem Possible Reason Solution 
Mouse is not falling 
asleep 
Not enough avertin 
administered 
Administer more avertin, 50-100 µl at 
a time 
5 Mouse is over-
anesthetized and 
breathing very slowly 
Too much avertin 
administered 
Wait until breathing becomes more 
regular but ensure the mouse still 
lacks a reflex response before 
attempting to infect the mouse 
6Aiv Blood appears in mouth 
Catheter has slipped 
and exposed the 
needle 
Make sure that the catheter is held in 
place to cover the needle correctly 
(Supp. Fig. 2a, b) 
Light is not in the 
correct position 
Re-direct the light on the upper chest  
Not looking at the 
ventral surface of 
the throat 
Lean further over the mouth and 
push the tongue with the catheter 
towards the ventral surface of the 
throat 
6Avi Cannot visualize the white light 
Saliva is covering 
the opening of the 
trachea 
Gently probe at the back of the throat 
with the Exel Safelet IV catheter to 
expose the trachea 
6Axii 
Mouse does not 
inhale the virus (virus 
stays in the catheter) 
Catheter inserted 
into esophagus 
Pipette the virus out of the catheter 
for reuse, dispose of the catheter in 
50% bleach, and begin the procedure 
again at step 6Aiv with a new 
catheter  
Too much virus 
placed on nostril 
before being inhaled 
Let coughing subside before 
continuing. Pipette the virus resting 
on nostril for reuse 6B Mouse is coughing and sputtering virus Virus dispensed into 
both nostrils 
Only dispense virus into one nostril 
Mouse is too cold Mouse should be kept warm until it 
starts to wake up 
7 
Mouse does not 
recover well following 
anesthesia 
Mouse is too hot 
under heat lamp 
Turn off heat lamp temporarily or let 
mouse recover on a glove filled with 
warm water 
 
ANTICIPATED RESULTS 
We have reported that recombination of K-rasLSL-G12D and p53fl alleles in tumors can be 
examined by PCR for the presence of a “1 lox”, or recombined, product (see Reagents in 
Materials section for the protocols) (Jackson et al. 2001). Although it is possible to perform PCR 
on DNA isolated from whole lung after infection to assess infection efficiency, this is not 
recommended. Typically very few cells in the lung have undergone recombination of these 
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alleles, making it difficult to detect recombination. Instead, it is more informative to examine Cre 
expression after infection by using conditional reporter strains such as Rosa26LSL-LacZ or 
Rosa26LSL-eGFP and examining reporter expression by immunohistochemistry, 
immunofluorescence, or fluorescent activated cell sorting (Soriano 1999). Polyclonal antibodies 
that can specifically detect the oncogenic K-rasG12D protein are no longer available; however, 
increased Ras-GTP levels in tumors or cells can be assessed using a Raf-GST pulldown assay 
(Tuveson et al. 2004). 
The time to tumor development and progression will vary depending upon the model chosen 
(K v. KP), while survival time will also depend on the amount and type of virus administered to 
the mice. The survival of mice is reduced approximately twofold in KP mice compared to K mice 
(median survival with Ad-Cre: K, 185 days; KP, 76 days, with Lenti-Cre: K, 266 days; KP, 170 
days) (Fig. 3a, b). Decreased survival is due to a greater growth rate of tumors lacking p53, 
leading to the more rapid development of a tumor burden that disrupts the normal function of the 
lungs. Reduced survival after p53 loss is not due to an increased number of tumors or 
metastatic disease. Survival of mice is also reduced after infection with Ad-Cre as compared to 
Lenti-Cre (Fig. 3a, b). This is due to the higher titer of virus typically administered to mice with 
Ad-Cre but may also reflect the viral tropism or the efficiency of the virus to infect the cell of 
origin of the disease. Mice infected with 2.5x107 infectious particles of Ad-Cre (Univ. Iowa, Gene 
Transfer Vector Core) can generate greater than 200 tumors per mouse, whereas mice infected 
with roughly 104-105 infectious particles of Lenti-Cre (3TZ titered) can generate 10-100 tumors 
per mouse. Our laboratory has had success titrating the viruses to lower levels (Ad-Cre: 5x106 
infectious particles/mouse, Lenti-Cre: 5x103 infectious particles/mouse) which reduce the 
number of primary tumors and increase the survival time of mice, allowing for a greater 
frequency of metastatic disease in the KP model. 
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Monitoring tumor development and progression histologically is an important, though 
difficult, way to follow the disease, and it is especially useful in experiments where genetic 
events or modifications in addition to K-ras activation and/or p53 loss may be expected to 
impact tumor progression. We stress that the NSCLC model generates a multi-focal disease 
and therefore, investigators should expect some tumor heterogeneity; tumors do not always 
progress in exactly the same way or at the same time. To follow these changes objectively, we 
have employed a 4-stage grading system for tumor progression in our NSCLC models (adapted 
from ref. 18). The earliest lesions, designated as grade 1, are atypical adenomatous 
hyperpasias (AAH) or small adenomas that feature uniform nuclei and can appear as early as 2-
3 weeks post-infection (Fig. 4a). These earliest lesions can only be identified through careful 
histological analysis. To see visible lesions on the surface of the lung, investigators should wait 
until 6-8 weeks after tumor initiation or later. Grade 2 tumors are larger adenomas that have 
slightly enlarged nuclei with prominent nucleoli and are observed 6-8 weeks post-infection (Fig. 
4b, c). Adenocarcinomas are classified as grade 3; they have a great degree of cellular 
pleomorphism and nuclear atypia and can develop as early as 16 weeks post-infection (Fig. 4d, 
e). Grade 4 tumors are invasive adenocarcinomas (Fig. 4f) that harbor all the cellular 
characteristics of Grade 3 tumors but with a higher mitotic index - including irregular mitoses, a 
distinctive highly invasive stromal reaction (desmoplasia) (Fig. 4g), and invasive edges 
bordering lymphatic vessels, blood vessels, or the pleura (Fig. 4h). Grade 4 tumors may 
develop as early as 18 weeks post-infection in KP animals, but are not observed in K animals. 
Finally, locally metastatic disease to the mediastinal lymph nodes (Fig. 4i) or the pleural cavity 
develops in approximately 50% of KP mice as early as 18-20 weeks post-infection. In some 
mice, distant metastases can be found seeding the liver or the kidneys as early as 20 weeks 
post-infection (Fig. 4j). Although the time to progression in K and KP mice is described here to 
be similar up to Grade 3 lesions, mice with p53 deficient tumors often harbor cells that exhibit 
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nuclear atypia at very early time points after tumor initiation. In addition, a greater proportion of 
tumors that lack p53 progress to higher grades during tumor development (Jackson et al. 2005). 
For example, at 6 weeks after infection the distribution of tumor grades in the K model is ~90% 
grade 1 and ~10 grade 2, whereas in the KP model it is ~40% grade 1, ~40% grade 2 and 
~20% grade 3  (Jackson et al. 2005). At 19 weeks after infection in the KP model, the tumor 
distribution is ~5% grade 1, ~20% grade 2, ~70% grade 3 and ~5% grade 4  (Jackson et al. 
2005). At 26 weeks after infection in the K model, ~30% of tumors are grade 1, ~40% are grade 
2 and ~30% are grade 3  (Jackson et al. 2005). However, as with most autochthonous mouse 
tumor models, there is some variation in the results, such as tumor number and approximate 
time to progression, depending on the strain/ background of mice as well as other factors that 
vary between institutions. 
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Figure 1. Intratracheal infection technique. Anesthetized mice are placed on the platform by 
their front teeth so that their chest hangs vertically beneath them (a, b). The light is directed on 
the mouse’s upper chest (a, c), on the spot marked by the ‘X’ (c). The mouth is opened using 
the Exel Safelet IV catheter (d), and the tongue is gently pulled out using the flat forceps. After 
locating the white light emitted from the trachea (e), the Exel Safelet IV catheter is slid into the 
trachea (f), and the needle is removed (g). The mouse with the inserted catheter (h) on the 
platform is moved into a biosafety hood, where the virus is dispensed into the opening of the 
catheter (i). 
CAUTION All experiments should be done in accordance with protocols approved by the 
Institutional Animal Care and Use Committee. 
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Figure 2. Intranasal infection technique. The anesthetized mouse lies gently in the hand of 
the investigator (a), and the virus is administered dropwise (b) into one nostril until the virus is 
completely inhaled (b, c). 
CAUTION All experiments should be done in accordance with protocols approved by the 
Institutional Animal Care and Use Committee. 
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Figure 3. Survival is reduced in KP model compared to K model. Kaplan-Meier plot of KP 
mice (median survival 76 days) and K mice (median survival 185 days) infected with 2.5x107 
PFU of Ad-Cre per mouse (provided by T. Oliver) (a). Kaplan-Meier plot of KP mice (median 
survival 170 days) and K mice (median survival 266 days) infected with 105 Lenti-Cre viruses 
per mouse (provided by P. Sandy and M. DuPage) (b). 
CAUTION All experiments should be done in accordance with protocols approved by the 
Institutional Animal Care and Use Committee. 
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Figure 4. Tumor progression and histopathological phenotype in KP model. Haematoxylin 
and eosin stained (H&E) tumors from KP mice at various times after infection with Lenti-Cre: (a) 
Grade 1 lesion of an AAH progressing to a small adenoma. (b) Grade 2 adenoma. (c) Uniform 
nuclei in a grade 2 adenoma. (d) Pleomorphic nuclei in a Grade 3 adenocarcinoma. (e) Grade 3 
adenocarcinoma displaying mixed cellular phenotypes. (f) Grade 4 invasive adenocarcinoma. 
(g) Grade 4 adenocarcinoma with glandular/acinar architecture and desmoplasia. (h) 
Adenocarcinoma from the lung (L) invading across the mesothelium into the pleural cavity (P). 
(i) Local lung tumor metastasis (T) to mediastinal lymph node (LN). (j) Distant lung tumor 
metastasis (T) to the kidney (K). Panels a, b, e, f, i and j are at 100X magnification. Panels c, d, 
g and h are at 400X magnification. Scale bar = 100 µm. 
CAUTION All experiments should be done in accordance with protocols approved by the 
Institutional Animal Care and Use Committee. 
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Supplementary Figure 1. Genetically controlled events in a mouse model of lung 
cancer. Engineering of LoxP elements and a stop element allow for the controlled 
expression of oncogenic K-ras and the loss of p53 function after Cre expression. 
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Supplementary Figure 2. Preparation of the Exel Safelet IV catheter for intratracheal 
infection. Upon opening the Exel Safelet IV catheter, the needle is exposed (a). Slide the 
catheter over the end of the needle to completely cover the tip (b) and the Exel Safelet IV 
catheter is now ready to use. 
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Supplementary Figure 3. Recovery following intranasal or intratracheal infection. Mice 
can be placed under a heat lamp (a) or on a glove filled with warm water (b) to recover following 
anesthesia in the biosafety hood.  
CAUTION All experiments should be done in accordance with protocols approved by the 
Institutional Animal Care and Use Committee. 
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